citalopram has been researched along with Depression in 582 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "TECAS was comparable to escitalopram in improving depression and related symptoms, with high acceptability, better safety profile, and particular efficacy in reducing trauma-associated depression." | 9.69 | Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for mild-to-moderate depression: An assessor-blinded, randomized, non-inferiority trial. ( Cai, JF; Chen, GB; He, JK; Hou, XB; Jiao, Y; Jin, GX; Liu, Y; Qin, ZS; Rong, PJ; Shi, L; Wang, Y; Wong, YK; Xiao, HB; Xiao, X; Xu, FQ; Yang, XJ; Zhang, JN; Zhang, LL; Zhang, SY; Zhang, ZJ; Zhao, YY; Zheng, Y, 2023) |
| "A secondary analysis of data from the multicentre randomised controlled trial The Efficacy of Citalopram Treatment in Acute Ischemic Stroke (TALOS)." | 9.69 | Impact of prestroke physical activity and citalopram treatment on poststroke depressive symptoms: a secondary analysis of data from the TALOS randomised controlled trial in Denmark. ( Andersen, G; Blauenfeldt, RA; Damsbo, AG; Johnsen, SP; Mortensen, JK; Vestergaard, SB, 2023) |
| "Drugs that target glutamate neuronal transmission, such as memantine, offer a novel approach to the treatment of late-life depression, which is frequently comorbid with cognitive impairment." | 9.41 | Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression. ( Grzenda, A; Laird, KT; Lavretsky, H; Siddarth, P; Yeargin, J, 2021) |
| "gov, NCT01278498), a randomized, placebo-controlled, double-blind trial that examined the efficacy of escitalopram on depression in acute stroke patients (237 with placebo, 241 with escitalopram)." | 9.41 | Post-Stroke Depressive Symptoms: Varying Responses to Escitalopram by Individual Symptoms and Lesion Location. ( Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, MS; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Lee, JS; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2021) |
| "These results provide novel information on the efficacy of sertraline and escitalopram in the treatment of apathy and depression, respectively, in patients with AD." | 9.34 | The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP). ( Abe, K; Hishikawa, N; Matsumoto, N; Nomura, E; Ohta, Y; Omote, Y; Sasaki, R; Tadokoro, K; Takemoto, M; Tsunoda, K; Yamashita, T, 2020) |
| " Larger longitudinal clinical trials can further examine the neuroprotective effect of memantine in geriatric depression." | 9.34 | Combined treatment with escitalopram and memantine increases gray matter volume and cortical thickness compared to escitalopram and placebo in a pilot study of geriatric depression. ( Ercoli, L; Kilpatrick, L; Krause-Sorio, B; Laird, KT; Lavretsky, H; Milillo, MM; Narr, KL; Siddarth, P, 2020) |
| " One hundred and sixty patients with MDD and comorbid obesity will be randomised 1:1 to simvastatin or placebo as add-on to standard antidepressant medication with escitalopram." | 9.34 | Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial. ( Chae, WR; Ettrich, B; Friede, T; Gold, SM; Grabe, HJ; Hegerl, U; Hinkelmann, K; Hofmann, T; Janowitz, D; Junghanns, K; Kaczmarczyk, M; Kahl, KG; Klein, JP; Krueger, THC; Leicht, G; Lischewski, S; Märschenz, S; Nowacki, J; Otte, C; Piber, D; Prvulovic, D; Reif, A; Roepke, S; Schmidt, S; Schoettle, D; Strauss, M; Westermair, A, 2020) |
| " We conducted a 52 week, placebo-controlled add-on trial of citalopram in patients with FES who did not meet criteria for major depression to determine whether maintenance therapy with citalopram would improve outcomes by preventing or improving negative and depressive symptoms." | 9.30 | Citalopram in first episode schizophrenia: The DECIFER trial. ( Ardekani, BA; Bello, I; Cather, C; Diminich, E; Fan, X; Freudenreich, O; Goff, DC; Holt, D; Li, C; Tang, Y; Troxel, A; Wang, J; Worthington, M; Wu, R; Zeng, B; Zhao, J, 2019) |
| "To investigate the effect on long-term major adverse cardiac events (MACE) of escitalopram treatment of depression in patients with recent ACS." | 9.27 | Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JH; Kim, JM; Kim, JW; Kim, MC; Kim, SW; Lee, HJ; Lee, YS; Shin, IS; Stewart, R; Yoon, JS, 2018) |
| " Patients who had had an acute stroke within the past 21 days were randomly assigned in a 1:1 ratio to receive oral escitalopram (10 mg/day) or placebo for 3 months." | 9.24 | Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. ( Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2017) |
| "This study re-examined patients from a 1-year randomized controlled double-blind trial of escitalopram, problem-solving therapy (PST), or placebo to prevent depression among patients less than 3 months after a stroke." | 9.24 | Prevention of Poststroke Mortality Using Problem-Solving Therapy or Escitalopram. ( Jorge, RE; Long, J; Robinson, RG, 2017) |
| " Successful treatment of depression and anxiety with escitalopram had significant beneficial effects on suicidal ideation in these patients." | 9.22 | Determinants and escitalopram treatment effects on suicidal ideation in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, H; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Yoon, JS, 2016) |
| "To determine whether 24 months of treatment with escitalopram improves mortality, morbidity, and mood in patients with chronic systolic heart failure and depression." | 9.22 | Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. ( Angermann, CE; Blankenberg, S; Böhm, M; Deckert, J; Edelmann, F; Ertl, G; Faller, H; Gelbrich, G; Gottwik, M; Graf, T; Gunold, H; Haass, M; Kindermann, I; Pankuweit, S; Prettin, C; Schunkert, H; Störk, S; Wachter, R, 2016) |
| "We investigated roles of plasma homocysteine and MTHFR gene in relation to risks and treatment responses of depression in ACS." | 9.22 | Predictive value of homocysteine for depression after acute coronary syndrome. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, H; Kang, HJ; Kim, JM; Kim, SW; Moon, WJ; Shin, IS; Stewart, R; Yoon, JS, 2016) |
| "The aim of this open trial was to assess the antidepressant/anxiolytic effects of oxytocin used as an adjunct to antidepressant in treatment-resistant depression." | 9.20 | Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: an open trial. ( Ansseau, M; Geenen, V; Hansenne, M; Legros, JJ; Scantamburlo, G, 2015) |
| "To investigate the correlates of sleep disturbance and to assess escitalopram treatment effects of depression on sleep disturbance in patients with acute coronary syndrome (ACS)." | 9.20 | Correlates and Escitalopram Treatment Effects on Sleep Disturbance in Patients with Acute Coronary Syndrome: K-DEPACS and EsDEPACS. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Stewart, R; Yoon, JS, 2015) |
| "The objectives were to characterize latent depression subtypes by symptoms, evaluate sex differences in and examine correlates of these subtypes, and examine the association between subtype and symptom remission after citalopram treatment." | 9.20 | The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. ( Lapane, KL; Rothschild, AJ; Ulbricht, CM, 2015) |
| "In this study, we assessed the efficacy of 2 pharmacodynamically different antidepressants, citalopram (a selective serotonin reuptake inhibitor) and reboxetine (a norepinephrine reuptake inhibitor), as adjunctive therapy to risperidone and olanzapine for the treatment of negative symptoms in schizophrenia." | 9.19 | Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. ( Bernardo, M; Caballero, M; Corripio, I; Felipe, AE; Fernandez de Corres, B; González Piqueras, JC; Huerta, R; Ibáñez, A; Iniesta, R; López-Carrilero, R; Oliveira, C; Roca, M; Rodriguez-Jimenez, R; Sindreu, SD; Usall, J, 2014) |
| "Depression occurred in 14 patients receiving placebo and in 5 patients receiving escitalopram (Pearson χ², P = ." | 9.19 | Effects of escitalopram prophylaxis during antiviral treatment for chronic hepatitis C in patients with a history of intravenous drug use and depression. ( Bezemer, G; de Knegt, RJ; Hansen, BE; Hotho, DM; Janssen, HL; Van Gool, AR; Veldt, BJ, 2014) |
| " We investigated the effectiveness of citalopram in the treatment of childhood functional abdominal pain (FAP)." | 9.19 | Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial. ( Gholamrezaei, A; Pourmoghaddas, Z; Roohafza, H; Saneian, H, 2014) |
| "Of 120 patients treated with escitalopram 2 developed depression versus 10 in placebo treated group (log rank, p=0." | 9.16 | Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD). ( Andersen, NL; Birket-Smith, M; Hanash, JA; Hansen, BH; Hansen, JF; Nielsen, OW; Rasmussen, A, 2012) |
| "This was an active-controlled, parallel-group, double-blind, randomized study in a general community comparing escitalopram and duloxetine in patients with severe depression; patients who did not respond (<50% Montgomery-Åsberg Depression Rating Scale [MADRS] improvement) to 2 weeks of single-blind escitalopram 10 mg/day during the lead-in period were randomized to 8 weeks of double-blind treatment." | 9.16 | Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. ( Bose, A; Li, D; Tsai, J, 2012) |
| "To examine whether preemptive antidepressant treatment with escitalopram can decrease the incidence or severity of depression associated with pegylated IFN-α in HCV-infected patients without a history of psychiatric disorders." | 9.16 | Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. ( Baumert, TF; Berg, T; Buggisch, P; Discher, T; Effenberger, S; Friebe, A; Fromm, G; Heinz, A; Heinze, L; Knop, V; Lieb, K; Link, R; Neumann, K; Ockenga, J; Reimer, J; Rentrop, M; Sarkar, R; Schaefer, M; Schlaepfer, T; Spengler, U; Weidenbach, H; Zeuzem, S, 2012) |
| "The DECARD (DEpression in patients with Coronary ARtery Disease) trial assessed the prophylactic effect of escitalopram on depression after ACS." | 9.16 | Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial. ( Birket-Smith, M; Hanash, JA; Hansen, BH; Hansen, JF; Nielsen, OW; Rasmussen, A, 2012) |
| "The authors sought to determine the relative efficacy and tolerability of duloxetine versus citalopram and sertraline in the treatment of poststroke depression (PSD), anxiety, and fatigue." | 9.16 | Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. ( Karaiskos, D; Paparrigopoulos, T; Spengos, K; Tzavellas, E; Vassilopoulou, S, 2012) |
| "Fluoxetine and Citalopram can effectively reduce the severity of depression in diabetic patients without an adverse effect on glycemic control." | 9.15 | Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram? ( Khazaie, H; Najafi, F; Rahimi, M; Rezaei, M; Tahmasian, M; Tatari, F, 2011) |
| "Outpatients with chronic or recurrent major depression (MDD) were randomized to initial treatment with escitalopram+placebo (the MONO condition), bupropion-sustained release+escitalopram, or venlafaxine-extended release+mirtazapine (the COMB conditions) in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial." | 9.15 | Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. ( Bobo, WV; Chen, H; Cook, IA; Fava, M; Husain, MM; Kornstein, SG; Kurian, BT; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Shelton, RC; Stewart, JW; Trivedi, MH; Warden, D; Wisniewski, SR, 2011) |
| "The findings suggest that cortical and limbic SERT occupancy may be an underlying mechanism for the regional cerebral metabolic effects of citalopram in geriatric depression." | 9.15 | Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression. ( Flint, A; Kahn, A; Rusjan, P; Sacher, J; Smith, GS; van Eimeren, T; Wilson, AA, 2011) |
| "This study investigated the psychological characteristics and clinical features of 55 patients with geriatric depression, and evaluated the efficacy and safety of escitalopram in the treatment of geriatric depression, in a randomized controlled trial." | 9.15 | Clinical features and efficacy of escitalopram treatment for geriatric depression. ( Chen, YM; Huang, XM; Thompson, R; Zhao, YB, 2011) |
| "Two hundred forty non-depressed patients with acute coronary syndrome are randomized to treatment with either escitalopram or placebo for 1 year." | 9.14 | Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD). ( Birket-Smith, M; Hanash, JA; Hansen, BH; Hansen, JF; Rasmussen, A, 2009) |
| "This study sought to investigate the efficacy of escitalopram at different dosages for the treatment of obsessive-compulsive disorder (OCD)." | 9.14 | Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. ( Deckersbach, T; Dougherty, DD; Jameson, M; Jenike, M; Keuthen, NJ; Loh, R; Thompson-Hollands, J, 2009) |
| "5 mg), B6 (25 mg) and folic acid (2 mg) or citalopram (20 to 40 mg) plus placebo for the treatment of depression in later life." | 9.14 | The B-VITAGE trial: a randomized trial of homocysteine lowering treatment of depression in later life. ( Almeida, OP; Fenner, S; Flicker, L; Ford, AH; Hegarty, S; Hirani, V; McCaul, K; van Bockxmeer, F, 2010) |
| "This study examined the potential of an antidepressant drug, escitalopram, to improve depression, resilience to stress, and quality of life in family dementia caregivers in a randomized placebo-controlled double-blinded trial." | 9.14 | Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram. ( Irwin, MR; Lavretsky, H; Siddarth, P, 2010) |
| "To examine the effects of citalopram augmentation of antipsychotics on suicidal ideation in middle-aged and older people with schizophrenia and subthreshold depressive symptoms." | 9.14 | Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. ( Fellows, I; Golshan, S; Kasckow, JW; Lanouette, NM; Mohamed, S; Rao, S; Vahia, I; Zisook, S, 2010) |
| "To determine the efficacy of citalopram in the treatment of chronic pelvic pain by measuring changes in pain severity, depressive symptoms and functional disability." | 9.13 | Citalopram in the treatment of women with chronic pelvic pain: an open-label trial. ( Brown, CS; Franks, AS; Ling, FW; Wan, J, 2008) |
| "To determine whether treatment with escitalopram or problem-solving therapy over the first year following acute stroke will decrease the number of depression cases that develop compared with placebo medication." | 9.13 | Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. ( Acion, L; Arndt, S; Fonzetti, P; Hegel, M; Jorge, RE; Moser, DJ; Robinson, RG; Small, SL; Solodkin, A, 2008) |
| "After three and six weeks of treatment, citalopram significantly improved abdominal pain, bloating, impact of symptoms on daily life, and overall well being compared with placebo." | 9.12 | A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. ( Broekaert, D; Fischler, B; Gevers, AM; Janssens, J; Tack, J; Van Oudenhove, L, 2006) |
| "A similar decrease in weekly rate of panic attacks, in the scores of Hamilton Scale for anxiety and depression and in the Cooper Disability Scale scores, was observed in both groups after 8 weeks, but a significant variation of outcome measures from baseline was observed already after 2 weeks in the escitalopram group (P < 0." | 9.12 | New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. ( Alvano, A; Malaguarnera, M; Raffaele, R; Rampello, L; Vecchio, I, 2006) |
| "This study is an open-label, 8-week trial of escitalopram for perimenopausal depression and somatic symptoms associated with perimenopause." | 9.12 | Escitalopram for perimenopausal depression: an open-label pilot study. ( Brumbach, BH; Freeman, MP; Hill, R, 2006) |
| "To assess the potential efficacy, tolerability, and safety of citalopram in the treatment of functional pediatric recurrent abdominal pain and comorbid internalizing disorders." | 9.11 | Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study. ( Axelson, D; Birmaher, B; Brent, DA; Bridge, J; Campo, JV; Di Lorenzo, C; Ehmann, M; Kalas, C; Lucas, A; Monk, K; Perel, J; Ryan, N, 2004) |
| "Patients (n=28) with mild to moderate hypertension and depression were given enalapril (20 mg/day)." | 9.11 | [Clinical efficacy of citalopram in patients with hypertension and concomitant depression]. ( Gudkova, OA; Iufereva, IuM; Pogosova, GV; Tikhomirova, EA, 2004) |
| "Although citalopram has gained wide acceptance in the treatment of depression and anxiety disorders, its use during pregnancy and lactation has been poorly characterized." | 9.10 | Citalopram in pregnancy and lactation. ( Ekblad, S; Ekblad, U; Heikkinen, T; Kero, P; Laine, K, 2002) |
| "We undertook an open-label pilot study using citalopram in 30 cancer patients who reported a high level of depressive symptoms on the Zung Self-Rating Depression Scale (ZSDS)." | 9.10 | An open label pilot study of citalopram for depression and boredom in ambulatory cancer patients. ( Donaghy, K; Holtsclaw, E; Kirsh, KL; Passik, SD; Theobald, DE, 2003) |
| "The effect of the selective serotonin reuptake inhibitor citalopram was studied in a randomized, double-blind, placebo-controlled, 4-month trial in patients with the fibromyalgia syndrome (FMS) who all fulfilled the American College of Rheumatology criteria." | 9.09 | Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study. ( Anderberg, UM; Marteinsdottir, I; von Knorring, L, 2000) |
| "We conducted a 10-week single-blind trial of citalopram (20-40 mg/day) vs no citalopram augmentation in 19 middle-aged and elderly patients with schizophrenia hospitalized for more than six of the last 12 months." | 9.09 | Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. ( Carroll, B; Jeste, DV; Kasckow, JW; Mohamed, S; Thallasinos, A; Zisook, S, 2001) |
| "We have investigated the ability of citalopram, a serotonin reuptake inhibitor, to alter the functional sensitivity to a neuroactive steroid during the late luteal phase in twelve women with premenstrual syndrome." | 9.08 | Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. ( Bäckström, T; Sundström, I, 1998) |
| "The aim of the study was to investigate the efficacy and safety of the selective serotonin reuptake inhibitor citalopram in treating poststroke depression, since available treatments are usually poorly tolerated." | 9.07 | Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. ( Andersen, G; Lauritzen, L; Vestergaard, K, 1994) |
| "To objectively evaluate the efficacy and safety of citalopram versus other antidepressant drugs in poststroke depression (PSD) treatment." | 8.98 | Efficacy and Safety of Citalopram for the Treatment of Poststroke Depression: A Meta-Analysis. ( Cui, M; Huang, CY; Wang, F, 2018) |
| "83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed." | 8.93 | Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016) |
| "To evaluate the citalopram in post-stroke depression treatment, we compared its use to other selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and traditional Chinese medicines (TCMs)." | 8.91 | Efficacy and Safety of Citalopram in Treating Post-Stroke Depression: A Meta-Analysis. ( Ding, L; Hong, H; Huang, X; Tan, S, 2015) |
| "Antidepressants are effective in treating interferon-α/ribavirin (IFN-α/RBV)-associated depression during or after treatment of chronic hepatitis C (CHC)." | 8.89 | Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials? ( Hou, XJ; Wang, J; Xu, JH; Yu, YY, 2013) |
| " Citalopram, one of the first selective serotonin reuptake inhibitors (SSRI) introduced in the market, is one of these antidepressant drugs that clinicians use for routine depression care." | 8.88 | Citalopram versus other anti-depressive agents for depression. ( Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; Imperadore, G; Purgato, M; Signoretti, A; Trespidi, C; Watanabe, N, 2012) |
| "To assess the evidence for the efficacy, acceptability and tolerability of escitalopram in comparison with tricyclics, other SSRIs, heterocyclics and newer agents in the acute-phase treatment of major depression." | 8.85 | Escitalopram versus other antidepressive agents for depression. ( Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; McGuire, H; Nakagawa, A; Santilli, C; Signoretti, A, 2009) |
| "All five published placebo-controlled clinical studies in depression as per January 1, 2005, with escitalopram, were included in this pooled analysis." | 8.83 | The onset of effect for escitalopram and its relevance for the clinical management of depression. ( Friis Andersen, H; Wade, A, 2006) |
| "Although escitalopram is known to be an effective drug for adult depression, its disease-modifying efficacy on adolescents remains controversial." | 8.31 | Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression. ( Choi, JY; Han, SJ; Kang, KJ; Lee, N; Nam, KR; Oh, SJ, 2023) |
| "Treatment of major depression disorder with Selective serotonin reuptake inhibitors (SSRIs), such as citalopram (CTM), during pregnancy effects on the neurological trajectory of the offspring and induces enduring consequences, notably emotional and cognitive impairment." | 8.12 | Prenatal exposure of citalopram elicits depression-like and anxiety-like behaviors and alteration of morphology and protein expression of medial prefrontal cortex in young adult mice. ( Butt, MU; Du, L; Jia, M; Wang, Q; Wang, Y; Wu, J; Zahra, A, 2022) |
| " Eighty-seven participants in the first Canadian Biomarker Integration Network in Depression (CAN-BIND-1) protocol received 8 weeks of open-label escitalopram." | 7.96 | Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. ( Arnott, SR; Ceniti, AK; Davis, AD; Downar, J; Dunlop, K; Foster, JA; Frey, BN; Harris, JK; Hassel, S; Kennedy, SH; Lam, RW; MacQueen, GM; Mansouri, F; Milev, R; Parikh, SV; Rizvi, SJ; Rotzinger, S; Schulze, L; Soares, CN; Strother, SC; Turecki, G; Uher, R; Zamyadi, M, 2020) |
| "This study aims to assess the efficacy and safety of citalopram for the treatment of patients with post-stroke depression (PSD)." | 7.96 | Does citalopram effectively treat post-stroke depression?: A protocol for systematic review and meta analysis. ( Hu, J; Ma, L; Yang, ZY, 2020) |
| "Escitalopram, a drug of choice in the treatment of depression, was recently shown to possess an anti-inflammatory activity." | 7.91 | Potential Anti-Inflammatory Effect of Escitalopram in Iodoacetamide-Induced Colitis in Depressed Ovariectomized Rats: Role of α7-nAChR. ( Abdelsalam, RM; Abdo, SA; Khattab, MM; Wadie, W, 2019) |
| " A treatment with escitalopram reversed depression-like behavior accompanied by reductions in BDNF levels in serum and the nucleus accumbens, while a treatment with blonanserin ameliorated abnormal social interaction behavior with reductions in serum BDNF levels." | 7.91 | Antidepressant activities of escitalopram and blonanserin on prenatal and adolescent combined stress-induced depression model: Possible role of neurotrophic mechanism change in serum and nucleus accumbens. ( Deriha, K; Furuse, K; Hashiguchi, H; Hashimoto, E; Ishii, T; Kawanishi, C; Kigawa, Y; Shiraishi, M; Tayama, M; Ukai, W, 2019) |
| " In this study, we examined the molecular effects associated with a response to a week-long treatment with escitalopram in the chronic escape deficit (CED) model, a validated model of depression based on the induction of an escape deficit after exposure of rats to an unavoidable stress." | 7.88 | Molecular changes associated with escitalopram response in a stress-based model of depression. ( Alboni, S; Benatti, C; Blom, JMC; Brunello, N; Mendlewicz, J; Tascedda, F, 2018) |
| "This retrospective study investigated the efficacy and safety of escitalopram oxalate (ESO) for the treatment of post-stroke depression (PSD)." | 7.88 | Efficacy of escitalopram oxalate for patients with post-stroke depression. ( Jiang, P; Xu, JH, 2018) |
| " Using maternal separation (MS), a paradigm of early adversity, we investigated the effects of adolescent (PND 33-54) escitalopram (ES; 10mg/kg) exposure on depression- and anxiety-like behaviours and the levels of inflammatory cytokines (interleukin [IL]-1β, tumor necrosis factor [TNF]-α, and IL-10) in the ventral hippocampus (HPV), prefrontal cortex (PFC), and serum in adult (PND 61) male offspring mice." | 7.85 | Adolescent escitalopram prevents the effects of maternal separation on depression- and anxiety-like behaviours and regulates the levels of inflammatory cytokines in adult male mice. ( Dong, X; Geng, Z; Jin, Y; Li, N; Li, X; Lin, Y; Liu, M; Sun, A; Wang, Q; Wang, Y, 2017) |
| "A 63-year-old woman with a history of long-standing depression, maintained on escitalopram, presented with altered mental status." | 7.85 | Serotonin syndrome caused by drug to drug interaction between escitalopram and dextromethorphan. ( Arcega, V; Dy, P; Ghali, W; Wolfe, W, 2017) |
| " The aim of the present study was to investigate whether stress-induced anhedonia could be prevented by treatments with escitalopram or novel herbal treatment (NHT) in an animal model of depression." | 7.85 | Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. ( Barak, S; Burstein, O; Chen, G; Doron, R; Franko, M; Gale, E; Handelsman, A; Hirshler, Y; Motsan, S; Shamir, A; Simhon, O; Toledano, R, 2017) |
| " The aim of the present study was to clarify whether plant-derived isoflavone puerarin could ameliorate comorbid depression and pain." | 7.85 | Plant Natural Product Puerarin Ameliorates Depressive Behaviors and Chronic Pain in Mice with Spared Nerve Injury (SNI). ( Lao, L; Liang, Z; Luo, D; Rong, J; Zhao, J, 2017) |
| " We report the development of severe hyponatremia leading to adverse clinical effects due to escitalopram and thiazide diuretic use concomitantly in a patient with depression after emergency coronary artery bypass grafting." | 7.83 | Hyponatremia Due to Escitalopram and Thiazide Use After Cardiac Surgery. ( Aksoy, E; Çağlı, K; Diken, Aİ; Doğan, İ; Erçen Diken, Ö; Yalçınkaya, A; Yılmaz, S, 2016) |
| "Considering the gene X environment hypothesis of depression, the present study investigated the effect of chronic ozone inhalation on depression and anxiety-related behavior, cognition, and brain markers of oxidative stress in the Flinders Sensitive Line (FSL) rat." | 7.81 | Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response. ( Brink, CB; Ellis, SM; Harvey, BH; Mokoena, ML; Viljoen, F, 2015) |
| "The authors reported a case of serotonin syndrome associated with combined therapy of monoamine oxidase-B inhibitors and selective serotonin reuptake inhibitor A 77-year-old Thai man had been taking escitalopram for depression for three years." | 7.81 | Combination of Escitalopram and Rasagiline Induced Serotonin Syndrome: A Case Report and Review Literature. ( Santimaleeworagun, W; Supasyndh, O; Suphanklang, J, 2015) |
| "Female rats implanted with 28-day osmotic minipumps delivering the SSRI escitalopram throughout pregnancy had serum escitalopram concentrations in a clinically observed range (17-65 ng/ml)." | 7.79 | Prenatal exposure to escitalopram and/or stress in rats: a prenatal stress model of maternal depression and its treatment. ( Boss-Williams, KA; Bourke, CH; Capello, CF; Owens, MJ; Rogers, SM; Stowe, ZN; Weiss, JM; Yu, ML, 2013) |
| "To evaluate the risk factors of psychiatric adverse events associated with PEG interferon and ribavirin treatment for chronic hepatitis C and assess the efficacy of escitalopram intervention for these adverse effects." | 7.79 | [Escitalopram for intervention of psychiatric adverse events during peginterferon-alfa-2a and ribavirin treatment for chronic hepatitis C]. ( Pan, J; Qi, M; Su, M; Zhang, H; Zhou, B, 2013) |
| "In C6 glioma cells, we studied acute administration of SSRI antidepressants - fluoxetine, sertraline and citalopram." | 7.78 | Effect of fluoxetine and adenosine receptor NECA agonist on G alpha q/11 protein of C6 glioma cells. ( Kováru, F; Kovárů, H; Lisá, V, 2012) |
| "We investigated the hypothesis that hippocampal neurogenesis related to Notch1 signaling could be a valid index for a combined citalopram and WAY100635 pharmacotherapy for the treatment of depression arising after stroke." | 7.76 | Notch1 signaling related hippocampal neurogenesis in adult poststroke depression rats: a valid index for an efficient combined citalopram and WAY100635 pharmacotherapy. ( Guo, YJ; Sui, YX; Sun, Y; Wang, SH; Zhang, ZJ, 2010) |
| "Breast cancer patients with indications for an SSRI may be prescribed citalopram - and possibly other SSRI - without adversely affecting the outcome of adjuvant therapy with tamoxifen." | 7.76 | Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2010) |
| " Citalopram, a newer generation SSRI, is commonly prescribed, but despite its low toxicity profile has a potential to cause seizures and dysarrythmias in overdose." | 7.76 | Metabolic acidosis and generalized seizures secondary to citalopram overdose: a case report. ( Al Anazi, T; Al Hayyan, H; Al Hussein, M; Al Modaimegh, H; Al Qahtani, M; Bin Salih, S, 2010) |
| "The aim of this study was to investigate the relationship between plasma glutamate, glutamine and gamma-aminobutyric acid (GABA) levels in female patients with major depression treated with S-citalopram or fluoxetine." | 7.75 | The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. ( Calişkan, M; Gören, MZ; Kaplan, OK; Küçükibrahimoğlu, E; Saygin, MZ; Unsal, C, 2009) |
| " Recent findings have shown, that adipocytokines leptin and adiponectin might play a role in both depression and MetS." | 7.75 | Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women. ( Jachymova, M; Jirak, R; Tvrzicka, E; Vecka, M; Zak, A; Zeman, M, 2009) |
| "We describe the case of a pregnancy healthy outcome after in utero consecutive exposure to lamotrigine and citalopram." | 7.74 | Consecutive exposure to lamotrigine and citalopram during pregnancy. ( Gentile, S; Vozzi, F, 2007) |
| " Several hours after presentation, she developed sinus arrest and junctional bradycardia that resolved after infusion of intravenous sodium bicarbonate solution." | 7.73 | Reversal of citalopram-induced junctional bradycardia with intravenous sodium bicarbonate. ( Brucculeri, M; Kaplan, J; Lande, L, 2005) |
| " Changes in kinetic parameters (V(max), maximal velocity and K(M), apparent Michaelis constant) of L-T3 uptake into red blood cells (RBCs) and changes in membrane fluidity in a group of 24 patients with major depression were measured before treatment and after 1 month of treatment with citalopram." | 7.73 | Red blood cell triiodothyronine uptake as membrane parameter of depression. ( Fisar, Z; Hanus, Z; Kalisová-Stárková, L; Paclt, I; Vevera, J, 2006) |
| "In order to study the gene-environment interaction as well as investigate prophylactic/ameliorative effects of early intervention on development of adult life psychopathology, we superimposed maternal separation on an animal model of depression the Flinders Sensitive Line (FSL) rats and their controls the Flinders Resistant Line (FRL) rats and studied behavior following treatment with escitalopram." | 7.73 | Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression. ( El Khoury, A; Gruber, SH; Mathé, AA; Mørk, A, 2006) |
| "Citalopram, a selective serotonin reuptake inhibitor (SSRI) recently approved in the United States for treatment of depression, has similar efficacy to and a lower acquisition cost than other SSRIs." | 7.72 | A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges. ( Eaddy, MT; Grudzinski, AN; McLaughlin, TP, 2004) |
| "Citalopram is a relatively new selective serotonin reuptake inhibitor (SSRI) that is becoming widely administered for the treatment of depression." | 7.71 | Citalopram-induced priapism. ( Brown, WC; Dent, LA; Murney, JD, 2002) |
| "The authors report the case of a 47-year-old depressive woman treated with citalopram 20 mg day-1 for 3 months who presented a marked sinus bradycardia (34 beats/min) 11 days after the citalopram dose was increased to 40 mg day-1." | 7.70 | Bradycardia during citalopram treatment: a case report. ( Bertschy, G; Favre, MP; Sztajzel, J, 1999) |
| "We investigated the effect of the selective serotonin reuptake inhibitor (SSRI) citalopram after 6-8 weeks and 6 months of treatment on clinical and peripheral indexes for central serotonergic function: platelet [14C]serotonin uptake and [3H]paroxetine- and [3H]LSD-binding to platelets membranes in 33 patients with panic disorder." | 7.70 | The effect of citalopram treatment on platelet serotonin function in panic disorders. ( Aberg-Wistedt, A; Neuger, J; Sinner, B; Stain-Malmgren, R; Wistedt, B, 2000) |
| "The selective sigma2 (sigma2) ligand Lu 28-179, or 1'-[4[1-(4-fluorophenyl)-1H-indol-3-yl]-l-butyl]spiro[isobenzofuran++ +-1(3H),4'-piperidine], was studied in the chronic mild stress (CMS) model of depression." | 7.70 | The selective sigma2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. ( Papp, M; Sánchez, C, 2000) |
| "Administration of imipramine, which blocks noradrenergic, serotonergic and cholinergic reuptake, to rats for 4 days counteracts the shuttlebox escape failures otherwise seen in rats which have been exposed to inescapable shock (the "learned helplessness" model of depression)." | 7.68 | Effect of imipramine in the "learned helplessness" model of depression in rats is not mimicked by combinations of specific reuptake inhibitors and scopolamine. ( Christensen, AV; Geoffroy, M; Scheel-Krüger, J, 1990) |
| " Adverse effects were assessed by the Adverse Events Scale." | 7.01 | The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression. ( Chen, S; Feng, L; He, J; Luan, X; Wang, Q; Xiao, M, 2021) |
| "Antidepressants are widely used to treat major depressive disorder." | 7.01 | Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial. ( Abe, T; Furukawa, TA; Iwanami, A; Mimura, M; Nakagawa, A; Nakagome, K; Nishioka, G; Tani, M; Watanabe, K; Yokoi, Y; Yoshimura, N, 2021) |
| " Adverse events (AEs) were assessed with the Treatment Emergent Symptom Scale (TESS)." | 6.90 | A controlled study of the efficacy and safety of tandospirone citrate combined with escitalopram in the treatment of vascular depression: A pilot randomized controlled trial at a single-center in China. ( Chen, H; Chen, R; Lin, F; Lin, Q; Lin, T; Lin, X; Lin, Y; Luo, L; Xiao, Y, 2019) |
| "Depression is a common affective disorder or mood disorder, which seriously affects people's physical and mental health and the quality of life." | 6.87 | Analysis of curative effect of fluoxetine and escitalopram in the depression treatment based on clinical observation. ( Xiaoling, Z; Yingdong, L; Yunping, H, 2018) |
| " The aim of this study was to describe characteristics of dosing history in participants with depression receiving once daily escitalopram." | 6.77 | Adherence to escitalopram treatment in depression: a study of electronically compiled dosing histories in the 'Depression: the search for phenotypes' study. ( Anderton, J; Bies, RR; Buttenfield, J; Fagiolini, A; Frank, E; Jin, Y; Kepple, G; Kupfer, DJ; Lange, AC; Pollock, BG; Rucci, P; Vrijens, B; Wessels, AM, 2012) |
| "Pain is common among opioid-dependent patients, yet pharmacologic strategies are limited." | 6.76 | Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms. ( Anderson, BJ; Herman, DS; Kettavong, M; Stein, MD; Tsui, JI, 2011) |
| "Citalopram was not superior to placebo in treating non-depressed IBS patients." | 6.75 | Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. ( Bacchetti, P; Chung, E; Grimes, B; Jin, C; Ladabaum, U; Levin, TR; Pepin, CJ; Sharabidze, A; Zhao, WK, 2010) |
| "Escitalopram is a good therapeutic option for the long-term treatment of MDD, particularly in severely depressed patients." | 6.74 | Superiority of escitalopram to paroxetine in the treatment of depression. ( Baldwin, DS; Boulenger, JP; Kasper, S; Larsson Lönn, S, 2009) |
| "Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD)." | 6.73 | Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. ( Bordet, R; Cottencin, O; Defebvre, L; Destée, A; Devos, D; Dujardin, K; Moreau, C; Poirot, I; Thomas, P, 2008) |
| " Participants were adult outpatients who, following 8 weeks of monotherapy with an adequate dosing regimen of an SSRI other than citalopram and had not responded, met the diagnostic criteria for depression as described in the Diagnostic and statistical manual of mental disorders, fourth edition, and had a score > or =20 on the 21-item Hamilton Rating Scale for Depression (HAM-D21)." | 6.73 | Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. ( Jiang, Q; Lenox-Smith, AJ, 2008) |
| " Study durations ranged from 8 to 16 weeks and MPH dosing ranged from 5 to 90 mg per day." | 6.72 | Methylphenidate use in geriatric depression: A systematic review. ( Britt, RB; Brown, JN; Kahlon, CH; Smith, KR, 2021) |
| "reboxetine) has provided potentially important avenues of treatment for the disorder." | 6.71 | Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. ( Mohr, N; Muller, JE; Seedat, S; Stein, DJ; van Rheede van Oudtshoorn, E, 2003) |
| "Depression in Parkinson's disease (PD) is associated with faster progression of physical symptoms, greater decline in cognitive skills, and greater decline in the ability to care for oneself." | 6.71 | Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. ( Kaufman, K; Lauritano, M; Marin, H; Mark, M; Menza, M, 2004) |
| "Escitalopram has been shown to have better efficacy and safety profile than other selective serotonin reuptake inhibitor and serotonin norepinephrine reuptake inhibitor drugs, including racemic citalopram." | 6.50 | Clinical pharmacology review of escitalopram for the treatment of depression. ( Gobburu, J; Pastoor, D, 2014) |
| "Its efficacy in treating depression was evident in both placebo-controlled and comparator trials." | 6.40 | Citalopram in the treatment of depression and other potential uses in psychiatry. ( Levin, GM; Tan, JY, 1999) |
| "Escitalopram metabolism was estimated by the log-transformed dose-corrected concentrations and compared within subpopulations differing in age, gender, renal function, smoking status, body mass index, and comedication." | 5.91 | Low Escitalopram Concentrations in Patients with Depression predict Treatment Failure: A Naturalistic Retrospective Study. ( Amann, F; Brand, J; Eichentopf, L; Gründer, G; Hart, XM, 2023) |
| " It has a narrow therapeutic window and can cause severe toxicity and mortality if the dosage exceeds the safe level." | 5.91 | Toward Personalized Treatment of Depression: An Affordable Citalopram Test based on a Solid-Contact Potentiometric Electrode for at-Home Monitoring of the Antidepressant Dosage. ( Amirghasemi, F; Chen, R; Ma, H; Mousavi, MPS; Ong, V; Tran, A, 2023) |
| "TECAS was comparable to escitalopram in improving depression and related symptoms, with high acceptability, better safety profile, and particular efficacy in reducing trauma-associated depression." | 5.69 | Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for mild-to-moderate depression: An assessor-blinded, randomized, non-inferiority trial. ( Cai, JF; Chen, GB; He, JK; Hou, XB; Jiao, Y; Jin, GX; Liu, Y; Qin, ZS; Rong, PJ; Shi, L; Wang, Y; Wong, YK; Xiao, HB; Xiao, X; Xu, FQ; Yang, XJ; Zhang, JN; Zhang, LL; Zhang, SY; Zhang, ZJ; Zhao, YY; Zheng, Y, 2023) |
| "In 92 patients with MDD, we measured MDD severity with 6- and 17-item versions of the Hamilton Depression Rating Scale (HDRS6 and HDRS17) and the level of sexual function with the Changes in Sexual Functioning Questionnaire at baseline and 4, 8, and 12 weeks after initiating treatment with escitalopram." | 5.69 | Sexual function improves as depressive symptoms decrease during treatment with escitalopram: results of a naturalistic study of patients with major depressive disorder. ( Armand, S; Frokjaer, VG; Giraldi, A; Joergensen, MB; Knudsen, GM; Nielsen, JH; Stenbaek, DS; Weber, S, 2023) |
| "A secondary analysis of data from the multicentre randomised controlled trial The Efficacy of Citalopram Treatment in Acute Ischemic Stroke (TALOS)." | 5.69 | Impact of prestroke physical activity and citalopram treatment on poststroke depressive symptoms: a secondary analysis of data from the TALOS randomised controlled trial in Denmark. ( Andersen, G; Blauenfeldt, RA; Damsbo, AG; Johnsen, SP; Mortensen, JK; Vestergaard, SB, 2023) |
| "This secondary analysis of a randomized clinical trial implemented data-driven clustering in findings from the International Study to Predict Optimized Treatment in Depression, a pragmatic biomarker trial in which patients with MDD were randomized in a 1:1:1 ratio to antidepressant treatment with escitalopram, sertraline, or venlafaxine extended-release and assessed at baseline and 8 weeks on multimodal outcomes between December 1, 2008, and September 30, 2013." | 5.69 | A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. ( Hack, LM; Hilton, R; Jubeir, J; Korgaonkar, MS; O'Hara, R; Olmsted, AM; Schatzberg, AF; Tozzi, L; Williams, LM; Yesavage, JA; Zenteno, S, 2023) |
| "Depression is a common and heterogeneous mental disorder." | 5.62 | Characterization of gut microbiome in mice model of depression with divergent response to escitalopram treatment. ( Chai, T; Duan, J; Fang, L; Hu, X; Huang, Y; Ji, P; Li, Y; Song, J; Tan, X; Wu, J; Xie, P; Yang, D; Zhang, H; Zhao, L; Zheng, P, 2021) |
| "Depression is characterized by significant and low mood." | 5.56 | Folic acid ameliorates depression-like behaviour in a rat model of chronic unpredictable mild stress. ( Cong, Y; Liu, H; Zhou, Y, 2020) |
| "During the study period, a total of 207,946 elderly patients with depression received one of the following 11 antidepressants: sertraline, fluoxetine, paroxetine, escitalopram, citalopram, fluvoxamine, venlafaxine, duloxetine, moclobemide, mirtazapine, and bupropion." | 5.51 | Comparative effectiveness of antidepressants on geriatric depression: Real-world evidence from a population-based study. ( Hsu, CW; Kao, HY; Lin, PY; Tseng, WT; Wang, LJ; Yang, YH, 2022) |
| "Posttraumatic stress disorder (PTSD) is a trauma-induced mental disorder characterised by fear extinction dysfunction in which fear circuit monoamines are possibly associated." | 5.43 | Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory. ( Lin, CC; Liu, YP; Tung, CS, 2016) |
| "Drugs that target glutamate neuronal transmission, such as memantine, offer a novel approach to the treatment of late-life depression, which is frequently comorbid with cognitive impairment." | 5.41 | Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression. ( Grzenda, A; Laird, KT; Lavretsky, H; Siddarth, P; Yeargin, J, 2021) |
| "gov, NCT01278498), a randomized, placebo-controlled, double-blind trial that examined the efficacy of escitalopram on depression in acute stroke patients (237 with placebo, 241 with escitalopram)." | 5.41 | Post-Stroke Depressive Symptoms: Varying Responses to Escitalopram by Individual Symptoms and Lesion Location. ( Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, MS; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Lee, JS; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2021) |
| "Escitalopram treatment did not effect the reduced levels of NR2B resulting from depression." | 5.37 | Effects of venlafaxine and escitalopram treatments on NMDA receptors in the rat depression model. ( Cure, MC; Demirdas, A; Eren, I; Kirbas, A; Sutcu, R; Yilmaz, M; Yilmaz, N, 2011) |
| "One hypothesis of depression is that it is caused by reduced neuronal plasticity including hippocampal neurogenesis." | 5.36 | The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression. ( Bjørnebekk, A; Brené, S; Mathé, AA, 2010) |
| "Weekly antidepressant dose was measured in 380 men and women with major depression treated with escitalopram or nortriptyline for 12 weeks as part of the Genome Based Therapeutic Drugs for Depression (GENDEP) study." | 5.34 | Estimating dose-response for time to remission with instrumental variable adjustment: the obscuring effects of drug titration in Genome Based Therapeutic Drugs for Depression Trial (GENDEP): clinical trial data. ( Emsley, R; Hellier, J; Pickles, A, 2020) |
| "gov, NCT01278498), a randomized, placebo-controlled, double-blind trial that examined the efficacy of escitalopram for 3 months on depression in patients with acute stroke." | 5.34 | Depressive Symptoms in Stroke Patients: Are There Sex Differences? ( Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2020) |
| "These results provide novel information on the efficacy of sertraline and escitalopram in the treatment of apathy and depression, respectively, in patients with AD." | 5.34 | The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP). ( Abe, K; Hishikawa, N; Matsumoto, N; Nomura, E; Ohta, Y; Omote, Y; Sasaki, R; Tadokoro, K; Takemoto, M; Tsunoda, K; Yamashita, T, 2020) |
| " One hundred and sixty patients with MDD and comorbid obesity will be randomised 1:1 to simvastatin or placebo as add-on to standard antidepressant medication with escitalopram." | 5.34 | Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial. ( Chae, WR; Ettrich, B; Friede, T; Gold, SM; Grabe, HJ; Hegerl, U; Hinkelmann, K; Hofmann, T; Janowitz, D; Junghanns, K; Kaczmarczyk, M; Kahl, KG; Klein, JP; Krueger, THC; Leicht, G; Lischewski, S; Märschenz, S; Nowacki, J; Otte, C; Piber, D; Prvulovic, D; Reif, A; Roepke, S; Schmidt, S; Schoettle, D; Strauss, M; Westermair, A, 2020) |
| "Depression is a common problem in elderly patients and frequently is treated with antidepressants." | 5.33 | Recurrent hyponatremia associated with citalopram and mirtazapine. ( Akcay, A; Bavbek, N; Kargili, A; Kaya, A, 2006) |
| " After 4 weeks of open-label treatment with 10-20 mg of escitalopram per day, non-remitters [Montgomery-Åsberg Depression Rating Scale (MADRS) score > 10] were randomized 1:1 for double-blind treatment with either escitalopram (30 mg per day) or escitalopram (20 mg per day) plus placebo for 6 weeks." | 5.30 | A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder. ( Ahn, YM; Kim, EY; Kim, HY; Kim, SH; Lee, HJ; Lee, NY; Park, CHK, 2019) |
| "To test the role of escitalopram on blood pressure and heart rate of individuals with hypertension and depression." | 5.30 | Effects of SSRI medication on heart rate and blood pressure in individuals with hypertension and depression. ( Cesaretti, M; Hood, SD; Peixoto, MF; Tavares, A, 2019) |
| "This study aimed to investigate whether social support deficit has moderating effects on depressive and cardiac outcomes in an antidepressant trial for depressed patients with acute coronary syndrome as a secondary analysis using Escitalopram for DEPression in acute coronary syndrome study (ClinicalTrial." | 5.30 | Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: Findings from the EsDEPACS study. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, JW; Kim, SW; Shin, IS; Yoon, JS, 2019) |
| "A large, randomized, multicenter practical trial (International Study to Predict Optimized Treatment in Depression) in patients with current nonpsychotic MDD (N = 1,008; 722 completers) had three arms: escitalopram, sertraline, and venlafaxine-extended release." | 5.30 | Heart rate variability as a biomarker of anxious depression response to antidepressant medication. ( Gotlib, IH; Kircanski, K; Williams, LM, 2019) |
| "This report used acute treatment data from a clinically representative sample of outpatients with nonpsychotic major depressive disorder (N = 665) participating in the Combining Medications to Enhance Depression Outcomes trial, who received up to 12 weeks of escitalopram, escitalopram plus bupropion SR, or venlafaxine XR plus mirtazapine." | 5.30 | The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. ( Carmody, TJ; De La Garza, N; Grannemann, BD; Killian, MO; Rush, AJ; Trivedi, MH, 2019) |
| " We conducted a 52 week, placebo-controlled add-on trial of citalopram in patients with FES who did not meet criteria for major depression to determine whether maintenance therapy with citalopram would improve outcomes by preventing or improving negative and depressive symptoms." | 5.30 | Citalopram in first episode schizophrenia: The DECIFER trial. ( Ardekani, BA; Bello, I; Cather, C; Diminich, E; Fan, X; Freudenreich, O; Goff, DC; Holt, D; Li, C; Tang, Y; Troxel, A; Wang, J; Worthington, M; Wu, R; Zeng, B; Zhao, J, 2019) |
| " Eligible participants are those who: are between the ages of 18 and 74 years; have had at least two episodes of depression; and have been taking antidepressants for 9 months or more and are currently taking citalopram 20 mg, sertraline 100 mg, fluoxetine 20 mg or mirtazapine 30 mg but are well enough to consider stopping their medication." | 5.30 | A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRes ( Bacon, F; Clarke, CS; Donkor, Y; Duffy, L; Freemantle, N; Gilbody, S; Hunter, R; Kendrick, T; Kessler, D; King, M; Lanham, P; Lewis, G; Mangin, D; Marston, L; Moore, M; Nazareth, I; Wiles, N, 2019) |
| "Data were analyzed from 174 patients aged 75 years and older with unipolar depression who were randomly assigned to citalopram or placebo." | 5.27 | A Machine Learning Approach to Identifying Placebo Responders in Late-Life Depression Trials. ( Brown, PJ; Roose, SP; Rutherford, BR; Zilcha-Mano, S, 2018) |
| "To investigate the effect on long-term major adverse cardiac events (MACE) of escitalopram treatment of depression in patients with recent ACS." | 5.27 | Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JH; Kim, JM; Kim, JW; Kim, MC; Kim, SW; Lee, HJ; Lee, YS; Shin, IS; Stewart, R; Yoon, JS, 2018) |
| "136 elderly patients with depression were divided into EGb + citalopram (Cit) group and Cit group equally." | 5.27 | Role of Ginkgo biloba extract as an adjunctive treatment of elderly patients with depression and on the expression of serum S100B. ( Dai, CX; Hu, CC; Shang, YS; Xie, J, 2018) |
| " Of the 125 evaluable patients with stages II through IV HNC but without baseline depression, 60 were randomized to prophylactic antidepressant escitalopram oxalate and 65 to placebo at the time of the initial diagnosis." | 5.27 | Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial. ( Burke, WJ; Lydiatt, WM; Panwar, A; Rieke, K; Sayles, H, 2018) |
| "We analyzed data (collected during 1999-2002) from 174 patients 75 years or older, with unipolar depression (based on DSM-IV), who were randomly assigned to citalopram or placebo." | 5.27 | Abrupt Symptom Improvements in Antidepressant Clinical Trials: Transient Placebo Effects or Therapeutic Reality? ( Brown, PJ; Roose, SP; Rutherford, BR; Zilcha-Mano, S, 2018) |
| "We reanalyzed data of 174 patients aged 75 years and older with unipolar depression who were randomly assigned to citalopram or placebo." | 5.24 | Early Symptom Trajectories as Predictors of Treatment Outcome for Citalopram Versus Placebo. ( Brown, PJ; Roose, SP; Rutherford, BR; Zilcha-Mano, S, 2017) |
| "To investigate the efficacy and tolerability of escitalopram in the treatment of depression in AD." | 5.24 | The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects. ( An, H; Choi, B; Han, SH; Hong, CH; Kim, DH; Kim, SY; Park, KW; Yang, DW, 2017) |
| " Patients who had had an acute stroke within the past 21 days were randomly assigned in a 1:1 ratio to receive oral escitalopram (10 mg/day) or placebo for 3 months." | 5.24 | Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. ( Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2017) |
| "This study re-examined patients from a 1-year randomized controlled double-blind trial of escitalopram, problem-solving therapy (PST), or placebo to prevent depression among patients less than 3 months after a stroke." | 5.24 | Prevention of Poststroke Mortality Using Problem-Solving Therapy or Escitalopram. ( Jorge, RE; Long, J; Robinson, RG, 2017) |
| "Citalopram and venlafaxine are equally more effective than placebo in reducing sleep disturbance and severity of hot flashes, while citalopram is more effective in reducing frequency of hot flashes than venlafaxine." | 5.22 | Comparison of citalopram and venlafaxine's role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial. ( Asadi, M; Davari-Tanha, F; Hadizadeh, H; Shariat, M; Shirazi, M; Soleymani-Farsani, M, 2016) |
| "We measured changes in BDNF messenger RNA (mRNA) expression and whole-blood BDNF levels in 80 healthy first-degree relatives of patients with depression randomly allocated to receive daily tablets of escitalopram 10 mg versus placebo for 4 weeks." | 5.22 | No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial. ( Gether, U; Gluud, C; Kessing, LV; Knorr, U; Koefoed, P; Soendergaard, MH; Vinberg, M; Wetterslev, J; Winkel, P, 2016) |
| " Of the 294 patients with depression, 207 participated in a 24-week double blind trial of escitalopram or placebo." | 5.22 | Influences of the Big Five personality traits on the treatment response and longitudinal course of depression in patients with acute coronary syndrome: A randomised controlled trial. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kim, JM; Kim, SW; Kim, SY; Shin, IS; Stewart, R; Yoon, JS, 2016) |
| " Successful treatment of depression and anxiety with escitalopram had significant beneficial effects on suicidal ideation in these patients." | 5.22 | Determinants and escitalopram treatment effects on suicidal ideation in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, H; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Yoon, JS, 2016) |
| "To determine whether 24 months of treatment with escitalopram improves mortality, morbidity, and mood in patients with chronic systolic heart failure and depression." | 5.22 | Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. ( Angermann, CE; Blankenberg, S; Böhm, M; Deckert, J; Edelmann, F; Ertl, G; Faller, H; Gelbrich, G; Gottwik, M; Graf, T; Gunold, H; Haass, M; Kindermann, I; Pankuweit, S; Prettin, C; Schunkert, H; Störk, S; Wachter, R, 2016) |
| "We investigated roles of plasma homocysteine and MTHFR gene in relation to risks and treatment responses of depression in ACS." | 5.22 | Predictive value of homocysteine for depression after acute coronary syndrome. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, H; Kang, HJ; Kim, JM; Kim, SW; Moon, WJ; Shin, IS; Stewart, R; Yoon, JS, 2016) |
| "Escitalopram may prevent depression following acute coronary syndrome." | 5.20 | Prevention of depression in patients with acute coronary syndrome (DECARD) randomized trial: effects on and by self-reported health. ( Birket-Smith, M; Hanash, JA; Hansen, BH; Hjorthøj, CR; Rasmussen, A, 2015) |
| "The aim of this open trial was to assess the antidepressant/anxiolytic effects of oxytocin used as an adjunct to antidepressant in treatment-resistant depression." | 5.20 | Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: an open trial. ( Ansseau, M; Geenen, V; Hansenne, M; Legros, JJ; Scantamburlo, G, 2015) |
| "To investigate the correlates of sleep disturbance and to assess escitalopram treatment effects of depression on sleep disturbance in patients with acute coronary syndrome (ACS)." | 5.20 | Correlates and Escitalopram Treatment Effects on Sleep Disturbance in Patients with Acute Coronary Syndrome: K-DEPACS and EsDEPACS. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Stewart, R; Yoon, JS, 2015) |
| "Two hundred and sixty-five patients meeting criteria for a DSM-IV diagnosis of alcohol abuse or dependence were randomly assigned to receive placebo or citalopram 20 mg per day for the first week, followed by 40 mg per day from weeks 2 through 12." | 5.20 | Poorer Drinking Outcomes with Citalopram Treatment for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial. ( Charney, DA; Gill, KJ; Heath, LM; Palacios-Boix, J; Zikos, E, 2015) |
| "The objectives were to characterize latent depression subtypes by symptoms, evaluate sex differences in and examine correlates of these subtypes, and examine the association between subtype and symptom remission after citalopram treatment." | 5.20 | The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. ( Lapane, KL; Rothschild, AJ; Ulbricht, CM, 2015) |
| " Escitalopram provided no advantage over placebo in either abstinence rates from cannabis or anxiety and depression scores during the withdrawal and abstinent periods." | 5.19 | Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. ( Bar-Hamburger, R; Bloch, M; Bluvstein, I; Miller, H; Rapoport, E; Schreiber, S; Weinstein, AM, 2014) |
| "In this study, we assessed the efficacy of 2 pharmacodynamically different antidepressants, citalopram (a selective serotonin reuptake inhibitor) and reboxetine (a norepinephrine reuptake inhibitor), as adjunctive therapy to risperidone and olanzapine for the treatment of negative symptoms in schizophrenia." | 5.19 | Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. ( Bernardo, M; Caballero, M; Corripio, I; Felipe, AE; Fernandez de Corres, B; González Piqueras, JC; Huerta, R; Ibáñez, A; Iniesta, R; López-Carrilero, R; Oliveira, C; Roca, M; Rodriguez-Jimenez, R; Sindreu, SD; Usall, J, 2014) |
| "Depression occurred in 14 patients receiving placebo and in 5 patients receiving escitalopram (Pearson χ², P = ." | 5.19 | Effects of escitalopram prophylaxis during antiviral treatment for chronic hepatitis C in patients with a history of intravenous drug use and depression. ( Bezemer, G; de Knegt, RJ; Hansen, BE; Hotho, DM; Janssen, HL; Van Gool, AR; Veldt, BJ, 2014) |
| " We investigated the effectiveness of citalopram in the treatment of childhood functional abdominal pain (FAP)." | 5.19 | Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial. ( Gholamrezaei, A; Pourmoghaddas, Z; Roohafza, H; Saneian, H, 2014) |
| "Objective: To assess the efficacy of selective serotonin reuptake inhibitor (SSRI) escitalopram in patients with functional dyspepsia (FD)." | 5.19 | [Psychopharmacological approach with the usage of selective serotonin reuptake inhibitors in functional dyspepsia treatment]. ( Korendovych, IV; Maliarov, SO; Revenok, KM; Svintsits'kyĭ, AS, 2014) |
| "Employed depressed outpatients 18-75 years old who completed the Work Productivity and Activity Impairment scale (N=1,928) were treated with citalopram (20-40 mg/day) in the Sequenced Treatment Alternatives to Relieve Depression study." | 5.17 | Increase in work productivity of depressed individuals with improvement in depressive symptom severity. ( Balasubramani, GK; Daly, E; Gaynes, BN; Kurian, BT; Lesser, I; Morris, DW; Nierenberg, AA; Rush, AJ; Trivedi, MH; Wisniewski, SR, 2013) |
| " In the clinical study, sarcosine substantially improved scores of Hamilton Depression Rating Scale, Clinical Global Impression, and Global Assessment of Function more than citalopram treatment." | 5.17 | Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. ( Chang, YC; Chen, KT; Huang, CC; Huang, CL; Huang, KH; Lane, HY; Tsai, GE; Tsai, MH; Tsai, P; Tun, R; Wei, IH, 2013) |
| "5 years) who had a major depressive disorder diagnosed with a Beck Depression Inventory (BDI) test score greater than 16 and confirmed with a structured interview, were prescribed citalopram 20mg once daily." | 5.17 | Treatment of depression in type 2 diabetic patients: effects on depressive symptoms, quality of life and metabolic control. ( Chacártegui, B; Francés, C; Masmiquel, L; Nicolau, J; Rivera, R, 2013) |
| "This was an active-controlled, parallel-group, double-blind, randomized study in a general community comparing escitalopram and duloxetine in patients with severe depression; patients who did not respond (<50% Montgomery-Åsberg Depression Rating Scale [MADRS] improvement) to 2 weeks of single-blind escitalopram 10 mg/day during the lead-in period were randomized to 8 weeks of double-blind treatment." | 5.16 | Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. ( Bose, A; Li, D; Tsai, J, 2012) |
| "To examine whether preemptive antidepressant treatment with escitalopram can decrease the incidence or severity of depression associated with pegylated IFN-α in HCV-infected patients without a history of psychiatric disorders." | 5.16 | Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. ( Baumert, TF; Berg, T; Buggisch, P; Discher, T; Effenberger, S; Friebe, A; Fromm, G; Heinz, A; Heinze, L; Knop, V; Lieb, K; Link, R; Neumann, K; Ockenga, J; Reimer, J; Rentrop, M; Sarkar, R; Schaefer, M; Schlaepfer, T; Spengler, U; Weidenbach, H; Zeuzem, S, 2012) |
| "The DECARD (DEpression in patients with Coronary ARtery Disease) trial assessed the prophylactic effect of escitalopram on depression after ACS." | 5.16 | Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial. ( Birket-Smith, M; Hanash, JA; Hansen, BH; Hansen, JF; Nielsen, OW; Rasmussen, A, 2012) |
| "The authors sought to determine the relative efficacy and tolerability of duloxetine versus citalopram and sertraline in the treatment of poststroke depression (PSD), anxiety, and fatigue." | 5.16 | Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. ( Karaiskos, D; Paparrigopoulos, T; Spengos, K; Tzavellas, E; Vassilopoulou, S, 2012) |
| "The Sequenced Treatment Alternatives to Relieve Depression sample was used to examine the relationship between variations in the CYP2C19 and CYP2D6 genes and remission of depressive symptoms and tolerance to treatment with citalopram." | 5.15 | CYP2C19 variation and citalopram response. ( Biernacka, JM; Black, JL; Cunningham, JM; Drews, MS; Mrazek, DA; O'Kane, DJ; Rush, AJ; Snyder, KA; Stevens, SR; Weinshilboum, RM, 2011) |
| "Fluoxetine and Citalopram can effectively reduce the severity of depression in diabetic patients without an adverse effect on glycemic control." | 5.15 | Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram? ( Khazaie, H; Najafi, F; Rahimi, M; Rezaei, M; Tahmasian, M; Tatari, F, 2011) |
| "Outpatients with chronic or recurrent major depression (MDD) were randomized to initial treatment with escitalopram+placebo (the MONO condition), bupropion-sustained release+escitalopram, or venlafaxine-extended release+mirtazapine (the COMB conditions) in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial." | 5.15 | Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. ( Bobo, WV; Chen, H; Cook, IA; Fava, M; Husain, MM; Kornstein, SG; Kurian, BT; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Shelton, RC; Stewart, JW; Trivedi, MH; Warden, D; Wisniewski, SR, 2011) |
| "The findings suggest that cortical and limbic SERT occupancy may be an underlying mechanism for the regional cerebral metabolic effects of citalopram in geriatric depression." | 5.15 | Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression. ( Flint, A; Kahn, A; Rusjan, P; Sacher, J; Smith, GS; van Eimeren, T; Wilson, AA, 2011) |
| "This study sought to investigate the efficacy of escitalopram at different dosages for the treatment of obsessive-compulsive disorder (OCD)." | 5.14 | Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. ( Deckersbach, T; Dougherty, DD; Jameson, M; Jenike, M; Keuthen, NJ; Loh, R; Thompson-Hollands, J, 2009) |
| "5 mg), B6 (25 mg) and folic acid (2 mg) or citalopram (20 to 40 mg) plus placebo for the treatment of depression in later life." | 5.14 | The B-VITAGE trial: a randomized trial of homocysteine lowering treatment of depression in later life. ( Almeida, OP; Fenner, S; Flicker, L; Ford, AH; Hegarty, S; Hirani, V; McCaul, K; van Bockxmeer, F, 2010) |
| "This study examined the potential of an antidepressant drug, escitalopram, to improve depression, resilience to stress, and quality of life in family dementia caregivers in a randomized placebo-controlled double-blinded trial." | 5.14 | Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram. ( Irwin, MR; Lavretsky, H; Siddarth, P, 2010) |
| "To examine the effects of citalopram augmentation of antipsychotics on suicidal ideation in middle-aged and older people with schizophrenia and subthreshold depressive symptoms." | 5.14 | Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. ( Fellows, I; Golshan, S; Kasckow, JW; Lanouette, NM; Mohamed, S; Rao, S; Vahia, I; Zisook, S, 2010) |
| "The authors hypothesized that age would moderate the response of patients with schizophrenia and subsyndromal depression (SSD) treated citalopram with depressive symptoms and other outcomes." | 5.14 | Treatment of subsyndromal depressive symptoms in middle-age and older patients with schizophrenia: effect of age on response. ( Fellows, I; Golshan, S; Kasckow, J; Meeks, T; Solorzano, E; Zisook, S, 2010) |
| "To determine the efficacy of citalopram in the treatment of chronic pelvic pain by measuring changes in pain severity, depressive symptoms and functional disability." | 5.13 | Citalopram in the treatment of women with chronic pelvic pain: an open-label trial. ( Brown, CS; Franks, AS; Ling, FW; Wan, J, 2008) |
| "To determine whether treatment with escitalopram or problem-solving therapy over the first year following acute stroke will decrease the number of depression cases that develop compared with placebo medication." | 5.13 | Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. ( Acion, L; Arndt, S; Fonzetti, P; Hegel, M; Jorge, RE; Moser, DJ; Robinson, RG; Small, SL; Solodkin, A, 2008) |
| "Based on available RCTs of fluoxetine and citalopram, SSRIs used for 6 months doubled the risk of fractures in stroke survivors." | 5.12 | Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. ( Almeida, OP; Hankey, GJ; Jones, JS; Kimata, R, 2021) |
| "After three and six weeks of treatment, citalopram significantly improved abdominal pain, bloating, impact of symptoms on daily life, and overall well being compared with placebo." | 5.12 | A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. ( Broekaert, D; Fischler, B; Gevers, AM; Janssens, J; Tack, J; Van Oudenhove, L, 2006) |
| "A similar decrease in weekly rate of panic attacks, in the scores of Hamilton Scale for anxiety and depression and in the Cooper Disability Scale scores, was observed in both groups after 8 weeks, but a significant variation of outcome measures from baseline was observed already after 2 weeks in the escitalopram group (P < 0." | 5.12 | New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. ( Alvano, A; Malaguarnera, M; Raffaele, R; Rampello, L; Vecchio, I, 2006) |
| "Fifty-one elders with major depression participated in a 12-week escitalopram trial." | 5.12 | White-matter integrity predicts stroop performance in patients with geriatric depression. ( Alexopoulos, GS; Ardekani, B; Gunning-Dixon, FM; Hoptman, MJ; Hrabe, J; Kanellopoulos, D; Lim, KO; Murphy, CF; Shanmugham, BR; Shields, JK, 2007) |
| "MOOD-HF is a prospective, randomised, double-blind, placebo-controlled, 2-armed, parallel-group multicenter trial investigating the effects of the serotonin re-uptake inhibitor (SSRI) escitalopram on morbidity and mortality (primary endpoint), severity of depression, anxiety, cognitive function, quality of life and health care expenditure in 700 patients with symptomatic systolic CHF and major depression diagnosed by structured clinical interview." | 5.12 | Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). ( Angermann, CE; Deckert, J; Ertl, G; Faller, H; Fallgatter, A; Gelbrich, G; Störk, S, 2007) |
| "To assess the potential efficacy, tolerability, and safety of citalopram in the treatment of functional pediatric recurrent abdominal pain and comorbid internalizing disorders." | 5.11 | Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study. ( Axelson, D; Birmaher, B; Brent, DA; Bridge, J; Campo, JV; Di Lorenzo, C; Ehmann, M; Kalas, C; Lucas, A; Monk, K; Perel, J; Ryan, N, 2004) |
| "Patients (n=28) with mild to moderate hypertension and depression were given enalapril (20 mg/day)." | 5.11 | [Clinical efficacy of citalopram in patients with hypertension and concomitant depression]. ( Gudkova, OA; Iufereva, IuM; Pogosova, GV; Tikhomirova, EA, 2004) |
| " The patients were assessed on measures of interpretative bias (homophone task), anxiety and depression before being prescribed an SSRI (paroxetine or citalopram)." | 5.11 | Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. ( Baldwin, DS; Bradley, BP; Brodrick, P; Mogg, K, 2004) |
| "The effect of aging on steady-state plasma concentrations of citalopram (CIT) and desmethylcitalopram (DCIT) was investigated in 128 depressive patients treated with 10-80 mg/day CIT." | 5.11 | Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. ( Baumann, P; Brawand-Amey, M; Brogli, C; Cochard, N; de Mendonça Lima, CA; Eap, CB; Jacquet, S; Powell-Golay, K, 2005) |
| "A total of 112 nondemented elderly patients with major depression participated in an 8-week citalopram trial at a target daily dose of 40 mg." | 5.11 | Executive dysfunction and the course of geriatric depression. ( Alexopoulos, GS; Gunning-Dixon, F; Heo, M; Kiosses, DN; Murphy, CF; Shanmugham, B, 2005) |
| "Although citalopram has gained wide acceptance in the treatment of depression and anxiety disorders, its use during pregnancy and lactation has been poorly characterized." | 5.10 | Citalopram in pregnancy and lactation. ( Ekblad, S; Ekblad, U; Heikkinen, T; Kero, P; Laine, K, 2002) |
| "We undertook an open-label pilot study using citalopram in 30 cancer patients who reported a high level of depressive symptoms on the Zung Self-Rating Depression Scale (ZSDS)." | 5.10 | An open label pilot study of citalopram for depression and boredom in ambulatory cancer patients. ( Donaghy, K; Holtsclaw, E; Kirsh, KL; Passik, SD; Theobald, DE, 2003) |
| "The effect of the selective serotonin reuptake inhibitor citalopram was studied in a randomized, double-blind, placebo-controlled, 4-month trial in patients with the fibromyalgia syndrome (FMS) who all fulfilled the American College of Rheumatology criteria." | 5.09 | Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study. ( Anderberg, UM; Marteinsdottir, I; von Knorring, L, 2000) |
| "We conducted a 10-week single-blind trial of citalopram (20-40 mg/day) vs no citalopram augmentation in 19 middle-aged and elderly patients with schizophrenia hospitalized for more than six of the last 12 months." | 5.09 | Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. ( Carroll, B; Jeste, DV; Kasckow, JW; Mohamed, S; Thallasinos, A; Zisook, S, 2001) |
| "We have investigated the ability of citalopram, a serotonin reuptake inhibitor, to alter the functional sensitivity to a neuroactive steroid during the late luteal phase in twelve women with premenstrual syndrome." | 5.08 | Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. ( Bäckström, T; Sundström, I, 1998) |
| "The aim of the study was to investigate the efficacy and safety of the selective serotonin reuptake inhibitor citalopram in treating poststroke depression, since available treatments are usually poorly tolerated." | 5.07 | Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. ( Andersen, G; Lauritzen, L; Vestergaard, K, 1994) |
| " For the key efficacy outcomes, escitalopram, mirtazapine, sertraline, citalopram, venlafaxine and paroxetine were associated with larger reduction of the Hamilton Depression Scale (HAMD) total score compared with placebo at 2 weeks." | 5.05 | Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: A network meta-analysis. ( Li, X; Zhang, C, 2020) |
| "We obtained access to IPD from seven placebo-controlled trials comparing bupropion, duloxetine, escitalopram, mirtazapine, paroxetine or venlafaxine with placebo in the acute phase treatment of major depression (total n = 2803)." | 5.01 | Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. ( Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S, 2019) |
| "To objectively evaluate the efficacy and safety of citalopram versus other antidepressant drugs in poststroke depression (PSD) treatment." | 4.98 | Efficacy and Safety of Citalopram for the Treatment of Poststroke Depression: A Meta-Analysis. ( Cui, M; Huang, CY; Wang, F, 2018) |
| "Sertraline and citalopram should be first-line drug treatments for anxiety and depression in pregnant women in the SSRI class." | 4.95 | What are the risks associated with different Selective Serotonin Re-uptake Inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence. ( Agius, M; Ripullone, K; Womersley, K, 2017) |
| "Sertraline might be effective, though not statistically significant, in treating patients with post-traumatic brain injury depression." | 4.95 | Antidepressants for Depression Associated with Traumatic Brain Injury: A Meta-analytical Study of Randomised Controlled Trials. ( Katsanos, AH; Paraschakis, A, 2017) |
| "83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed." | 4.93 | Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016) |
| "To evaluate the citalopram in post-stroke depression treatment, we compared its use to other selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and traditional Chinese medicines (TCMs)." | 4.91 | Efficacy and Safety of Citalopram in Treating Post-Stroke Depression: A Meta-Analysis. ( Ding, L; Hong, H; Huang, X; Tan, S, 2015) |
| "Antidepressants are effective in treating interferon-α/ribavirin (IFN-α/RBV)-associated depression during or after treatment of chronic hepatitis C (CHC)." | 4.89 | Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials? ( Hou, XJ; Wang, J; Xu, JH; Yu, YY, 2013) |
| " Citalopram, one of the first selective serotonin reuptake inhibitors (SSRI) introduced in the market, is one of these antidepressant drugs that clinicians use for routine depression care." | 4.88 | Citalopram versus other anti-depressive agents for depression. ( Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; Imperadore, G; Purgato, M; Signoretti, A; Trespidi, C; Watanabe, N, 2012) |
| "The recent clinical studies on hypericum extract support the present indications for its use in mild to moderate depression and depressive episodes." | 4.84 | [New developments in hypericum extracts: data on efficacy and interactions]. ( Kraft, K, 2007) |
| "Escitalopram oxalate (S-citalopram, Lexapro), a selective serotonin re-uptake inhibitor antidepressant which is the S-enantiomer of citalopram, is in clinical development worldwide for the treatment of depression and anxiety disorders." | 4.81 | Escitalopram. ( Burke, WJ, 2002) |
| "Data of 1296 outpatients with nonpsychotic depression who entered a 12-month naturalistic follow-up period after achieving remission with citalopram for up to 14 weeks were analyzed." | 4.31 | Predicting relapse from the time to remission during the acute treatment of depression: A re-analysis of the STAR*D data. ( Kubo, K; Mimura, M; Sakurai, H; Tani, H; Uchida, H; Watanabe, K, 2023) |
| "Although escitalopram is known to be an effective drug for adult depression, its disease-modifying efficacy on adolescents remains controversial." | 4.31 | Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression. ( Choi, JY; Han, SJ; Kang, KJ; Lee, N; Nam, KR; Oh, SJ, 2023) |
| "Treatment of major depression disorder with Selective serotonin reuptake inhibitors (SSRIs), such as citalopram (CTM), during pregnancy effects on the neurological trajectory of the offspring and induces enduring consequences, notably emotional and cognitive impairment." | 4.12 | Prenatal exposure of citalopram elicits depression-like and anxiety-like behaviors and alteration of morphology and protein expression of medial prefrontal cortex in young adult mice. ( Butt, MU; Du, L; Jia, M; Wang, Q; Wang, Y; Wu, J; Zahra, A, 2022) |
| " monnieri improves depression comparable to citalopram in reserpine-induced depression." | 4.12 | Neuroprotective role of Bacopa monnieri extract in modulating depression in an experimental rat model. ( Al-Shafei, AI; Daoud, NN; El-Gendy, OA; Zaazaa, AM, 2022) |
| "This study was done to evaluate the effect of co-treatment of orexin agents along with citalopram on the modulation of depression-like behavior and the expression of BDNF in the prefrontal cortex (PFC) of sleep-deprived male mice." | 4.12 | Synergistic antidepressant effects of citalopram and SB-334867 in the REM sleep-deprived mice: Possible role of BDNF. ( Alibeik, H; Bananej, M; Khakpai, F; Saadati, N; Zarrindast, MR, 2022) |
| " Individual and combinations of 19 immunomarkers were modeled as moderators between the three treatment arms (escitalopram monotherapy, escitalopram-bupropion and venlafaxine-mirtazapine) across a variety of depression outcomes." | 4.02 | Comparison of inflammatory markers as moderators of depression outcomes: A CO-MED study. ( Carmody, T; Chin-Fatt, C; Czysz, AH; Li, Q; Mason, BL; Minhajuddin, A; Trivedi, MH, 2021) |
| " The current work leverages genome-wide genetic variation and machine learning to predict response to the antidepressant citalopram using data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial (n = 1257 with both valid genomic and outcome data)." | 4.02 | Inclusion of genetic variants in an ensemble of gradient boosting decision trees does not improve the prediction of citalopram treatment response. ( Beevers, CG; Mallard, TT; McGeary, JE; Shumake, J, 2021) |
| "Intranasal treatment with oxytocin showed beneficial effects in post-traumatic stress disorder and autism spectrum disorders; however, it was not investigated as much in depression." | 4.02 | Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy. ( Batinić, B; Gurwitz, D; Israel-Elgali, I; Jukić, M; Oved, K; Pešić, V; Puškaš, N; Shomron, N; Stanić, D, 2021) |
| " Eighty-seven participants in the first Canadian Biomarker Integration Network in Depression (CAN-BIND-1) protocol received 8 weeks of open-label escitalopram." | 3.96 | Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. ( Arnott, SR; Ceniti, AK; Davis, AD; Downar, J; Dunlop, K; Foster, JA; Frey, BN; Harris, JK; Hassel, S; Kennedy, SH; Lam, RW; MacQueen, GM; Mansouri, F; Milev, R; Parikh, SV; Rizvi, SJ; Rotzinger, S; Schulze, L; Soares, CN; Strother, SC; Turecki, G; Uher, R; Zamyadi, M, 2020) |
| "This study aims to assess the efficacy and safety of citalopram for the treatment of patients with post-stroke depression (PSD)." | 3.96 | Does citalopram effectively treat post-stroke depression?: A protocol for systematic review and meta analysis. ( Hu, J; Ma, L; Yang, ZY, 2020) |
| "Long-term treatment with tricyclic antidepressants, Hypericum perforatum, or escitalopram may be associated with reduced incidence of dementia." | 3.96 | To Be Continued? Long-Term Treatment Effects of Antidepressant Drug Classes and Individual Antidepressants on the Risk of Developing Dementia: A German Case-Control Study. ( Bartels, C; Belz, M; Bohlken, J; Hessmann, P; Kostev, K; Vogelgsang, J; Wiltfang, J, 2020) |
| "Escitalopram, a drug of choice in the treatment of depression, was recently shown to possess an anti-inflammatory activity." | 3.91 | Potential Anti-Inflammatory Effect of Escitalopram in Iodoacetamide-Induced Colitis in Depressed Ovariectomized Rats: Role of α7-nAChR. ( Abdelsalam, RM; Abdo, SA; Khattab, MM; Wadie, W, 2019) |
| "A recent review proposed four criteria for an animal model of treatment-resistant depression (TRD): a phenotypic resemblance to a risk factor for depression; enhanced response to stress; nonresponse to antidepressant drugs and response to treatments effective in TRD, such as deep brain stimulation (DBS) of the prefrontal cortex or ketamine." | 3.91 | Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression. ( Gruca, P; Lason, M; Litwa, E; Niemczyk, M; Papp, M; Tota-Glowczyk, K; Willner, P, 2019) |
| "We therefore superimposed maternal separation (MS) onto a genetic rat model (Flinders-sensitive and -resistant lines, FSL/FRL) of depression, treated these rats with antidepressants (escitalopram and nortriptyline) and measured CGRP-LI in selected brain regions." | 3.91 | CGRP in a gene-environment interaction model for depression: effects of antidepressant treatment. ( Angelucci, F; El Khoury, A; Ellenbroek, BA; Mathé, AA, 2019) |
| " A treatment with escitalopram reversed depression-like behavior accompanied by reductions in BDNF levels in serum and the nucleus accumbens, while a treatment with blonanserin ameliorated abnormal social interaction behavior with reductions in serum BDNF levels." | 3.91 | Antidepressant activities of escitalopram and blonanserin on prenatal and adolescent combined stress-induced depression model: Possible role of neurotrophic mechanism change in serum and nucleus accumbens. ( Deriha, K; Furuse, K; Hashiguchi, H; Hashimoto, E; Ishii, T; Kawanishi, C; Kigawa, Y; Shiraishi, M; Tayama, M; Ukai, W, 2019) |
| "Citalopram (CTM), a selective serotonin reuptake inhibitor (SSRI), has been widely used to treat panic disorders, such as depression which is one of the most disabling, yet common, psychiatric disorders." | 3.91 | Exposure to prenatal antidepressant alters medial prefrontal-striatal synchronization in mice. ( Chen, Y; Jiang, J; Long, C; Yang, L; Zahra, A; Zheng, Y, 2019) |
| "This study compares the risks of arrhythmia among patients with depression receiving selective serotonin reuptake inhibitors (SSRIs) and those receiving other classes of antidepressants and among patients with depression receiving citalopram-escitalopram and those receiving other SSRIs." | 3.91 | Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study. ( Hansen, RA; Lin, YT; Lu, TS; Wang, CC, 2019) |
| "In this item-based, patient-level, post-hoc analysis, we pooled data from all completed, acute-phase, placebo-controlled, industry-sponsored, HDRS-based trials of the SSRIs citalopram, paroxetine, or sertraline in adult major depression." | 3.91 | Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. ( Eriksson, E; Hieronymus, F; Lisinski, A; Nilsson, S, 2019) |
| " In this study, we examined the molecular effects associated with a response to a week-long treatment with escitalopram in the chronic escape deficit (CED) model, a validated model of depression based on the induction of an escape deficit after exposure of rats to an unavoidable stress." | 3.88 | Molecular changes associated with escitalopram response in a stress-based model of depression. ( Alboni, S; Benatti, C; Blom, JMC; Brunello, N; Mendlewicz, J; Tascedda, F, 2018) |
| "This retrospective study investigated the efficacy and safety of escitalopram oxalate (ESO) for the treatment of post-stroke depression (PSD)." | 3.88 | Efficacy of escitalopram oxalate for patients with post-stroke depression. ( Jiang, P; Xu, JH, 2018) |
| "Thirty-two medication-free patients with depression were treated for 6 weeks with a selective serotonin reuptake inhibitor, escitalopram." | 3.88 | Predicting Treatment Response in Depression: The Role of Anterior Cingulate Cortex. ( Browning, M; Cowen, PJ; Godlewska, BR; Harmer, CJ; Igoumenou, A; Norbury, R, 2018) |
| "The effect of two second-generation antidepressants escitalopram and venlafaxine on the activity of brain and liver cytochrome P450 2D (CYP2D) involved in the metabolism of psychotropics and neurotransmitters was determined in the chronic mild stress (CMS) model of depression." | 3.88 | The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat. ( Daniel, WA; Haduch, A; Papp, M; Rysz, M, 2018) |
| " Using maternal separation (MS), a paradigm of early adversity, we investigated the effects of adolescent (PND 33-54) escitalopram (ES; 10mg/kg) exposure on depression- and anxiety-like behaviours and the levels of inflammatory cytokines (interleukin [IL]-1β, tumor necrosis factor [TNF]-α, and IL-10) in the ventral hippocampus (HPV), prefrontal cortex (PFC), and serum in adult (PND 61) male offspring mice." | 3.85 | Adolescent escitalopram prevents the effects of maternal separation on depression- and anxiety-like behaviours and regulates the levels of inflammatory cytokines in adult male mice. ( Dong, X; Geng, Z; Jin, Y; Li, N; Li, X; Lin, Y; Liu, M; Sun, A; Wang, Q; Wang, Y, 2017) |
| "A 63-year-old woman with a history of long-standing depression, maintained on escitalopram, presented with altered mental status." | 3.85 | Serotonin syndrome caused by drug to drug interaction between escitalopram and dextromethorphan. ( Arcega, V; Dy, P; Ghali, W; Wolfe, W, 2017) |
| " The aim of the present study was to investigate whether stress-induced anhedonia could be prevented by treatments with escitalopram or novel herbal treatment (NHT) in an animal model of depression." | 3.85 | Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. ( Barak, S; Burstein, O; Chen, G; Doron, R; Franko, M; Gale, E; Handelsman, A; Hirshler, Y; Motsan, S; Shamir, A; Simhon, O; Toledano, R, 2017) |
| " The aim of the present study was to clarify whether plant-derived isoflavone puerarin could ameliorate comorbid depression and pain." | 3.85 | Plant Natural Product Puerarin Ameliorates Depressive Behaviors and Chronic Pain in Mice with Spared Nerve Injury (SNI). ( Lao, L; Liang, Z; Luo, D; Rong, J; Zhao, J, 2017) |
| " Despite extended residual persistence of dichlorodiphenyltrichloroethane (DDT) in the environment, the mechanisms of perinatal actions of DDT that could account for adult-onset of depression are largely unknown." | 3.85 | Depressive-like effect of prenatal exposure to DDT involves global DNA hypomethylation and impairment of GPER1/ESR1 protein levels but not ESR2 and AHR/ARNT signaling. ( Grochowalski, A; Kajta, M; Lason, W; Litwa, E; Nalepa, I; Rogóż, Z; Rzemieniec, J; Wnuk, A; Wojtowicz, AK; Zelek-Molik, A, 2017) |
| "To characterize the association between functional impairment and major depression subtypes at baseline and to characterize changes in subtypes by functional impairment level in women receiving citalopram in level 1 of the Sequenced Treatment Alternatives to Relieve Depression trial." | 3.83 | Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis. ( Lapane, KL; Rothschild, AJ; Ulbricht, CM, 2016) |
| " We report the development of severe hyponatremia leading to adverse clinical effects due to escitalopram and thiazide diuretic use concomitantly in a patient with depression after emergency coronary artery bypass grafting." | 3.83 | Hyponatremia Due to Escitalopram and Thiazide Use After Cardiac Surgery. ( Aksoy, E; Çağlı, K; Diken, Aİ; Doğan, İ; Erçen Diken, Ö; Yalçınkaya, A; Yılmaz, S, 2016) |
| "The combination of acamprosate and escitalopram suppressed EtOH intake in both nonstressed and stressed mice; hence, this combination is potentially helpful for AUD individuals with or without comorbid depression to reduce alcohol use." | 3.83 | Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice. ( Aguiar, FS; Choi, DS; Hinton, DJ; Ho, AM; Jia, YF; Karpyak, VM; Qiu, Y; Weinshilboum, RM, 2016) |
| " This study, therefore, sought to compare the therapeutic effects of 10-Hz pulsed wave NIR (810 nm) laser with red (630 nm) laser using the same delivered energy density and Citalopram in rat chronic mild stress (CMS) model of depression and anxiety." | 3.83 | Therapeutic effects of 10-HzPulsed wave lasers in rat depression model: A comparison between near-infrared and red wavelengths. ( Mohaddes, G; Rasta, SH; Sadigh-Eteghad, S; Salarirad, S; Salehpour, F, 2016) |
| " Moreover we also investigated their utility as adjunct treatment in depression in combination with the SSRI citalopram." | 3.83 | Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study. ( Björkholm, C; Feltmann, K; Jardemark, K; Konradsson-Geuken, Å; Malmerfelt, A; Marcus, MM; Möller, A; Påhlsson, N; Schilström, B; Svensson, TH, 2016) |
| "Several clinical reports have documented a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants, in particular selective serotonin reuptake inhibitors (SSRI), in the treatment of drug-resistant depression and treatment-resistant anxiety disorders." | 3.83 | The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats. ( Kaminska, K; Rogoz, Z, 2016) |
| "5, 5 or 10mg/kg) significantly reversed depression-like behaviours in chronically stressed rats, including reduced sucrose preference, decreased locomotor activity, and prolonged time to begin eating." | 3.81 | The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor. ( Chen, HX; Gao, N; Jin, ZL; Li, XR; Li, YF; Tang, Y; Xiong, J; Xue, R, 2015) |
| "We explored the links between both P450 genotype and serum concentrations of antidepressant with antidepressant side effects, using data from the Genome-Based Therapeutic Drugs for Depression Project (GENDEP), which is a large (n = 868), pharmacogenetic study of depressed individuals treated with escitalopram or nortriptyline." | 3.81 | Exploring the role of drug-metabolising enzymes in antidepressant side effects. ( Aitchison, KJ; Craig, IW; Dernovšek, MZ; Dobson, RJ; Farmer, AE; Hauser, J; Henigsberg, N; Hodgson, K; Maier, W; McGuffin, P; Mors, O; Placentino, A; Rietschel, M; Souery, D; Tansey, KE; Uher, R, 2015) |
| "Considering the gene X environment hypothesis of depression, the present study investigated the effect of chronic ozone inhalation on depression and anxiety-related behavior, cognition, and brain markers of oxidative stress in the Flinders Sensitive Line (FSL) rat." | 3.81 | Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response. ( Brink, CB; Ellis, SM; Harvey, BH; Mokoena, ML; Viljoen, F, 2015) |
| "Dysfunction of cognitive control functions, but not reward-related decision making, may influence the decline of symptoms and the probability of remission of late-life depression treated with escitalopram." | 3.81 | Cognitive control, reward-related decision making and outcomes of late-life depression treated with an antidepressant. ( Alexopoulos, GS; Banerjee, S; Gunning, F; Kanellopoulos, D; Manning, K; McGovern, A; Seirup, JK, 2015) |
| "The authors reported a case of serotonin syndrome associated with combined therapy of monoamine oxidase-B inhibitors and selective serotonin reuptake inhibitor A 77-year-old Thai man had been taking escitalopram for depression for three years." | 3.81 | Combination of Escitalopram and Rasagiline Induced Serotonin Syndrome: A Case Report and Review Literature. ( Santimaleeworagun, W; Supasyndh, O; Suphanklang, J, 2015) |
| "Using data from the GenPod trial this study investigates: (i) if depressed individuals with multiple physical symptoms have a poorer response to antidepressants before and after adjustment for baseline Beck Depression Inventory II (BDI-II); and (ii) if reboxetine is more effective than citalopram in depression with multiple physical symptoms." | 3.80 | Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial. ( Button, KS; Crawford, A; Green, A; Lewis, G; Nutt, D; Peters, TJ; Wiles, N, 2014) |
| "Female rats implanted with 28-day osmotic minipumps delivering the SSRI escitalopram throughout pregnancy had serum escitalopram concentrations in a clinically observed range (17-65 ng/ml)." | 3.79 | Prenatal exposure to escitalopram and/or stress in rats: a prenatal stress model of maternal depression and its treatment. ( Boss-Williams, KA; Bourke, CH; Capello, CF; Owens, MJ; Rogers, SM; Stowe, ZN; Weiss, JM; Yu, ML, 2013) |
| "To evaluate the risk factors of psychiatric adverse events associated with PEG interferon and ribavirin treatment for chronic hepatitis C and assess the efficacy of escitalopram intervention for these adverse effects." | 3.79 | [Escitalopram for intervention of psychiatric adverse events during peginterferon-alfa-2a and ribavirin treatment for chronic hepatitis C]. ( Pan, J; Qi, M; Su, M; Zhang, H; Zhou, B, 2013) |
| "To assess the comparative-effectiveness of three antidepressants (escitalopram, citalopram, sertraline) commonly-prescribed for depression in Medicare." | 3.78 | Assessing the comparative-effectiveness of antidepressants commonly prescribed for depression in the US Medicare population. ( Kaplan, C; Zhang, Y, 2012) |
| "In C6 glioma cells, we studied acute administration of SSRI antidepressants - fluoxetine, sertraline and citalopram." | 3.78 | Effect of fluoxetine and adenosine receptor NECA agonist on G alpha q/11 protein of C6 glioma cells. ( Kováru, F; Kovárů, H; Lisá, V, 2012) |
| "Out-patients (n=2876) with MDD were treated in the first step of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial with citalopram up to 60 mg/day for up to 14 weeks." | 3.76 | Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. ( Cook, IA; Fava, M; Gilmer, WS; Husain, MM; Leuchter, AF; Luther, JF; Rush, AJ; Trivedi, MH; Wisniewski, SR, 2010) |
| "We investigated the hypothesis that hippocampal neurogenesis related to Notch1 signaling could be a valid index for a combined citalopram and WAY100635 pharmacotherapy for the treatment of depression arising after stroke." | 3.76 | Notch1 signaling related hippocampal neurogenesis in adult poststroke depression rats: a valid index for an efficient combined citalopram and WAY100635 pharmacotherapy. ( Guo, YJ; Sui, YX; Sun, Y; Wang, SH; Zhang, ZJ, 2010) |
| "Breast cancer patients with indications for an SSRI may be prescribed citalopram - and possibly other SSRI - without adversely affecting the outcome of adjuvant therapy with tamoxifen." | 3.76 | Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2010) |
| "The purpose of this study was to analyze the antidepressant-like actions of estradiol valerate (1 or 2 mg/rat, single injection) or citalopram (5 or 10 mg/kg, chronically administered for 21 days) given independently or combined at low doses, to middle-aged ovariectomized female rats, as a model of human menopause." | 3.76 | Estradiol valerate elicits antidepressant-like effects in middle-aged female rats under chronic mild stress. ( Fernández-Guasti, A; Romano-Torres, M, 2010) |
| "To retrospectively compare the 12-month healthcare utilisation and direct medical costs associated with the use of escitalopram, generic SSRIs, and venlafaxine in patients with severe depression in the United Kingdom (UK)." | 3.76 | Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK. ( Despiégel, N; François, C; Guelfucci, F; Saragoussi, D; Toumi, M; Wade, AG, 2010) |
| " Patients also received prophylactic citalopram to minimize the risk of interferon-induced depression." | 3.76 | High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. ( Ackermann, G; Waizmann, M, 2010) |
| "An open, multi-centre study was designed to address the effectiveness and tolerability profile of treatment with escitalopram under naturalistic conditions, in elderly outpatients (above 65 years of age) with depression." | 3.76 | Factors associated with response in depressed elderly outpatients treated with escitalopram in a naturalistic setting in Germany. ( Flürenbrock, W; Möller, HJ; Schnitker, J, 2010) |
| "Escitalopram is a serotonin reuptake inhibitor used in the treatment of depression and anxiety disorders." | 3.76 | Involvement of NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test. ( Engel, D; Gabilan, NH; Rodrigues, AL; Zomkowski, AD, 2010) |
| " Citalopram, a newer generation SSRI, is commonly prescribed, but despite its low toxicity profile has a potential to cause seizures and dysarrythmias in overdose." | 3.76 | Metabolic acidosis and generalized seizures secondary to citalopram overdose: a case report. ( Al Anazi, T; Al Hayyan, H; Al Hussein, M; Al Modaimegh, H; Al Qahtani, M; Bin Salih, S, 2010) |
| " Here, we attempt to expand upon and replicate these results by (i) resequencing the exonic and putatively regulatory regions of five serotonin-related candidate genes (HTR1A, HTR2A, TPH1, TPH2, and MAOA) in our fluoxetine-treated sample to uncover novel variants; (ii) selecting tagging single nucleotide polymorphisms (SNPs) for these genes from the resequencing data; and (iii) evaluating these tagging SNPs for association with response to the selective serotonin reuptake inhibitor citalopram in an independent sample of participants who are enrolled in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) clinical study (N=1953)." | 3.75 | Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. ( Garriock, HA; Hamilton, SP; Jenkins, GD; Kraft, JB; McGrath, PJ; Peters, EJ; Reinalda, MS; Shyn, SI; Slager, SL, 2009) |
| "The aim of this study was to investigate the relationship between plasma glutamate, glutamine and gamma-aminobutyric acid (GABA) levels in female patients with major depression treated with S-citalopram or fluoxetine." | 3.75 | The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. ( Calişkan, M; Gören, MZ; Kaplan, OK; Küçükibrahimoğlu, E; Saygin, MZ; Unsal, C, 2009) |
| " Recent findings have shown, that adipocytokines leptin and adiponectin might play a role in both depression and MetS." | 3.75 | Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women. ( Jachymova, M; Jirak, R; Tvrzicka, E; Vecka, M; Zak, A; Zeman, M, 2009) |
| " A 52-year-old man with a history of depression treated with escitalopram 10 mg/day, extended-release morphine 30 mg/day and zopiclone 15 mg/day was found unconscious at his home." | 3.74 | Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. ( Baranchuk, A; Gibson, K; Methot, M; Simpson, CS; Strum, D, 2008) |
| "We describe the case of a pregnancy healthy outcome after in utero consecutive exposure to lamotrigine and citalopram." | 3.74 | Consecutive exposure to lamotrigine and citalopram during pregnancy. ( Gentile, S; Vozzi, F, 2007) |
| " The aim of this study was to investigate the effects of the SSRIs citalopram and fluoxetine, on the corticocerebral blood flow (cCBF) in rabbits with unilateral carotid occlusion induced cerebral ischemia." | 3.74 | Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits. ( Csete, K; Papp, JG; Sas, K; Sztriha, L; Vécseil, L; Vezekényi, Z, 2007) |
| "To evaluate the effect of citalopram treatment on quality of life (QoL) and depression in 141 patients with chronic renal failure (CRF), QoL was measured by means of the Short Form 36 (SF-36)." | 3.74 | Antidepressant treatment increases quality of life in patients with chronic renal failure. ( Dervisoglu, E; Kalender, B; Ozdemir, AC; Yalug, I, 2007) |
| " Several hours after presentation, she developed sinus arrest and junctional bradycardia that resolved after infusion of intravenous sodium bicarbonate solution." | 3.73 | Reversal of citalopram-induced junctional bradycardia with intravenous sodium bicarbonate. ( Brucculeri, M; Kaplan, J; Lande, L, 2005) |
| "Fluoxetine, citalopram, paroxetine and venlafaxine have been widely used in the treatment of depression." | 3.73 | Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ( Huande, L; Juan, H; Zhiling, Z, 2005) |
| " Changes in kinetic parameters (V(max), maximal velocity and K(M), apparent Michaelis constant) of L-T3 uptake into red blood cells (RBCs) and changes in membrane fluidity in a group of 24 patients with major depression were measured before treatment and after 1 month of treatment with citalopram." | 3.73 | Red blood cell triiodothyronine uptake as membrane parameter of depression. ( Fisar, Z; Hanus, Z; Kalisová-Stárková, L; Paclt, I; Vevera, J, 2006) |
| "Depression, a common condition in MS patients, was precipitated in this patient by the spontaneous discontinuation of citalopram and not influenced by IFN beta-1a therapy, which the patient resumed at 44 mug 3 times per week." | 3.73 | Interferon beta-1a overdose in a multiple sclerosis patient. ( Falcone, NP; Nappo, A; Neuteboom, B, 2005) |
| "In order to study the gene-environment interaction as well as investigate prophylactic/ameliorative effects of early intervention on development of adult life psychopathology, we superimposed maternal separation on an animal model of depression the Flinders Sensitive Line (FSL) rats and their controls the Flinders Resistant Line (FRL) rats and studied behavior following treatment with escitalopram." | 3.73 | Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression. ( El Khoury, A; Gruber, SH; Mathé, AA; Mørk, A, 2006) |
| "A stress-induced decrease in sucrose preference in rodents is regarded as an analog of anhedonia, a key symptom of depression." | 3.73 | Selective effects of citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress. ( Bartsch, D; Dolgov, O; Gorenkova, N; Schunk, E; Strekalova, T, 2006) |
| "A 47-year-old white man with a history of bipolar disorder was being maintained on citalopram 40 mg once daily and zolpidem 5 mg at bedtime." | 3.72 | Somnambulism due to probable interaction of valproic acid and zolpidem. ( Bhatia, SC; Petty, F; Ramaswamy, S; Sattar, SP, 2003) |
| "Citalopram is a relatively new selective serotonin reuptake inhibitor (SSRI) that is becoming widely administered for the treatment of depression." | 3.71 | Citalopram-induced priapism. ( Brown, WC; Dent, LA; Murney, JD, 2002) |
| "The authors report the case of a 47-year-old depressive woman treated with citalopram 20 mg day-1 for 3 months who presented a marked sinus bradycardia (34 beats/min) 11 days after the citalopram dose was increased to 40 mg day-1." | 3.70 | Bradycardia during citalopram treatment: a case report. ( Bertschy, G; Favre, MP; Sztajzel, J, 1999) |
| "We investigated the effect of the selective serotonin reuptake inhibitor (SSRI) citalopram after 6-8 weeks and 6 months of treatment on clinical and peripheral indexes for central serotonergic function: platelet [14C]serotonin uptake and [3H]paroxetine- and [3H]LSD-binding to platelets membranes in 33 patients with panic disorder." | 3.70 | The effect of citalopram treatment on platelet serotonin function in panic disorders. ( Aberg-Wistedt, A; Neuger, J; Sinner, B; Stain-Malmgren, R; Wistedt, B, 2000) |
| "The selective sigma2 (sigma2) ligand Lu 28-179, or 1'-[4[1-(4-fluorophenyl)-1H-indol-3-yl]-l-butyl]spiro[isobenzofuran++ +-1(3H),4'-piperidine], was studied in the chronic mild stress (CMS) model of depression." | 3.70 | The selective sigma2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. ( Papp, M; Sánchez, C, 2000) |
| "A 53-year-old man with multiple chemical sensitivities (MCS) received the selective serotonin reuptake inhibitor (SSRI) citalopram for treatment of depression." | 3.69 | Successful use of a selective serotonin reuptake inhibitor in a patient with multiple chemical sensitivities. ( Andiné, P; Järvholm, B; Rönnbäck, L, 1997) |
| "Administration of imipramine, which blocks noradrenergic, serotonergic and cholinergic reuptake, to rats for 4 days counteracts the shuttlebox escape failures otherwise seen in rats which have been exposed to inescapable shock (the "learned helplessness" model of depression)." | 3.68 | Effect of imipramine in the "learned helplessness" model of depression in rats is not mimicked by combinations of specific reuptake inhibitors and scopolamine. ( Christensen, AV; Geoffroy, M; Scheel-Krüger, J, 1990) |
| "Depression is a common complication after stroke and is closely related to the poor prognosis of stroke." | 3.01 | Clinical efficacy of Danzhi Xiaoyao Powder in the treatment of post-stroke depression: A protocol for randomized, double-blind clinical study. ( Ding, C; Gao, L; Guo, M; Wang, X; Xu, M; Xu, W; Yao, J, 2021) |
| " Adverse effects were assessed by the Adverse Events Scale." | 3.01 | The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression. ( Chen, S; Feng, L; He, J; Luan, X; Wang, Q; Xiao, M, 2021) |
| "Antidepressants are widely used to treat major depressive disorder." | 3.01 | Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial. ( Abe, T; Furukawa, TA; Iwanami, A; Mimura, M; Nakagawa, A; Nakagome, K; Nishioka, G; Tani, M; Watanabe, K; Yokoi, Y; Yoshimura, N, 2021) |
| "Citalopram was not more effective in women compared with men and there was no difference in tolerability." | 3.01 | Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial. ( Gougoulaki, M; Lewis, G; Nutt, DJ; Peters, TJ; Wiles, NJ, 2021) |
| "Depressive disorder was diagnosed according to DSM-IV criteria and included prevalent depressive disorder at baseline and incident or persistent depressive disorder at follow-up based on depression status at the two examinations." | 2.90 | Methylation of the glucocorticoid receptor gene associated with depression in patients with acute coronary syndrome. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, HR; Kim, JM; Kim, SW; Shin, IS; Shin, MG; Yoon, JS, 2019) |
| " Adverse events (AEs) were assessed with the Treatment Emergent Symptom Scale (TESS)." | 2.90 | A controlled study of the efficacy and safety of tandospirone citrate combined with escitalopram in the treatment of vascular depression: A pilot randomized controlled trial at a single-center in China. ( Chen, H; Chen, R; Lin, F; Lin, Q; Lin, T; Lin, X; Lin, Y; Luo, L; Xiao, Y, 2019) |
| "Depression is a mental disorder, affecting the quality of life." | 2.87 | Amelioration of mild and moderate depression through Pranic Healing as adjuvant therapy: randomised double-blind controlled trial. ( Anil Kumar, MN; Jois, SN; Mallikarjuna Majgi, S; Rajagopal, R; Shashidhar, HB, 2018) |
| "Depression is a common affective disorder or mood disorder, which seriously affects people's physical and mental health and the quality of life." | 2.87 | Analysis of curative effect of fluoxetine and escitalopram in the depression treatment based on clinical observation. ( Xiaoling, Z; Yingdong, L; Yunping, H, 2018) |
| "For 2 years, a depression care manager worked with primary care physicians to provide algorithm-based care for depression, offering psychotherapy, increasing the antidepressant dose if indicated, and monitoring symptoms, medication adverse effects, and treatment adherence." | 2.82 | Multimorbidity, Depression, and Mortality in Primary Care: Randomized Clinical Trial of an Evidence-Based Depression Care Management Program on Mortality Risk. ( Bogner, HR; Bruce, ML; Gallo, JJ; Hwang, S; Joo, JH; Morales, KH; Reynolds, CF, 2016) |
| "Depression is associated with impairments in higher-order cognitive functions and information processing, which persist independently of clinical symptom change with treatment." | 2.82 | Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study. ( Etkin, A; Gyurak, A; Harris, A; Shilyansky, C; Usherwood, T; Williams, LM, 2016) |
| "We investigated whether treating depression in older participants impacted on arterial stiffness, a known cardiovascular disease risk factor and a clinical marker of arterial aging." | 2.78 | Depression treatment selectively modifies arterial stiffness in older participants. ( Assisi, AP; Fedullo, F; Gianni, W; Modestino, A; Scuteri, A, 2013) |
| "Depression has been associated with changes in responses within the medial prefrontal cortex (mPFC) during emotional information processing." | 2.77 | Short-term antidepressant administration reduces negative self-referential processing in the medial prefrontal cortex in subjects at risk for depression. ( Di Simplicio, M; Harmer, CJ; Norbury, R, 2012) |
| "While treatment of depression in major depressive disorder may partially ameliorate cognitive deficits, the cognitive effects of antidepressant medications in patients with schizophrenia or schizoaffective disorder and SSD are unknown." | 2.77 | Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression? ( Dawes, SE; Golshan, S; Kasckow, J; Meeks, T; Mohamed, S; Palmer, BW; Zisook, S, 2012) |
| "Pain is common among opioid-dependent patients, yet pharmacologic strategies are limited." | 2.76 | Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms. ( Anderson, BJ; Herman, DS; Kettavong, M; Stein, MD; Tsui, JI, 2011) |
| "Citalopram was not superior to placebo in treating non-depressed IBS patients." | 2.75 | Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. ( Bacchetti, P; Chung, E; Grimes, B; Jin, C; Ladabaum, U; Levin, TR; Pepin, CJ; Sharabidze, A; Zhao, WK, 2010) |
| "With nortriptyline the increase in impedance was reduced by 29% after ADP induction (p=0." | 2.75 | Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline. ( Bauriedel, G; Flöck, A; Hammerstingl, C; Höfels, S; Maier, W; Nickenig, G; Schuhmacher, A; Skowasch, D; Tuleta, I; Zobel, A, 2010) |
| " Treatment dropout was defined as missing seven consecutive buprenorphine dosing days." | 2.75 | Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. ( Anderson, BJ; Cioe, PA; Friedmann, PD; Herman, DS; Kettavong, M; Stein, MD; Tellioglu, T, 2010) |
| "Depression is a common disorder in the elderly handicapping patients with affective and cognitive symptoms." | 2.73 | Antidepressive therapy with escitalopram improves mood, cognitive symptoms, and identity memory for angry faces in elderly depressed patients. ( Böhringer, A; Müller, SE; Savaskan, E; Schächinger, H; Schulz, A, 2008) |
| "Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD)." | 2.73 | Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. ( Bordet, R; Cottencin, O; Defebvre, L; Destée, A; Devos, D; Dujardin, K; Moreau, C; Poirot, I; Thomas, P, 2008) |
| " Participants were adult outpatients who, following 8 weeks of monotherapy with an adequate dosing regimen of an SSRI other than citalopram and had not responded, met the diagnostic criteria for depression as described in the Diagnostic and statistical manual of mental disorders, fourth edition, and had a score > or =20 on the 21-item Hamilton Rating Scale for Depression (HAM-D21)." | 2.73 | Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. ( Jiang, Q; Lenox-Smith, AJ, 2008) |
| " Study durations ranged from 8 to 16 weeks and MPH dosing ranged from 5 to 90 mg per day." | 2.72 | Methylphenidate use in geriatric depression: A systematic review. ( Britt, RB; Brown, JN; Kahlon, CH; Smith, KR, 2021) |
| "reboxetine) has provided potentially important avenues of treatment for the disorder." | 2.71 | Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. ( Mohr, N; Muller, JE; Seedat, S; Stein, DJ; van Rheede van Oudtshoorn, E, 2003) |
| "Treatment with fluoxetine and citalopram reversed these biochemical parameters." | 2.71 | Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. ( Dakhale, GN; Khanzode, SD; Khanzode, SS; Palasodkar, R; Saoji, A, 2003) |
| "Depression is the strongest risk factor for late-life suicide and for suicide's precursor, suicidal ideation." | 2.71 | Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. ( Alexopoulos, GS; Brown, GK; Bruce, ML; Katz, II; McAvay, GJ; Mulsant, BH; Pearson, JL; Reynolds, CF; Schulberg, HC; Ten Have, TR, 2004) |
| "Depression in Parkinson's disease (PD) is associated with faster progression of physical symptoms, greater decline in cognitive skills, and greater decline in the ability to care for oneself." | 2.71 | Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. ( Kaufman, K; Lauritano, M; Marin, H; Mark, M; Menza, M, 2004) |
| "Escitalopram was well tolerated with an adverse event profile similar to that of citalopram." | 2.70 | Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. ( Loft, H; Montgomery, SA; Papp, M; Reines, EH; Sánchez, C, 2001) |
| "Citalopram, a newer SSRI used in the treatment of depression, has not been studied for GAD." | 2.70 | Treatment of generalized anxiety disorder with citalopram. ( Rauscher, F; Varia, I, 2002) |
| " One group (N = 17 completers) was administered citalopram continuously at a constant dosage (20+/-10 mg/day) throughout the menstrual cycle." | 2.69 | Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? ( Andersch, B; Bengtsson, F; Dagnell, I; Eriksson, E; Sundblad, C; Wikander, I; Zylberstein, D, 1998) |
| "Moreover, the treatment of depression and anxiety can be associated with a reduced mortality." | 2.66 | Mood disorders and outcomes in lung cancer patients undergoing surgery: a brief summery. ( Aguglia, E; Migliore, M; Signorelli, MS; Surace, T, 2020) |
| "Sertraline is a reasonable first-line choice in patients with IHD and depression, whereas the role of citalopram as the first-line agent should be reconsidered." | 2.61 | Efficacy and acceptability of antidepressants in patients with ischemic heart disease: systematic review and meta-analysis. ( Barbui, C; Caruso, R; Gastaldon, C; Grassi, L; Hotopf, M; Ostuzzi, G; Papola, D; Rayner, L; Turrini, G, 2019) |
| "To assess the risk of headache associated with commonly prescribed antidepressant medications and to examine the impact of medication class, pharmacodynamics and dosage on risk of headache." | 2.58 | Meta-analysis: Second generation antidepressants and headache. ( Bloch, MH; Olten, B; Telang, S; Walton, C, 2018) |
| "It has been suggested that the efficacy of antidepressants has been overestimated in clinical trials owing to unblinding of drug treatments by adverse events." | 2.53 | Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. ( Barbui, C; Barth, M; Cipriani, A; Klostermann, S; Kriston, L; Linde, K, 2016) |
| "Guidelines suggest treatment of depression in dialysis patients with pharmacological therapy, preferably a selective serotonin reuptake inhibitor." | 2.53 | Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis. ( Craig, JC; Natale, P; Palmer, SC; Rabindranath, KS; Ruospo, M; Saglimbene, VM; Strippoli, GF, 2016) |
| "Depression is a recurrent illness with high rates of chronicity, treatment-resistance and significant economic impact." | 2.53 | S-adenosyl methionine (SAMe) for depression in adults. ( Amari, E; Dougall, D; Galizia, I; Jones, TN; Lam, RW; Macritchie, K; Massei, GJ; Oldani, L; Yatham, LN; Young, AH, 2016) |
| "Escitalopram has been shown to have better efficacy and safety profile than other selective serotonin reuptake inhibitor and serotonin norepinephrine reuptake inhibitor drugs, including racemic citalopram." | 2.50 | Clinical pharmacology review of escitalopram for the treatment of depression. ( Gobburu, J; Pastoor, D, 2014) |
| "Duloxetine hydrochloride is a dual reuptake inhibitor of serotonin and norepinephrine and has been licensed by the Food and Drug Administration in the US for major depressive disorder (MDD), generalised anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain." | 2.48 | Duloxetine versus other anti-depressive agents for depression. ( Barbui, C; Cipriani, A; Furukawa, TA; Koesters, M; Nosè, M; Omori, IM; Purgato, M; Trespidi, C, 2012) |
| "Stroke is the major cause of adult disability." | 2.48 | Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. ( Claxton, A; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, MA; Lee, R; Mead, GE, 2012) |
| "Escitalopram has low protein binding (56%) and is not likely to cause interactions with highly protein-bound drugs." | 2.44 | The clinical pharmacokinetics of escitalopram. ( Rao, N, 2007) |
| "Citalopram treatment did not increase risk of suicide, overdose, seizure, or arrhythmia." | 2.42 | Overview of the safety of citalopram. ( Nemeroff, CB, 2003) |
| " The high bioavailability of citalopram indicates that the switch from intravenous to oral citalopram would prevent a deterioration of symptoms as plasma drug concentrations would be maintained." | 2.41 | Intravenous antidepressant treatment: focus on citalopram. ( Kasper, S; Müller-Spahn, F, 2002) |
| "Emphasis is given to the treatment of depression and how the potential of one pure enantiomer-escitalopram, the S-enantiomer of the selective serotonin reuptake inhibitor citalopram-appears to be fulfilling its preclinical promise in the clinic." | 2.41 | Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram. ( Baumann, P; Eap, CB; Zullino, DF, 2002) |
| "Citalopram is a selective serotonin re-uptake inhibitor that has demonstrated antidepressant efficacy in numerous controlled clinical trials." | 2.41 | Citalopram: a comprehensive review. ( Pollock, BG, 2001) |
| "Depression is a highly prevalent concomitant of dementia." | 2.40 | Depression and dementia: comorbidities, identification, and treatment. ( Meyers, BS, 1998) |
| "Its efficacy in treating depression was evident in both placebo-controlled and comparator trials." | 2.40 | Citalopram in the treatment of depression and other potential uses in psychiatry. ( Levin, GM; Tan, JY, 1999) |
| "Citalopram is an antidepressant belonging to a new class of drugs which enhance serotoninergic neurotransmission through potent and selective inhibition of serotonin reuptake." | 2.38 | Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. ( Goa, KL; Milne, RJ, 1991) |
| " However, it is important to acknowledge certain limitations of our research, such as the use of a single depression induction model and limited dosing regimens." | 1.91 | Vitamins C and D Exhibit Similar Antidepressant Effects to Escitalopram Mediated by NOx and FKBPL in a Stress-Induced Mice Model. ( Aljabali, AAA; Alqudah, A; Altaber, S; Gammoh, O; Ibrahim, A; Qnais, E; Tambuwala, MM, 2023) |
| "Late-life depression is associated with substantial heterogeneity in clinical presentation, disability, and response to antidepressant treatment." | 1.91 | Cognitive, Disability, and Treatment Outcome Implications of Symptom-Based Phenotyping in Late-Life Depression. ( Conway, C; Elson, D; Kang, H; Sudol, K; Szymkowicz, SM; Taylor, WD, 2023) |
| "Depression is characterized by significant and low mood." | 1.56 | Folic acid ameliorates depression-like behaviour in a rat model of chronic unpredictable mild stress. ( Cong, Y; Liu, H; Zhou, Y, 2020) |
| "Escitalopram treatment can significantly reverse NAc miRNA abnormality induced by chronic stress." | 1.51 | Expression alteration of microRNAs in Nucleus Accumbens is associated with chronic stress and antidepressant treatment in rats. ( Li, H; Li, X; Lin, GN; Ning, A; Peng, S; Shen, Y; Song, W; Yu, S; Zhang, R; Zhang, Y, 2019) |
| " The aim of this study was to investigate the expression of the eCB synthesizing enzymes (N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) and diacylglycerol lipase α (DAGLα)) and eCB degrading enzymes (fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)) after acute or chronic administration of antidepressant drugs (imipramine (IMI, 15 mg/kg), escitalopram (ESC, 10 mg/kg) and tianeptine (TIA, 10 mg/kg))." | 1.51 | Brain region-dependent changes in the expression of endocannabinoid-metabolizing enzymes in rats following antidepressant drugs. ( Brodowicz, J; Filip, M; Gawlinski, D; Smaga, I, 2019) |
| " Serum concentration of citalopram and daily dosage correlated positively while daily dosage and mother milk concentration did not (rho = 0." | 1.51 | Antidepressants in breast milk; comparative analysis of excretion ratios. ( Augustin, M; Franz, C; Gründer, G; Paulzen, M; Saßmannshausen, H; Schoretsanitis, G, 2019) |
| "Nonsudden cardiac death was treated as a competing event." | 1.51 | Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis. ( Assimon, MM; Brookhart, MA; Flythe, JE, 2019) |
| "Depression is associated with an increased risk of Alzheimer's disease." | 1.48 | Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression. ( Bartels, C; Ehrenreich, H; Schneider, A; Wagner, M; Wolfsgruber, S, 2018) |
| "The presence of Major Depressive Disorder (MDD) is often comorbid in patients with a variety of general medical conditions (GMCs) which could lead to less favorable outcomes." | 1.48 | Major Depression Comorbid with Medical Conditions: Analysis of Quality of Life, Functioning, and Depressive Symptom Severity. ( Dang, J; Danovitch, I; Elzahaby, C; IsHak, WW; Kauzor, K; Klimowicz, A; Reid, M; Steiner, AJ; Sumner, L; Vanle, B, 2018) |
| "As depression is known to be a risk factor for suicide and many antidepressants are P-gp substrates, it has been speculated that inadequate antidepressant treatment response or adverse side effects could be involved." | 1.48 | Post-mortem analysis of suicide victims shows ABCB1 haplotype 1236T-2677T-3435T as a candidate predisposing factor behind adverse drug reactions in females. ( Haukka, J; Palo, JU; Rahikainen, AL; Sajantila, A, 2018) |
| " Application of new drugs which could enhance the effectiveness of antidepressants drug and reduce side effects of their long-term use seems necessary." | 1.48 | Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice. ( Akhondzadeh, S; Nejatisafa, AA; Roohi-Azizi, M; Sadat-Shirazi, MS; Torkaman-Boutorabi, A; Zarrindast, MR, 2018) |
| " Here we investigated the effects of chronic administration of caffeine (5mg/kg, twice daily for 14days) and its withdrawal on day 15th on the activity of per se ineffective doses of fluoxetine (5mg/kg) and escitalopram (2mg/kg) given on day 15th." | 1.46 | Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt, Slc6a15 and Adora1 gene expression. ( Doboszewska, U; Dudka, J; Herbet, M; Kanadys, A; Korga, A; Ostrowska, M; Poleszak, E; Serefko, A; Świąder, K; Szopa, A; Terlecka, J; Wlaź, A; Wlaź, P; Wośko, S; Wróbel, A; Wyska, E, 2017) |
| "Depression is a common mental illness and a leading cause of disability." | 1.43 | Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse. ( Blakely, RD; McMeekin, AM; Moussa-Tooks, AB; Nackenoff, AG; Veenstra-VanderWeele, J, 2016) |
| " Food and Drug Administration (FDA) on the risk of suicidality among children associated with use of antidepressants, but the warning's effect on dosing of antidepressants has not been evaluated." | 1.43 | Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning. ( Azrael, D; Bushnell, GA; Miller, M; Pate, V; Stürmer, T; Swanson, SA; White, A, 2016) |
| "Posttraumatic stress disorder (PTSD) is a trauma-induced mental disorder characterised by fear extinction dysfunction in which fear circuit monoamines are possibly associated." | 1.43 | Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory. ( Lin, CC; Liu, YP; Tung, CS, 2016) |
| "Escitalopram treatment significantly decreased PAI-1 levels in the serum, but not in the CSF." | 1.43 | Plasminogen Activator Inhibitor-1 in depression: Results from Animal and Clinical Studies. ( Chen, S; Jiang, H; Li, X; Liang, J; Lu, N; Yuan, Y; Yue, Y; Zhang, Z, 2016) |
| "Dabigatran is an anti-aggregation agent used for the treatment of atrial fibrillation." | 1.42 | Depressive symptoms associated with dabigatran: a case report. ( Enez Darcin, A; Eryilmaz, G; Gogcegoz Gul, I; Saglam, E, 2015) |
| " Present findings may have implications for escitalopram dosage and side effect profile in younger MDD patients." | 1.42 | Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [123 I]β-CIT SPECT study. ( Bartenstein, P; Brendel, M; Cumming, P; Karch, S; Koch, W; la Fougère, C; Pogarell, O; Rominger, A; Tatsch, K; Xiong, G; Zach, C, 2015) |
| "Escitalopram-treated rats with >20% recovery in the sucrose consumption during the last 2 wk of treatment were defined as escitalopram responders." | 1.42 | Chronic selective serotonin reuptake inhibition modulates endothelial dysfunction and oxidative state in rat chronic mild stress model of depression. ( Aalkjaer, C; Bouzinova, EV; Kravtsova, VV; Matchkov, VV; Wiborg, O, 2015) |
| "Current treatments for depression are characterized by a low success rate and associated with a wide variety of side effects." | 1.40 | A novel herbal treatment reduces depressive-like behaviors and increases BDNF levels in the brain of stressed mice. ( Doron, R; Einat, N; Kately, N; Lotan, D; Marom, I; Meron, G; Rehavi, M; Winer, A; Yaffe, R, 2014) |
| "Mixed connective tissue disorder (MCTD) with predominant polymyositis and neuropsychiatric manifestations was diagnosed as the patient had anti-RNP positive with significantly raised muscle enzymes." | 1.40 | Depression and seizures as the main neuropsychiatric manifestation of mixed connective tissue disorder. ( Kiani, IG; Qureshi, SH; Shah, F, 2014) |
| "Depression is the leading psychiatric disorder with a high risk of morbidity and mortality." | 1.40 | Chronic but not acute antidepresant treatment alters serum zinc/copper ratio under pathological/zinc-deficient conditions in mice. ( Krakowska, A; Mlyniec, K; Nowak, G; Opoka, W; Ostachowicz, B; Reczynski, W, 2014) |
| "Intracranial stab wounds are low-velocity, penetrating injuries to the brain and fatality and outcome significantly depend on route, depth and location of cranial penetration." | 1.39 | Self-inflicted trans-oral intracranial stab wound. ( Han, ZA; Kim, JH; Kim, SW, 2013) |
| " Glycaemia values returned to normality only after suspension of escitalopram, despite antidiabetic dosage increase." | 1.39 | A case report on escitalopram-induced hyperglycaemia in a diabetic patient. ( Brasesco, PC; Fucile, C; Leone, S; Martelli, A; Mattioli, F; Milano, G; Zuccoli, ML, 2013) |
| "Escitalopram showed lower fasting and post-lunch blood sugar values on follow up, which was clinically and statistically significant." | 1.39 | Depression and diabetes: impact of antidepressant medications on glycaemic control. ( Agari, AD; Dhavale, HS; Ghulghule, M; Jadhav, BS; Panikkar, V, 2013) |
| "Fatigue is a common symptom in individuals with multiple sclerosis (MS)." | 1.39 | Reward responsiveness and fatigue in multiple sclerosis. ( Capello, E; Krueger, F; Mancardi, G; Pardini, M; Uccelli, A, 2013) |
| "SSR180711 is a recently described α7 nAChR agonist that has shown antidepressant-like activity in the rat forced swim test." | 1.38 | Combined α7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987. ( Andreasen, JT; Nielsen, EØ; Redrobe, JP, 2012) |
| " To assess the predictive validity of this behavior as a potential marker of "despair," we tested the effects of chronic administration of two common antidepressant drugs on this measure." | 1.38 | Antidepressants reduce extinction-induced withdrawal and biting behaviors: a model for depressive-like behavior. ( Huq, Y; Huston, JP; Komorowski, M; Topic, B; van den Brink, J, 2012) |
| "Citalopram is a selective serotonin reuptake inhibitor with a favorable cardiac-safety profile." | 1.38 | Prolonged QTc interval and torsades de pointes induced by citalopram. ( Abuissa, H; Airey, K; Alla, V; Deshmukh, A; Ulveling, K, 2012) |
| "Treatment with citalopram rescued behavior in the forced swim test in hamsters housed in dLAN, but had no effect on hamsters housed in LD." | 1.38 | Chronic citalopram treatment ameliorates depressive behavior associated with light at night. ( Bedrosian, TA; Nelson, RJ; Weil, ZM, 2012) |
| " We compared different phenotypes from the chronic mild stress (CMS) model of depression using chronic administration with two selective serotonin reuptake inhibitors (SSRIs), escitalopram and sertraline." | 1.38 | Vesicular signalling and immune modulation as hedonic fingerprints: proteomic profiling in the chronic mild stress depression model. ( Bak, S; Bisgaard, CF; Christensen, T; Enghild, JJ; Jensen, ON; Wiborg, O, 2012) |
| "Escitalopram treatment did not effect the reduced levels of NR2B resulting from depression." | 1.37 | Effects of venlafaxine and escitalopram treatments on NMDA receptors in the rat depression model. ( Cure, MC; Demirdas, A; Eren, I; Kirbas, A; Sutcu, R; Yilmaz, M; Yilmaz, N, 2011) |
| " Depression-related transcriptomic changes in gene expression profiles were investigated in laser-captured microdissected (LCM) rat hippocampal granular cell layers (GCL) using the chronic mild stress (CMS) rat model of depression and chronic administration of two selective serotonin reuptake inhibitors (SSRIs), escitalopram and sertraline." | 1.37 | Biomarkers of anhedonic-like behavior, antidepressant drug refraction, and stress resilience in a rat model of depression. ( Bisgaard, CF; Christensen, T; Wiborg, O, 2011) |
| "Rhabdomyolysis has rarely been associated with the correction of hyponatraemia." | 1.37 | Rhabdomyolysis associated with polydipsia induced hyponatraemia. ( Bennett, M; Donnelly, M; Fitzpatrick, G, 2011) |
| "One hypothesis of depression is that it is caused by reduced neuronal plasticity including hippocampal neurogenesis." | 1.36 | The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression. ( Bjørnebekk, A; Brené, S; Mathé, AA, 2010) |
| "Depression was assessed using the Hospital Anxiety and Depression Scale (HADS)." | 1.36 | Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression. ( Keicher, C; Kraus, MR; Rieger, P; Schäfer, A; Scheurlen, M; Seufert, J; Weissbrich, B, 2010) |
| "Escitalopram treatment restored some but not all alterations observed in FSL rats after early-life stress." | 1.36 | Early-life stress and antidepressant treatment involve synaptic signaling and Erk kinases in a gene-environment model of depression. ( El Khoury, A; Gruber, SH; Mallei, A; Mathé, AA; Musazzi, L; Popoli, M; Racagni, G; Tardito, D, 2010) |
| " CMS induced behavioural changes in the ischemic animals, including decreased locomotor and rearing activity and reduced sucrose preference (compared with baseline, control and stroke groups respectively), all these behaviours were reversed by chronic administration of citalopram." | 1.35 | Anhedonia and activity deficits in rats: impact of post-stroke depression. ( Chen, BA; Guo, YJ; Teng, GJ; Wang, SH; Zhang, ZJ; Zhou, H, 2009) |
| "A 30-year-old man, with no history of parasomnias or related precipitating factors, developed sexual behaviour during sleep after three weeks of treatment with escitalopram 10 mg daily." | 1.35 | [Sexsomnia during treatment with a selective serotonin reuptake inhibitor]. ( Krol, DG, 2008) |
| "We sought to determine whether clinical response or tolerance to the Selective Serotonin Reuptake Inhibitor (SSRI) citalopram is associated with genetic polymorphisms in potentially relevant pharmacokinetic enzymes." | 1.35 | Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. ( Hamilton, SP; Jenkins, GD; Kraft, JB; McGrath, PJ; Peters, EJ; Reinalda, MS; Slager, SL, 2008) |
| "Early diagnosis and effective treatment of depression will help the rehabilitation outcome of stroke patients." | 1.35 | Depression and functional outcome after stroke: the effect of antidepressant therapy on functional recovery. ( Bilge, C; Koçer, A; Koçer, E; Türk Börü, U, 2008) |
| "Depression is common in hepatitis C, exacerbated by interferon, and is a major reason for discontinuing interferon therapy." | 1.34 | Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study. ( Fucci, JC; Gleason, OC; Philipsen, MA; Yates, WR, 2007) |
| "Depression is the most common psychiatric complication in Parkinson's disease (PD)." | 1.34 | Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. ( Juckel, G; Klein, J; Kupsch, A; Lee, T; Morgenstern, R; Mundt, A; Petrus, D; von Rumohr, A; Winter, C, 2007) |
| "Depression is a common problem in elderly patients and frequently is treated with antidepressants." | 1.33 | Recurrent hyponatremia associated with citalopram and mirtazapine. ( Akcay, A; Bavbek, N; Kargili, A; Kaya, A, 2006) |
| "The seizure was successfully treated with benzodiazepines." | 1.32 | Seizure secondary to citalopram overdose. ( Cuenca, PJ; Hoefle, JD; Holt, KR, 2004) |
| "The article focuses on adverse drug reactions (ADR) to selective serotonin reuptake inhibitors (SSRI) concerning libido and sexual behaviour: cases of disinhibition of libido observed at the Psychiatric Hospital of Kilchberg near Zurich are described." | 1.31 | Disinhibition of libido: an adverse effect of SSRI? ( Erazo, N; Greil, W; Grohmann, R; Horvath, A; Sassim, N, 2001) |
| " The dose-response curve was biphasic for citalopram with a maximum of 64% inhibition." | 1.30 | Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? ( Meier, E; Sánchez, C, 1997) |
| "Treatment with zimeldine during 3 consecutive days induced in both helpless and control rats, a decrease in the inhibitory response of serotonergic neurons to the citalopram challenge, which resulted in a normalization of the neuronal reactivity in the helpless group (ED50 = 0." | 1.30 | Antidepressant treatment in helpless rats: effect on the electrophysiological activity of raphe dorsalis serotonergic neurons. ( Adrien, J; Dangoumau, L; Hamon, M; Martin, P; Maudhuit, C; Prévot, E, 1997) |
| "Pretreatment with buspirone (0." | 1.30 | Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. ( Bourin, M; Redrobe, JP, 1998) |
| "Citalopram was inactive when given alone but it potentiated the antidepressant-like effect of MK-801." | 1.28 | Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. ( Maj, J; Rogóz, Z; Skuza, G; Sowińska, H, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 26 (4.47) | 18.2507 |
| 2000's | 168 (28.87) | 29.6817 |
| 2010's | 318 (54.64) | 24.3611 |
| 2020's | 70 (12.03) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, W | 1 |
| Wang, H | 3 |
| Li, X | 6 |
| Xu, Y | 4 |
| Zhang, J | 1 |
| Wang, W | 1 |
| Gong, Q | 2 |
| Qiu, X | 1 |
| Zhu, J | 2 |
| Mao, F | 2 |
| Zhang, H | 4 |
| Li, J | 3 |
| Huang, Y | 2 |
| Fu, Y | 1 |
| Huang, J | 1 |
| You, H | 1 |
| Zhang, D | 2 |
| Shiroyama, T | 1 |
| Fukuyama, K | 1 |
| Okada, M | 1 |
| Kofod, J | 1 |
| Elfving, B | 1 |
| Nielsen, EH | 1 |
| Mors, O | 2 |
| Köhler-Forsberg, O | 1 |
| García-Durán, L | 1 |
| Flores-Burgess, A | 1 |
| Cantero-García, N | 1 |
| Puigcerver, A | 1 |
| Narváez, JÁ | 1 |
| Fuxe, K | 1 |
| Santín, L | 1 |
| Millón, C | 1 |
| Díaz-Cabiale, Z | 1 |
| Hsu, CW | 1 |
| Tseng, WT | 1 |
| Wang, LJ | 1 |
| Yang, YH | 1 |
| Kao, HY | 1 |
| Lin, PY | 1 |
| Ding, C | 1 |
| Xu, M | 1 |
| Gao, L | 1 |
| Wang, X | 2 |
| Xu, W | 1 |
| Guo, M | 1 |
| Yao, J | 1 |
| Czysz, AH | 1 |
| Mason, BL | 1 |
| Li, Q | 2 |
| Chin-Fatt, C | 1 |
| Minhajuddin, A | 2 |
| Carmody, T | 1 |
| Trivedi, MH | 9 |
| Strekalova, T | 2 |
| Pavlov, D | 1 |
| Trofimov, A | 1 |
| Anthony, DC | 1 |
| Svistunov, A | 1 |
| Proshin, A | 1 |
| Umriukhin, A | 1 |
| Lyundup, A | 1 |
| Lesch, KP | 2 |
| Cespuglio, R | 1 |
| Zahra, A | 2 |
| Du, L | 1 |
| Jia, M | 1 |
| Butt, MU | 1 |
| Wang, Q | 3 |
| Wang, Y | 6 |
| Wu, J | 2 |
| Zaazaa, AM | 1 |
| Daoud, NN | 1 |
| El-Gendy, OA | 1 |
| Al-Shafei, AI | 1 |
| Zhao, W | 1 |
| Liu, S | 2 |
| Zhao, Y | 1 |
| Pan, W | 1 |
| Liu, Z | 1 |
| Kim, JM | 9 |
| Stewart, R | 6 |
| Kang, HJ | 8 |
| Kim, SY | 4 |
| Kim, JW | 4 |
| Lee, HJ | 3 |
| Lee, JY | 2 |
| Kim, SW | 10 |
| Shin, IS | 9 |
| Kim, MC | 2 |
| Shin, HY | 1 |
| Hong, YJ | 9 |
| Ahn, Y | 9 |
| Jeong, MH | 9 |
| Yoon, JS | 9 |
| Saadati, N | 1 |
| Bananej, M | 1 |
| Khakpai, F | 1 |
| Zarrindast, MR | 2 |
| Alibeik, H | 1 |
| Peters, EM | 1 |
| Balbuena, L | 1 |
| Lodhi, RJ | 1 |
| Amasi-Hartoonian, N | 1 |
| Pariante, CM | 1 |
| Cattaneo, A | 1 |
| Sforzini, L | 1 |
| Kubo, K | 2 |
| Sakurai, H | 1 |
| Tani, H | 1 |
| Watanabe, K | 2 |
| Mimura, M | 2 |
| Uchida, H | 1 |
| Zhang, ZJ | 9 |
| Zhang, SY | 3 |
| Yang, XJ | 3 |
| Qin, ZS | 3 |
| Xu, FQ | 3 |
| Jin, GX | 3 |
| Hou, XB | 3 |
| Liu, Y | 4 |
| Cai, JF | 3 |
| Xiao, HB | 3 |
| Wong, YK | 3 |
| Zheng, Y | 4 |
| Shi, L | 3 |
| Zhang, JN | 3 |
| Zhao, YY | 3 |
| Xiao, X | 3 |
| Zhang, LL | 3 |
| Jiao, Y | 4 |
| He, JK | 3 |
| Chen, GB | 3 |
| Rong, PJ | 3 |
| Weber, S | 1 |
| Frokjaer, VG | 1 |
| Armand, S | 1 |
| Nielsen, JH | 1 |
| Knudsen, GM | 2 |
| Joergensen, MB | 1 |
| Stenbaek, DS | 1 |
| Giraldi, A | 1 |
| Hart, XM | 1 |
| Amann, F | 1 |
| Brand, J | 1 |
| Eichentopf, L | 1 |
| Gründer, G | 2 |
| Kukuia, KKE | 1 |
| Burns, FB | 1 |
| Adutwum-Ofosu, KK | 1 |
| Appiah, F | 1 |
| Amponsah, SK | 1 |
| Begyinah, R | 1 |
| Koomson, AE | 1 |
| Ferka, YT | 1 |
| Tagoe, TA | 1 |
| Amoateng, P | 1 |
| Vestergaard, SB | 1 |
| Damsbo, AG | 1 |
| Blauenfeldt, RA | 1 |
| Johnsen, SP | 1 |
| Andersen, G | 3 |
| Mortensen, JK | 1 |
| Ishtiak-Ahmed, K | 1 |
| Christensen, KS | 1 |
| Gasse, C | 1 |
| Olstad, EW | 1 |
| Nordeng, HME | 1 |
| Sandve, GK | 1 |
| Lyle, R | 1 |
| Gervin, K | 1 |
| Oh, SJ | 1 |
| Lee, N | 1 |
| Nam, KR | 1 |
| Kang, KJ | 1 |
| Han, SJ | 1 |
| Choi, JY | 1 |
| Hack, LM | 1 |
| Tozzi, L | 1 |
| Zenteno, S | 1 |
| Olmsted, AM | 1 |
| Hilton, R | 1 |
| Jubeir, J | 1 |
| Korgaonkar, MS | 1 |
| Schatzberg, AF | 2 |
| Yesavage, JA | 1 |
| O'Hara, R | 1 |
| Williams, LM | 4 |
| Gammoh, O | 1 |
| Ibrahim, A | 1 |
| Qnais, E | 1 |
| Alqudah, A | 1 |
| Altaber, S | 1 |
| Aljabali, AAA | 1 |
| Tambuwala, MM | 1 |
| Sudol, K | 1 |
| Conway, C | 1 |
| Szymkowicz, SM | 1 |
| Elson, D | 1 |
| Kang, H | 3 |
| Taylor, WD | 1 |
| Chen, R | 2 |
| Amirghasemi, F | 1 |
| Ma, H | 1 |
| Ong, V | 1 |
| Tran, A | 1 |
| Mousavi, MPS | 1 |
| Lu, Z | 1 |
| Xun, G | 1 |
| Abdo, SA | 1 |
| Wadie, W | 1 |
| Abdelsalam, RM | 1 |
| Khattab, MM | 3 |
| Kim, EY | 1 |
| Kim, SH | 1 |
| Lee, NY | 1 |
| Kim, HY | 4 |
| Park, CHK | 1 |
| Ahn, YM | 1 |
| Skritskaya, NA | 2 |
| Mauro, C | 2 |
| Garcia de la Garza, A | 2 |
| Meichsner, F | 1 |
| Lebowitz, B | 1 |
| Reynolds, CF | 5 |
| Simon, NM | 2 |
| Zisook, S | 7 |
| Shear, MK | 2 |
| Song, W | 1 |
| Shen, Y | 1 |
| Zhang, Y | 3 |
| Peng, S | 1 |
| Zhang, R | 1 |
| Ning, A | 1 |
| Li, H | 1 |
| Lin, GN | 1 |
| Yu, S | 1 |
| Smaga, I | 1 |
| Gawlinski, D | 1 |
| Brodowicz, J | 1 |
| Filip, M | 1 |
| Hellier, J | 1 |
| Emsley, R | 1 |
| Pickles, A | 1 |
| Szuhany, KL | 1 |
| Young, A | 1 |
| Spandorfer, J | 1 |
| Lubin, R | 1 |
| Hoeppner, SS | 1 |
| Li, M | 1 |
| Pace-Schott, E | 1 |
| Zhou, Y | 1 |
| Cong, Y | 1 |
| Liu, H | 2 |
| Lee, EJ | 3 |
| Kim, JS | 3 |
| Chang, DI | 3 |
| Park, JH | 3 |
| Ahn, SH | 3 |
| Cha, JK | 3 |
| Heo, JH | 3 |
| Sohn, SI | 3 |
| Lee, BC | 3 |
| Kim, DE | 3 |
| Kim, S | 3 |
| Kwon, DY | 3 |
| Kim, J | 4 |
| Seo, WK | 3 |
| Lee, J | 3 |
| Park, SW | 4 |
| Koh, SH | 3 |
| Kim, JY | 3 |
| Choi-Kwon, S | 3 |
| Zhang, C | 3 |
| Signorelli, MS | 1 |
| Surace, T | 1 |
| Migliore, M | 1 |
| Aguglia, E | 1 |
| Tomaz, VS | 1 |
| Chaves Filho, AJM | 1 |
| Cordeiro, RC | 1 |
| Jucá, PM | 1 |
| Soares, MVR | 1 |
| Barroso, PN | 1 |
| Cristino, LMF | 1 |
| Jiang, W | 1 |
| Teixeira, AL | 1 |
| de Lucena, DF | 1 |
| Macedo, DS | 1 |
| Siddarth, P | 4 |
| Funes, CM | 1 |
| Laird, KT | 3 |
| Ercoli, L | 2 |
| Lavretsky, H | 4 |
| Szoke-Kovacs, Z | 1 |
| More, C | 1 |
| Szoke-Kovacs, R | 1 |
| Mathe, E | 1 |
| Frecska, E | 1 |
| Dunlop, K | 1 |
| Rizvi, SJ | 1 |
| Kennedy, SH | 1 |
| Hassel, S | 1 |
| Strother, SC | 1 |
| Harris, JK | 1 |
| Zamyadi, M | 1 |
| Arnott, SR | 1 |
| Davis, AD | 1 |
| Mansouri, F | 1 |
| Schulze, L | 1 |
| Ceniti, AK | 1 |
| Lam, RW | 2 |
| Milev, R | 1 |
| Rotzinger, S | 1 |
| Foster, JA | 1 |
| Frey, BN | 1 |
| Parikh, SV | 1 |
| Soares, CN | 1 |
| Uher, R | 4 |
| Turecki, G | 2 |
| MacQueen, GM | 1 |
| Downar, J | 1 |
| Grzenda, A | 1 |
| Yeargin, J | 1 |
| Aguilar-Martinez, IS | 1 |
| Reyes-Mendez, ME | 1 |
| Herrera-Zamora, JM | 1 |
| Osuna-Lopez, F | 1 |
| Virgen-Ortiz, A | 1 |
| Mendoza-Munoz, N | 1 |
| Gongora-Alfaro, JL | 1 |
| Moreno-Galindo, EG | 1 |
| Alamilla, J | 1 |
| de la Salle, S | 1 |
| Jaworska, N | 2 |
| Blier, P | 3 |
| Smith, D | 1 |
| Knott, V | 2 |
| Takemoto, M | 1 |
| Ohta, Y | 1 |
| Hishikawa, N | 1 |
| Yamashita, T | 1 |
| Nomura, E | 1 |
| Tsunoda, K | 1 |
| Sasaki, R | 1 |
| Tadokoro, K | 1 |
| Matsumoto, N | 1 |
| Omote, Y | 1 |
| Abe, K | 1 |
| Tirmazi, SI | 1 |
| Imran, H | 1 |
| Rasheed, A | 1 |
| Mushtaq, S | 1 |
| Hu, J | 1 |
| Ma, L | 2 |
| Yang, ZY | 1 |
| Barakat, AK | 1 |
| Scholl, C | 1 |
| Steffens, M | 1 |
| Brandenburg, K | 1 |
| Ising, M | 1 |
| Lucae, S | 1 |
| Holsboer, F | 1 |
| Laje, G | 2 |
| Kalayda, GV | 1 |
| Jaehde, U | 1 |
| Stingl, JC | 1 |
| Nunes, JC | 1 |
| Botas, JL | 1 |
| Krause-Sorio, B | 1 |
| Kilpatrick, L | 1 |
| Milillo, MM | 1 |
| Narr, KL | 1 |
| Carboni, L | 4 |
| Pischedda, F | 1 |
| Piccoli, G | 1 |
| Lauria, M | 1 |
| Musazzi, L | 2 |
| Popoli, M | 3 |
| Mathé, AA | 11 |
| Domenici, E | 3 |
| Xiao, M | 1 |
| Feng, L | 1 |
| Luan, X | 1 |
| Chen, S | 2 |
| He, J | 1 |
| Bartels, C | 2 |
| Belz, M | 1 |
| Vogelgsang, J | 1 |
| Hessmann, P | 1 |
| Bohlken, J | 1 |
| Wiltfang, J | 1 |
| Kostev, K | 1 |
| Kim, MS | 1 |
| Lee, JS | 1 |
| Otte, C | 1 |
| Chae, WR | 1 |
| Nowacki, J | 1 |
| Kaczmarczyk, M | 1 |
| Piber, D | 1 |
| Roepke, S | 1 |
| Märschenz, S | 1 |
| Lischewski, S | 1 |
| Schmidt, S | 1 |
| Ettrich, B | 1 |
| Grabe, HJ | 1 |
| Hegerl, U | 1 |
| Hinkelmann, K | 1 |
| Hofmann, T | 1 |
| Janowitz, D | 1 |
| Junghanns, K | 1 |
| Kahl, KG | 1 |
| Klein, JP | 1 |
| Krueger, THC | 1 |
| Leicht, G | 1 |
| Prvulovic, D | 1 |
| Reif, A | 1 |
| Schoettle, D | 1 |
| Strauss, M | 1 |
| Westermair, A | 1 |
| Friede, T | 1 |
| Gold, SM | 1 |
| Goerigk, SA | 1 |
| Padberg, F | 1 |
| Bühner, M | 1 |
| Sarubin, N | 1 |
| Kaster, TS | 1 |
| Daskalakis, ZJ | 1 |
| Blumberger, DM | 1 |
| Borrione, L | 1 |
| Razza, LB | 1 |
| Brunoni, AR | 1 |
| Wigner, P | 1 |
| Synowiec, E | 1 |
| Jóźwiak, P | 1 |
| Czarny, P | 1 |
| Bijak, M | 1 |
| Białek, K | 1 |
| Szemraj, J | 1 |
| Gruca, P | 2 |
| Papp, M | 6 |
| Śliwiński, T | 1 |
| Shumake, J | 1 |
| Mallard, TT | 1 |
| McGeary, JE | 1 |
| Beevers, CG | 1 |
| Smith, GS | 5 |
| Kuwabara, H | 1 |
| Nandi, A | 1 |
| Gould, NF | 1 |
| Nassery, N | 1 |
| Savonenko, A | 1 |
| Joo, JH | 2 |
| Kraut, M | 1 |
| Brasic, J | 1 |
| Holt, DP | 1 |
| Hall, AW | 1 |
| Mathews, WB | 1 |
| Dannals, RF | 1 |
| Avramopoulos, D | 1 |
| Workman, CI | 2 |
| Nakagome, K | 1 |
| Yokoi, Y | 1 |
| Nakagawa, A | 2 |
| Tani, M | 1 |
| Nishioka, G | 1 |
| Yoshimura, N | 1 |
| Furukawa, TA | 5 |
| Iwanami, A | 1 |
| Abe, T | 1 |
| Gougoulaki, M | 1 |
| Lewis, G | 5 |
| Nutt, DJ | 1 |
| Peters, TJ | 2 |
| Wiles, NJ | 1 |
| MahmoudianDehkordi, S | 1 |
| Ahmed, AT | 1 |
| Bhattacharyya, S | 1 |
| Han, X | 1 |
| Baillie, RA | 1 |
| Arnold, M | 1 |
| Skime, MK | 1 |
| John-Williams, LS | 1 |
| Moseley, MA | 1 |
| Thompson, JW | 1 |
| Louie, G | 1 |
| Riva-Posse, P | 1 |
| Craighead, WE | 3 |
| McDonald, W | 1 |
| Krishnan, R | 1 |
| Rush, AJ | 10 |
| Frye, MA | 1 |
| Dunlop, BW | 3 |
| Weinshilboum, RM | 3 |
| Kaddurah-Daouk, R | 1 |
| Smith, KR | 1 |
| Kahlon, CH | 1 |
| Brown, JN | 1 |
| Britt, RB | 1 |
| Stanić, D | 1 |
| Oved, K | 1 |
| Israel-Elgali, I | 1 |
| Jukić, M | 1 |
| Batinić, B | 1 |
| Puškaš, N | 1 |
| Shomron, N | 1 |
| Gurwitz, D | 2 |
| Pešić, V | 1 |
| Sretavan Wong, K | 1 |
| Migó, M | 1 |
| Dougherty, DD | 3 |
| Ghaemi, SN | 1 |
| Duan, J | 1 |
| Tan, X | 1 |
| Chai, T | 1 |
| Li, Y | 2 |
| Hu, X | 2 |
| Zheng, P | 1 |
| Ji, P | 1 |
| Zhao, L | 1 |
| Yang, D | 1 |
| Fang, L | 2 |
| Song, J | 1 |
| Xie, P | 1 |
| Chmielarz, P | 1 |
| Kuśmierczyk, J | 1 |
| Rafa-Zabłocka, K | 1 |
| Chorązka, K | 1 |
| Kowalska, M | 1 |
| Satała, G | 1 |
| Nalepa, I | 2 |
| Jones, JS | 1 |
| Kimata, R | 1 |
| Almeida, OP | 2 |
| Hankey, GJ | 2 |
| Dionisie, V | 1 |
| Ciobanu, AM | 1 |
| Toma, VA | 1 |
| Manea, MC | 1 |
| Baldea, I | 1 |
| Olteanu, D | 1 |
| Sevastre-Berghian, A | 1 |
| Clichici, S | 1 |
| Manea, M | 1 |
| Riga, S | 1 |
| Filip, GA | 1 |
| Abdelwahab, LA | 1 |
| Galal, OO | 1 |
| Abd El-Rahman, SS | 1 |
| El-Brairy, AI | 1 |
| El-Khatib, AS | 1 |
| Zilcha-Mano, S | 3 |
| Roose, SP | 3 |
| Brown, PJ | 3 |
| Rutherford, BR | 3 |
| Fountoulakis, KN | 1 |
| Minami, S | 1 |
| Satoyoshi, H | 1 |
| Ide, S | 1 |
| Inoue, T | 1 |
| Yoshioka, M | 1 |
| Minami, M | 1 |
| Avitsur, R | 1 |
| Paley, S | 1 |
| Franko, M | 3 |
| Wolff, N | 1 |
| Eyal, N | 1 |
| Doron, R | 4 |
| Sun, Y | 2 |
| Liang, Y | 1 |
| Lin, J | 1 |
| Qu, H | 1 |
| Xu, J | 1 |
| Zhao, C | 1 |
| Dong, X | 1 |
| Liu, M | 1 |
| Sun, A | 1 |
| Li, N | 1 |
| Lin, Y | 2 |
| Geng, Z | 1 |
| Jin, Y | 2 |
| Dy, P | 1 |
| Arcega, V | 1 |
| Ghali, W | 1 |
| Wolfe, W | 1 |
| Jin, ZL | 3 |
| Chen, XF | 1 |
| Ran, YH | 1 |
| Li, XR | 3 |
| Xiong, J | 3 |
| Zheng, YY | 1 |
| Gao, NN | 1 |
| Li, YF | 3 |
| Rajagopal, R | 1 |
| Jois, SN | 1 |
| Mallikarjuna Majgi, S | 1 |
| Anil Kumar, MN | 1 |
| Shashidhar, HB | 1 |
| Womersley, K | 1 |
| Ripullone, K | 1 |
| Agius, M | 1 |
| Benatti, C | 1 |
| Alboni, S | 1 |
| Blom, JMC | 1 |
| Mendlewicz, J | 1 |
| Tascedda, F | 1 |
| Brunello, N | 1 |
| Szopa, A | 3 |
| Doboszewska, U | 2 |
| Herbet, M | 1 |
| Wośko, S | 3 |
| Wyska, E | 3 |
| Świąder, K | 3 |
| Serefko, A | 4 |
| Korga, A | 1 |
| Wlaź, A | 2 |
| Wróbel, A | 3 |
| Ostrowska, M | 1 |
| Terlecka, J | 1 |
| Kanadys, A | 1 |
| Poleszak, E | 5 |
| Dudka, J | 2 |
| Wlaź, P | 4 |
| Burstein, O | 2 |
| Gale, E | 1 |
| Handelsman, A | 2 |
| Barak, S | 1 |
| Motsan, S | 1 |
| Shamir, A | 2 |
| Toledano, R | 2 |
| Simhon, O | 1 |
| Hirshler, Y | 1 |
| Chen, G | 2 |
| Wagner, M | 1 |
| Wolfsgruber, S | 1 |
| Ehrenreich, H | 1 |
| Schneider, A | 1 |
| O'Connell, CP | 1 |
| Goldstein-Piekarski, AN | 1 |
| Nemeroff, CB | 4 |
| Debattista, C | 1 |
| Carrillo-Roa, T | 2 |
| Binder, EB | 2 |
| Mayberg, HS | 2 |
| Wang, M | 2 |
| Huang, W | 1 |
| Gao, T | 1 |
| Zhao, X | 3 |
| Lv, Z | 1 |
| Paraschakis, A | 1 |
| Katsanos, AH | 1 |
| Wang, P | 2 |
| Lv, Q | 2 |
| Mao, Y | 1 |
| Bao, C | 2 |
| Sun, H | 2 |
| Chen, H | 3 |
| Yi, Z | 2 |
| Cai, W | 2 |
| Fang, Y | 2 |
| de Dios, I | 1 |
| Rialp, G | 1 |
| Franco, S | 1 |
| Romero, M | 1 |
| Ortega, M | 1 |
| Nieto, Y | 1 |
| IsHak, WW | 1 |
| Steiner, AJ | 1 |
| Klimowicz, A | 1 |
| Kauzor, K | 1 |
| Dang, J | 1 |
| Vanle, B | 1 |
| Elzahaby, C | 1 |
| Reid, M | 1 |
| Sumner, L | 1 |
| Danovitch, I | 1 |
| Perez-Palomar, B | 1 |
| Mollinedo-Gajate, I | 1 |
| Berrocoso, E | 1 |
| Meana, JJ | 1 |
| Ortega, JE | 1 |
| Rahikainen, AL | 1 |
| Palo, JU | 1 |
| Haukka, J | 1 |
| Sajantila, A | 1 |
| Jha, MK | 1 |
| Wakhlu, S | 1 |
| Dronamraju, N | 1 |
| Greer, TL | 1 |
| Kamel, R | 1 |
| Abbas, H | 1 |
| El-Naa, M | 1 |
| Tsuchimine, S | 2 |
| Ochi, S | 1 |
| Tajiri, M | 1 |
| Suzuki, Y | 1 |
| Sugawara, N | 1 |
| Inoue, Y | 2 |
| Yasui-Furukori, N | 2 |
| Xu, JH | 2 |
| Jiang, P | 1 |
| Wu, C | 1 |
| Gong, WG | 1 |
| Wang, YJ | 1 |
| Sun, JJ | 1 |
| Zhou, H | 2 |
| Ren, QG | 1 |
| Telang, S | 1 |
| Walton, C | 1 |
| Olten, B | 1 |
| Bloch, MH | 1 |
| Xiaoling, Z | 1 |
| Yunping, H | 1 |
| Yingdong, L | 1 |
| Ma, G | 1 |
| Kim, Y | 1 |
| Aguilar-Valles, A | 1 |
| Haji, N | 1 |
| De Gregorio, D | 1 |
| Matta-Camacho, E | 1 |
| Eslamizade, MJ | 1 |
| Popic, J | 1 |
| Sharma, V | 1 |
| Cao, R | 1 |
| Rummel, C | 1 |
| Tanti, A | 1 |
| Wiebe, S | 1 |
| Nuñez, N | 1 |
| Comai, S | 1 |
| Nadon, R | 1 |
| Luheshi, G | 1 |
| Mechawar, N | 1 |
| Lacaille, JC | 1 |
| Gobbi, G | 1 |
| Sonenberg, N | 1 |
| Abeysundera, H | 1 |
| Gill, R | 1 |
| Misrani, A | 1 |
| Tabassum, S | 1 |
| Chen, X | 2 |
| Tan, SY | 1 |
| Wang, JC | 1 |
| Yang, L | 2 |
| Long, C | 2 |
| Lee, YS | 1 |
| Bae, KY | 7 |
| Kim, JH | 2 |
| Peixoto, MF | 1 |
| Cesaretti, M | 1 |
| Hood, SD | 1 |
| Tavares, A | 1 |
| Novick, AM | 1 |
| Ross, DA | 1 |
| Bogatko, K | 1 |
| Roohi-Azizi, M | 1 |
| Torkaman-Boutorabi, A | 1 |
| Akhondzadeh, S | 1 |
| Nejatisafa, AA | 1 |
| Sadat-Shirazi, MS | 1 |
| Schoretsanitis, G | 1 |
| Augustin, M | 1 |
| Saßmannshausen, H | 1 |
| Franz, C | 1 |
| Paulzen, M | 1 |
| Godlewska, BR | 1 |
| Browning, M | 2 |
| Norbury, R | 2 |
| Igoumenou, A | 1 |
| Cowen, PJ | 2 |
| Harmer, CJ | 5 |
| Rubin, R | 1 |
| Weigl, J | 1 |
| Vloet, T | 1 |
| Egberts, K | 1 |
| Briegel, W | 1 |
| Kratz, J | 1 |
| Romanos, M | 1 |
| Gerlach, M | 1 |
| Haduch, A | 1 |
| Rysz, M | 1 |
| Daniel, WA | 1 |
| Cui, M | 1 |
| Huang, CY | 1 |
| Wang, F | 1 |
| Willner, P | 1 |
| Lason, M | 1 |
| Tota-Glowczyk, K | 1 |
| Litwa, E | 2 |
| Niemczyk, M | 1 |
| Dai, CX | 1 |
| Hu, CC | 1 |
| Shang, YS | 1 |
| Xie, J | 1 |
| Panwar, A | 1 |
| Rieke, K | 1 |
| Burke, WJ | 2 |
| Sayles, H | 1 |
| Lydiatt, WM | 1 |
| Kircanski, K | 1 |
| Gotlib, IH | 1 |
| De La Garza, N | 1 |
| Killian, MO | 1 |
| Grannemann, BD | 1 |
| Carmody, TJ | 1 |
| Kim, HR | 1 |
| Shin, MG | 1 |
| Kingslake, J | 1 |
| Dourish, CT | 1 |
| Goodwin, GM | 1 |
| Dawson, GR | 1 |
| Thombs, BD | 1 |
| Ziegelstein, RC | 1 |
| Zimmermann, FM | 1 |
| El Farissi, M | 1 |
| Tonino, PAL | 1 |
| Rust, G | 1 |
| Angelucci, F | 1 |
| Ellenbroek, BA | 1 |
| El Khoury, A | 3 |
| Ostuzzi, G | 1 |
| Turrini, G | 1 |
| Gastaldon, C | 1 |
| Papola, D | 1 |
| Rayner, L | 1 |
| Caruso, R | 1 |
| Grassi, L | 1 |
| Hotopf, M | 1 |
| Barbui, C | 5 |
| Seo, MK | 1 |
| Lee, JG | 1 |
| Furuse, K | 1 |
| Ukai, W | 1 |
| Hashimoto, E | 1 |
| Hashiguchi, H | 1 |
| Kigawa, Y | 1 |
| Ishii, T | 1 |
| Tayama, M | 1 |
| Deriha, K | 1 |
| Shiraishi, M | 1 |
| Kawanishi, C | 1 |
| Goff, DC | 1 |
| Freudenreich, O | 1 |
| Cather, C | 1 |
| Holt, D | 1 |
| Bello, I | 1 |
| Diminich, E | 1 |
| Tang, Y | 3 |
| Ardekani, BA | 1 |
| Worthington, M | 1 |
| Zeng, B | 1 |
| Wu, R | 1 |
| Fan, X | 1 |
| Li, C | 1 |
| Troxel, A | 1 |
| Wang, J | 4 |
| Zhao, J | 2 |
| Prabhakar, D | 1 |
| Sablaban, I | 1 |
| Noma, H | 1 |
| Maruo, K | 1 |
| Imai, H | 1 |
| Shinohara, K | 1 |
| Tanaka, S | 1 |
| Ikeda, K | 1 |
| Yamawaki, S | 1 |
| Cipriani, A | 5 |
| Assimon, MM | 1 |
| Brookhart, MA | 1 |
| Flythe, JE | 1 |
| Roselle, A | 1 |
| Jiang, J | 1 |
| Chen, Y | 2 |
| Jacobsen, PL | 1 |
| Nomikos, GG | 1 |
| Zhong, W | 1 |
| Cutler, AJ | 1 |
| Affinito, J | 1 |
| Clayton, A | 1 |
| Lin, Q | 1 |
| Lin, T | 1 |
| Lin, X | 1 |
| Luo, L | 1 |
| Lin, F | 1 |
| Xiao, Y | 1 |
| Duffy, L | 1 |
| Bacon, F | 1 |
| Clarke, CS | 1 |
| Donkor, Y | 1 |
| Freemantle, N | 1 |
| Gilbody, S | 1 |
| Hunter, R | 1 |
| Kendrick, T | 1 |
| Kessler, D | 1 |
| King, M | 1 |
| Lanham, P | 1 |
| Mangin, D | 1 |
| Marston, L | 1 |
| Moore, M | 1 |
| Nazareth, I | 1 |
| Wiles, N | 2 |
| Hou, R | 1 |
| Ye, G | 1 |
| Pan, M | 1 |
| Zhu, F | 1 |
| Fu, J | 1 |
| Fu, T | 1 |
| Liu, Q | 1 |
| Gao, Z | 1 |
| Baldwin, DS | 4 |
| Tang, Z | 1 |
| Lin, YT | 1 |
| Lu, TS | 1 |
| Hansen, RA | 1 |
| Wang, CC | 1 |
| Versano, Z | 1 |
| Rehavi, M | 2 |
| Hieronymus, F | 1 |
| Lisinski, A | 1 |
| Nilsson, S | 1 |
| Eriksson, E | 2 |
| Quesseveur, G | 1 |
| Repérant, C | 2 |
| David, DJ | 3 |
| Gardier, AM | 2 |
| Sanchez, C | 6 |
| Guiard, BP | 1 |
| Proudfoot, M | 1 |
| Gormley, J | 1 |
| Bourke, CH | 1 |
| Capello, CF | 1 |
| Rogers, SM | 1 |
| Yu, ML | 1 |
| Boss-Williams, KA | 1 |
| Weiss, JM | 1 |
| Stowe, ZN | 1 |
| Owens, MJ | 2 |
| Kaplan, C | 1 |
| Keller, DL | 1 |
| Sheeler, RD | 2 |
| Ackerman, MJ | 2 |
| Richelson, E | 2 |
| Nelson, TK | 2 |
| Staab, JP | 2 |
| Tangalos, EG | 2 |
| Dieser, LM | 2 |
| Cunningham, JL | 2 |
| Morris, DW | 2 |
| Wisniewski, SR | 7 |
| Lesser, I | 1 |
| Nierenberg, AA | 2 |
| Daly, E | 1 |
| Kurian, BT | 2 |
| Gaynes, BN | 2 |
| Balasubramani, GK | 2 |
| Huang, CC | 1 |
| Wei, IH | 1 |
| Huang, CL | 1 |
| Chen, KT | 1 |
| Tsai, MH | 1 |
| Tsai, P | 1 |
| Tun, R | 1 |
| Huang, KH | 1 |
| Chang, YC | 1 |
| Lane, HY | 1 |
| Tsai, GE | 1 |
| Musselman, D | 1 |
| Royster, EB | 1 |
| Long, Q | 1 |
| Trimble, LM | 1 |
| Mann, TK | 1 |
| Graciaa, DS | 1 |
| McNutt, MD | 1 |
| Auyeung, NS | 1 |
| Oliver, L | 1 |
| Lawson, DH | 1 |
| Miller, AH | 1 |
| Dodd, S | 1 |
| Berk, M | 1 |
| Kelin, K | 1 |
| Mancini, M | 1 |
| Schacht, A | 1 |
| Shinozaki, G | 1 |
| Romanowicz, M | 1 |
| Mrazek, DA | 2 |
| Kung, S | 1 |
| Glitho, S | 1 |
| Boukari, L | 1 |
| Mekinian, A | 1 |
| Fain, O | 1 |
| Nicolau, J | 1 |
| Rivera, R | 1 |
| Francés, C | 1 |
| Chacártegui, B | 1 |
| Masmiquel, L | 1 |
| Han, ZA | 1 |
| Qi, M | 1 |
| Zhou, B | 1 |
| Su, M | 1 |
| Pan, J | 1 |
| Lotan, D | 1 |
| Einat, N | 1 |
| Yaffe, R | 1 |
| Winer, A | 1 |
| Marom, I | 1 |
| Meron, G | 1 |
| Kately, N | 1 |
| Hou, XJ | 1 |
| Yu, YY | 1 |
| Boston, CD | 1 |
| Munzer, A | 1 |
| Sack, U | 1 |
| Mergl, R | 1 |
| Schönherr, J | 1 |
| Petersein, C | 1 |
| Bartsch, S | 1 |
| Kirkby, KC | 1 |
| Bauer, K | 1 |
| Himmerich, H | 1 |
| Pastoor, D | 1 |
| Gobburu, J | 1 |
| Weinstein, AM | 1 |
| Miller, H | 1 |
| Bluvstein, I | 1 |
| Rapoport, E | 1 |
| Schreiber, S | 1 |
| Bar-Hamburger, R | 1 |
| Bloch, M | 1 |
| Wielpuetz, C | 1 |
| Kuepper, Y | 1 |
| Grant, P | 1 |
| Munk, AJ | 1 |
| Hennig, J | 1 |
| Reines, EH | 2 |
| Montgomery, SA | 2 |
| Martocchia, A | 1 |
| Curto, M | 1 |
| Scaccianoce, S | 1 |
| Comite, F | 1 |
| Xenos, D | 1 |
| Nasca, C | 1 |
| Falaschi, GM | 1 |
| Ferracuti, S | 1 |
| Girardi, P | 1 |
| Nicoletti, F | 2 |
| Falaschi, P | 1 |
| Pottegård, A | 1 |
| Zoëga, H | 1 |
| Hallas, J | 1 |
| Damkier, P | 1 |
| Zuccoli, ML | 1 |
| Milano, G | 1 |
| Leone, S | 1 |
| Fucile, C | 1 |
| Brasesco, PC | 1 |
| Martelli, A | 1 |
| Mattioli, F | 1 |
| Blondeau, C | 1 |
| Tessier, P | 1 |
| Norris, S | 1 |
| Fusee, W | 1 |
| Hjorthøj, CR | 1 |
| Hansen, BH | 4 |
| Hanash, JA | 5 |
| Rasmussen, A | 5 |
| Birket-Smith, M | 4 |
| Gao, N | 2 |
| Zhang, JR | 1 |
| Chen, HX | 2 |
| Ramírez-Rodríguez, G | 1 |
| Vega-Rivera, NM | 1 |
| Oikawa-Sala, J | 1 |
| Gómez-Sánchez, A | 1 |
| Ortiz-López, L | 1 |
| Estrada-Camarena, E | 1 |
| Green, A | 1 |
| Crawford, A | 1 |
| Button, KS | 1 |
| Nutt, D | 1 |
| Dennehy, EB | 1 |
| Marangell, LB | 1 |
| Martinez, J | 1 |
| Elnazer, HY | 1 |
| Kiani, IG | 1 |
| Qureshi, SH | 1 |
| Shah, F | 1 |
| Dhavale, HS | 1 |
| Panikkar, V | 1 |
| Jadhav, BS | 1 |
| Ghulghule, M | 1 |
| Agari, AD | 1 |
| Usall, J | 1 |
| López-Carrilero, R | 1 |
| Iniesta, R | 1 |
| Roca, M | 1 |
| Caballero, M | 1 |
| Rodriguez-Jimenez, R | 1 |
| Oliveira, C | 1 |
| Bernardo, M | 1 |
| Corripio, I | 1 |
| Sindreu, SD | 1 |
| González Piqueras, JC | 1 |
| Felipe, AE | 1 |
| Fernandez de Corres, B | 1 |
| Ibáñez, A | 1 |
| Huerta, R | 1 |
| Yuen, GS | 1 |
| Gunning, FM | 1 |
| Woods, E | 1 |
| Klimstra, SA | 1 |
| Hoptman, MJ | 2 |
| Alexopoulos, GS | 7 |
| Morimoto, SS | 1 |
| Wexler, BE | 1 |
| Liu, J | 2 |
| Hu, W | 1 |
| Seirup, J | 1 |
| Hotho, DM | 1 |
| Bezemer, G | 1 |
| Hansen, BE | 1 |
| Van Gool, AR | 1 |
| de Knegt, RJ | 1 |
| Janssen, HL | 1 |
| Veldt, BJ | 1 |
| Roohafza, H | 1 |
| Pourmoghaddas, Z | 1 |
| Saneian, H | 1 |
| Gholamrezaei, A | 1 |
| Affan, M | 1 |
| Shaikh, Q | 1 |
| Kamal, AK | 1 |
| Scantamburlo, G | 1 |
| Hansenne, M | 1 |
| Geenen, V | 1 |
| Legros, JJ | 1 |
| Ansseau, M | 1 |
| Mlyniec, K | 1 |
| Ostachowicz, B | 1 |
| Krakowska, A | 1 |
| Reczynski, W | 1 |
| Opoka, W | 1 |
| Nowak, G | 4 |
| Baranchuk, A | 2 |
| Hancox, JC | 1 |
| Eryilmaz, G | 1 |
| Enez Darcin, A | 1 |
| Saglam, E | 1 |
| Gogcegoz Gul, I | 1 |
| Korendovych, IV | 1 |
| Svintsits'kyĭ, AS | 1 |
| Revenok, KM | 1 |
| Maliarov, SO | 1 |
| Weissman, MM | 1 |
| Wickramaratne, P | 1 |
| Pilowsky, DJ | 1 |
| Poh, E | 1 |
| Batten, LA | 1 |
| Hernandez, M | 1 |
| Flament, MF | 1 |
| Stewart, JA | 1 |
| McGrath, P | 1 |
| Stewart, JW | 2 |
| Xue, R | 1 |
| Lin, DH | 1 |
| Zhang, XR | 1 |
| Ye, DQ | 1 |
| Xi, GJ | 1 |
| Hui, JJ | 1 |
| Liu, SS | 1 |
| Li, LJ | 1 |
| Schmidt, C | 1 |
| Hodgson, K | 1 |
| Tansey, KE | 1 |
| Dernovšek, MZ | 1 |
| Hauser, J | 1 |
| Souery, D | 1 |
| Maier, W | 2 |
| Henigsberg, N | 1 |
| Rietschel, M | 1 |
| Placentino, A | 1 |
| Craig, IW | 1 |
| Aitchison, KJ | 1 |
| Farmer, AE | 1 |
| Dobson, RJ | 1 |
| McGuffin, P | 3 |
| Tripathi, P | 1 |
| Tomar, LR | 1 |
| Goyal, P | 1 |
| Singh, P | 1 |
| Rominger, A | 1 |
| Cumming, P | 1 |
| Brendel, M | 1 |
| Xiong, G | 1 |
| Zach, C | 1 |
| Karch, S | 1 |
| Tatsch, K | 1 |
| Bartenstein, P | 1 |
| la Fougère, C | 1 |
| Koch, W | 1 |
| Pogarell, O | 1 |
| Młyniec, K | 3 |
| Gaweł, M | 1 |
| Mokoena, ML | 1 |
| Harvey, BH | 1 |
| Viljoen, F | 1 |
| Ellis, SM | 1 |
| Brink, CB | 1 |
| Suliman, S | 1 |
| Seedat, S | 2 |
| Pingo, J | 1 |
| Sutherland, T | 1 |
| Zohar, J | 1 |
| Stein, DJ | 2 |
| Coiro, MJ | 1 |
| Wolak, M | 1 |
| Siwek, A | 1 |
| Szewczyk, B | 1 |
| Bystrowska, B | 1 |
| Moniczewski, A | 1 |
| Rutkowska, A | 1 |
| Kelley, ME | 1 |
| McGrath, CL | 1 |
| Manning, K | 1 |
| Kanellopoulos, D | 2 |
| McGovern, A | 1 |
| Seirup, JK | 1 |
| Banerjee, S | 1 |
| Gunning, F | 1 |
| Kurhe, Y | 1 |
| Mahesh, R | 1 |
| Charney, DA | 1 |
| Heath, LM | 1 |
| Zikos, E | 1 |
| Palacios-Boix, J | 1 |
| Gill, KJ | 1 |
| Fu, W | 1 |
| Zhu, H | 1 |
| Yang, W | 1 |
| Liu, C | 1 |
| Han, R | 1 |
| Matchkov, VV | 1 |
| Kravtsova, VV | 1 |
| Wiborg, O | 9 |
| Aalkjaer, C | 1 |
| Bouzinova, EV | 1 |
| Ulbricht, CM | 2 |
| Rothschild, AJ | 2 |
| Lapane, KL | 2 |
| Liang, S | 1 |
| Wang, T | 1 |
| Luo, J | 1 |
| Li, W | 1 |
| Wu, X | 1 |
| Duan, Y | 1 |
| Jin, F | 1 |
| Grover, S | 1 |
| Avasthi, A | 1 |
| Tripathi, A | 1 |
| Tanra, AJ | 1 |
| Chee, KY | 1 |
| He, YL | 1 |
| Chiu, HF | 1 |
| Kuga, H | 1 |
| Lee, MS | 1 |
| Chong, MY | 1 |
| Udormatn, P | 1 |
| Kanba, S | 1 |
| Yang, SY | 1 |
| Si, TM | 1 |
| Sim, K | 1 |
| Tan, CH | 1 |
| Shen, WW | 1 |
| Xiang, YT | 1 |
| Sartorius, N | 1 |
| Shinfuku, N | 1 |
| Gallo, JJ | 1 |
| Hwang, S | 1 |
| Bogner, HR | 2 |
| Morales, KH | 2 |
| Bruce, ML | 3 |
| Davari-Tanha, F | 1 |
| Soleymani-Farsani, M | 1 |
| Asadi, M | 1 |
| Shariat, M | 1 |
| Shirazi, M | 1 |
| Hadizadeh, H | 1 |
| Foulds, JA | 1 |
| Mulder, RT | 1 |
| Newton-Howes, G | 1 |
| Adamson, SJ | 1 |
| Boden, JM | 1 |
| Sellman, JD | 1 |
| Nackenoff, AG | 1 |
| Moussa-Tooks, AB | 1 |
| McMeekin, AM | 1 |
| Veenstra-VanderWeele, J | 1 |
| Blakely, RD | 1 |
| Tan, S | 1 |
| Huang, X | 1 |
| Ding, L | 1 |
| Hong, H | 1 |
| Bushnell, GA | 1 |
| Stürmer, T | 1 |
| Swanson, SA | 1 |
| White, A | 1 |
| Azrael, D | 1 |
| Pate, V | 1 |
| Miller, M | 1 |
| Knorr, U | 3 |
| Koefoed, P | 2 |
| Soendergaard, MH | 1 |
| Vinberg, M | 2 |
| Gether, U | 2 |
| Gluud, C | 2 |
| Wetterslev, J | 2 |
| Winkel, P | 2 |
| Kessing, LV | 3 |
| Arns, M | 1 |
| Gordon, E | 1 |
| Boutros, NN | 1 |
| Diken, Aİ | 1 |
| Yalçınkaya, A | 1 |
| Erçen Diken, Ö | 1 |
| Aksoy, E | 1 |
| Doğan, İ | 1 |
| Yılmaz, S | 1 |
| Çağlı, K | 1 |
| Yang, SN | 1 |
| Wang, YH | 1 |
| Tung, CS | 2 |
| Ko, CY | 1 |
| Liu, YP | 2 |
| Lin, CC | 1 |
| Barth, M | 1 |
| Kriston, L | 1 |
| Klostermann, S | 1 |
| Linde, K | 1 |
| Dong, C | 1 |
| Zhang, JC | 1 |
| Yao, W | 1 |
| Ren, Q | 1 |
| Yang, C | 1 |
| Ma, M | 1 |
| Han, M | 1 |
| Saito, R | 1 |
| Hashimoto, K | 1 |
| Caccavale, S | 1 |
| Mea, EE | 1 |
| La Montagna, M | 1 |
| Stasiuk, W | 1 |
| Oniszczuk, A | 1 |
| Msetfi, RM | 1 |
| Kumar, P | 1 |
| Murphy, RA | 1 |
| Shilyansky, C | 1 |
| Gyurak, A | 1 |
| Harris, A | 1 |
| Usherwood, T | 1 |
| Etkin, A | 1 |
| Nil, R | 1 |
| Lütolf, S | 1 |
| Seifritz, E | 2 |
| Ishioka, M | 1 |
| Nakamura, K | 1 |
| Suphanklang, J | 1 |
| Santimaleeworagun, W | 1 |
| Supasyndh, O | 1 |
| Luo, D | 1 |
| Liang, Z | 1 |
| Lao, L | 1 |
| Rong, J | 1 |
| Gessel, L | 1 |
| Alcorn, J | 1 |
| Nobels, A | 1 |
| Geboes, K | 1 |
| Lemmens, GM | 1 |
| Jureidini, JN | 1 |
| Amsterdam, JD | 1 |
| McHenry, LB | 1 |
| Ho, AM | 1 |
| Qiu, Y | 1 |
| Jia, YF | 1 |
| Aguiar, FS | 1 |
| Hinton, DJ | 1 |
| Karpyak, VM | 1 |
| Choi, DS | 1 |
| Palmer, SC | 1 |
| Natale, P | 1 |
| Ruospo, M | 1 |
| Saglimbene, VM | 1 |
| Rabindranath, KS | 1 |
| Craig, JC | 1 |
| Strippoli, GF | 1 |
| Fitzpatrick, CM | 1 |
| Larsen, M | 1 |
| Madsen, LH | 1 |
| Caballero-Puntiverio, M | 1 |
| Pickering, DS | 1 |
| Clausen, RP | 1 |
| Andreasen, JT | 3 |
| Salehpour, F | 1 |
| Rasta, SH | 1 |
| Mohaddes, G | 1 |
| Sadigh-Eteghad, S | 1 |
| Salarirad, S | 1 |
| Angermann, CE | 3 |
| Gelbrich, G | 2 |
| Störk, S | 2 |
| Gunold, H | 1 |
| Edelmann, F | 1 |
| Wachter, R | 1 |
| Schunkert, H | 1 |
| Graf, T | 1 |
| Kindermann, I | 1 |
| Haass, M | 1 |
| Blankenberg, S | 1 |
| Pankuweit, S | 1 |
| Prettin, C | 1 |
| Gottwik, M | 1 |
| Böhm, M | 1 |
| Faller, H | 2 |
| Deckert, J | 3 |
| Ertl, G | 3 |
| Jiang, H | 1 |
| Lu, N | 1 |
| Yue, Y | 1 |
| Liang, J | 1 |
| Zhang, Z | 2 |
| Yuan, Y | 1 |
| Marcus, MM | 1 |
| Björkholm, C | 1 |
| Malmerfelt, A | 1 |
| Möller, A | 1 |
| Påhlsson, N | 1 |
| Konradsson-Geuken, Å | 1 |
| Feltmann, K | 1 |
| Jardemark, K | 1 |
| Schilström, B | 1 |
| Svensson, TH | 1 |
| Schindler, EA | 1 |
| Guo, XM | 1 |
| Schrag, M | 1 |
| Ghoshal, S | 1 |
| Schilsky, ML | 1 |
| Beslow, LA | 1 |
| Kaminska, K | 1 |
| Rogoz, Z | 3 |
| Sprowles, JL | 1 |
| Hufgard, JR | 1 |
| Gutierrez, A | 1 |
| Bailey, RA | 1 |
| Jablonski, SA | 1 |
| Williams, MT | 1 |
| Vorhees, CV | 1 |
| Moon, WJ | 1 |
| Ibrahim, WW | 1 |
| Safar, MM | 1 |
| Agha, AM | 1 |
| Solmi, M | 1 |
| Veronese, N | 1 |
| Zaninotto, L | 1 |
| van der Loos, ML | 1 |
| Gao, K | 1 |
| Schaffer, A | 1 |
| Reis, C | 1 |
| Normann, C | 1 |
| Anghelescu, IG | 1 |
| Correll, CU | 1 |
| Malki, K | 2 |
| Tosto, MG | 1 |
| Mouriño-Talín, H | 1 |
| Rodríguez-Lorenzo, S | 1 |
| Pain, O | 1 |
| Jumhaboy, I | 1 |
| Liu, T | 1 |
| Parpas, P | 1 |
| Newman, S | 1 |
| Malykh, A | 1 |
| Schalkwyk, LC | 2 |
| Bryson, K | 1 |
| Herbster, M | 1 |
| Madhoo, M | 1 |
| Levine, SZ | 1 |
| An, H | 1 |
| Choi, B | 1 |
| Park, KW | 1 |
| Kim, DH | 1 |
| Yang, DW | 1 |
| Hong, CH | 1 |
| Han, SH | 1 |
| Ströhle, A | 1 |
| Rieckmann, N | 1 |
| Galizia, I | 1 |
| Oldani, L | 1 |
| Macritchie, K | 1 |
| Amari, E | 1 |
| Dougall, D | 1 |
| Jones, TN | 1 |
| Massei, GJ | 1 |
| Yatham, LN | 1 |
| Young, AH | 1 |
| John, A | 1 |
| Marchant, AL | 1 |
| Fone, DL | 1 |
| McGregor, JI | 1 |
| Dennis, MS | 1 |
| Tan, JO | 1 |
| Lloyd, K | 1 |
| Jukić, MM | 1 |
| Opel, N | 1 |
| Ström, J | 1 |
| Miksys, S | 1 |
| Novalen, M | 1 |
| Renblom, A | 1 |
| Sim, SC | 1 |
| Peñas-Lledó, EM | 1 |
| Courtet, P | 1 |
| Llerena, A | 1 |
| Baune, BT | 1 |
| de Quervain, DJ | 1 |
| Papassotiropoulos, A | 1 |
| Tyndale, RF | 1 |
| Dannlowski, U | 1 |
| Ingelman-Sundberg, M | 1 |
| Kumar, S | 1 |
| Robinson, RG | 2 |
| Jorge, RE | 2 |
| Long, J | 1 |
| Carney, CE | 1 |
| Edinger, JD | 1 |
| Kuchibhatla, M | 1 |
| Lachowski, AM | 1 |
| Bogouslavsky, O | 1 |
| Krystal, AD | 1 |
| Shapiro, CM | 1 |
| Zhou, C | 1 |
| Zhong, J | 1 |
| Zou, B | 1 |
| Chen, J | 1 |
| Deng, X | 1 |
| Zhang, L | 1 |
| Qu, Z | 1 |
| Lei, Y | 1 |
| Lei, T | 1 |
| Kajta, M | 1 |
| Wnuk, A | 1 |
| Rzemieniec, J | 1 |
| Lason, W | 1 |
| Zelek-Molik, A | 1 |
| Grochowalski, A | 1 |
| Wojtowicz, AK | 1 |
| Wang, SH | 4 |
| Guo, YJ | 4 |
| Teng, GJ | 3 |
| Chen, BA | 3 |
| Olsen, GM | 1 |
| Redrobe, JP | 3 |
| Simpson, CS | 1 |
| Methot, M | 1 |
| Gibson, K | 1 |
| Strum, D | 1 |
| Vesteinsdottir, E | 1 |
| Matthiasson, P | 1 |
| Lacasse, J | 1 |
| Leo, J | 1 |
| Dettling, M | 1 |
| Opgen-Rhein, C | 1 |
| Anghelescu, I | 1 |
| Schulte-Herbrüggen, O | 1 |
| Röpke, S | 1 |
| Bech, P | 1 |
| Tixier, H | 1 |
| Feyeux, C | 1 |
| Girod, S | 1 |
| Thouvenot, S | 1 |
| Morisse, M | 1 |
| Douvier, S | 1 |
| Sagot, P | 1 |
| Krol, DG | 1 |
| Lekakis, J | 1 |
| Ikonomidis, I | 1 |
| Papoutsi, Z | 1 |
| Moutsatsou, P | 1 |
| Nikolaou, M | 1 |
| Parissis, J | 1 |
| Kremastinos, DT | 1 |
| Peters, EJ | 3 |
| Slager, SL | 3 |
| Jenkins, GD | 3 |
| Reinalda, MS | 3 |
| Garriock, HA | 1 |
| Shyn, SI | 1 |
| Kraft, JB | 3 |
| McGrath, PJ | 3 |
| Hamilton, SP | 3 |
| Kasper, S | 3 |
| Larsson Lönn, S | 1 |
| Boulenger, JP | 1 |
| Pjrek, E | 1 |
| Konstantinidis, A | 1 |
| Assem-Hilger, E | 1 |
| Praschak-Rieder, N | 1 |
| Willeit, M | 1 |
| Winkler, D | 1 |
| Deltheil, T | 1 |
| Tanaka, K | 1 |
| Hen, R | 1 |
| Pogosova, GV | 2 |
| Koltunov, IE | 1 |
| Karpova, AV | 1 |
| Eliseeva, NA | 1 |
| Sapunova, ID | 1 |
| Perlis, RH | 1 |
| Smoller, JW | 1 |
| Fava, M | 6 |
| McMahon, FJ | 1 |
| Arora, M | 1 |
| Praharaj, SK | 1 |
| Sinha, VK | 1 |
| Sarkar, S | 2 |
| Hansen, JF | 3 |
| Kramer, E | 3 |
| Hermann, C | 2 |
| Ma, Y | 3 |
| Dhawan, V | 3 |
| Chaly, T | 3 |
| Eidelberg, D | 3 |
| Santilli, C | 1 |
| Signoretti, A | 2 |
| McGuire, H | 1 |
| Churchill, R | 2 |
| Küçükibrahimoğlu, E | 1 |
| Saygin, MZ | 1 |
| Calişkan, M | 1 |
| Kaplan, OK | 1 |
| Unsal, C | 1 |
| Gören, MZ | 1 |
| Esposito, D | 1 |
| Wahl, P | 1 |
| Daniel, G | 1 |
| Stoto, MA | 1 |
| Erder, MH | 1 |
| Croghan, TW | 1 |
| Mowla, A | 1 |
| Khosravizadegan, F | 1 |
| Ebrahimi, AA | 1 |
| Sabayan, B | 1 |
| Pani, A | 1 |
| Licht, CL | 1 |
| Marcussen, AB | 1 |
| Wegener, G | 2 |
| Overstreet, DH | 2 |
| Aznar, S | 1 |
| Silver, JM | 1 |
| McAllister, TW | 1 |
| Arciniegas, DB | 1 |
| Leuchter, AF | 1 |
| Husain, MM | 2 |
| Cook, IA | 2 |
| Gilmer, WS | 1 |
| Luther, JF | 3 |
| Spyropoulou, AC | 1 |
| Derijks, HJ | 1 |
| Janknegt, R | 1 |
| Heerdink, ER | 2 |
| De Koning, FH | 1 |
| Krekels, MM | 1 |
| Looij, BJ | 1 |
| Egberts, AC | 2 |
| Tamburella, A | 2 |
| Micale, V | 2 |
| Navarria, A | 1 |
| Drago, F | 2 |
| Koenig, JI | 1 |
| Bjørnebekk, A | 1 |
| Brené, S | 1 |
| Kashner, TM | 1 |
| Wicker, A | 1 |
| Jameson, M | 2 |
| Deckersbach, T | 2 |
| Loh, R | 2 |
| Thompson-Hollands, J | 1 |
| Jenike, M | 1 |
| Keuthen, NJ | 2 |
| Ladabaum, U | 1 |
| Sharabidze, A | 1 |
| Levin, TR | 1 |
| Zhao, WK | 1 |
| Chung, E | 1 |
| Bacchetti, P | 1 |
| Jin, C | 1 |
| Grimes, B | 1 |
| Pepin, CJ | 1 |
| Zeman, M | 1 |
| Jirak, R | 1 |
| Jachymova, M | 1 |
| Vecka, M | 1 |
| Tvrzicka, E | 1 |
| Zak, A | 1 |
| Schäfer, A | 1 |
| Scheurlen, M | 1 |
| Seufert, J | 1 |
| Keicher, C | 1 |
| Weissbrich, B | 1 |
| Rieger, P | 1 |
| Kraus, MR | 1 |
| Raue, PJ | 1 |
| Post, EP | 1 |
| Have, TT | 1 |
| Papadopoulos, DP | 1 |
| Mourouzis, I | 1 |
| Votteas, V | 1 |
| Papademetriou, V | 1 |
| Mombereau, C | 1 |
| Gur, TL | 1 |
| Onksen, J | 1 |
| Blendy, JA | 1 |
| Mallei, A | 1 |
| Tardito, D | 1 |
| Gruber, SH | 3 |
| Racagni, G | 1 |
| Sui, YX | 1 |
| Wolter, H | 1 |
| Schneider, N | 1 |
| Pfeiffer, E | 1 |
| Lehmkuhl, U | 1 |
| Holm, MM | 1 |
| Nieto-Gonzalez, JL | 1 |
| Vardya, I | 1 |
| Henningsen, K | 1 |
| Jayatissa, MN | 4 |
| Jensen, K | 1 |
| Ford, AH | 1 |
| Flicker, L | 1 |
| McCaul, K | 1 |
| van Bockxmeer, F | 1 |
| Hegarty, S | 1 |
| Hirani, V | 1 |
| Fenner, S | 1 |
| Sarkisyan, G | 1 |
| Roberts, AJ | 1 |
| Hedlund, PB | 1 |
| Irwin, MR | 1 |
| Herrera-Pérez, JJ | 1 |
| Martínez-Mota, L | 1 |
| Fernández-Guasti, A | 2 |
| Trento, M | 1 |
| Kucich, C | 1 |
| Tibaldi, P | 1 |
| Gennari, S | 1 |
| Tedesco, S | 1 |
| Balbo, M | 1 |
| Arvat, E | 1 |
| Cavallo, F | 1 |
| Ghigo, E | 1 |
| Porta, M | 1 |
| Lash, TL | 2 |
| Cronin-Fenton, D | 2 |
| Ahern, TP | 1 |
| Rosenberg, CL | 1 |
| Lunetta, KL | 1 |
| Silliman, RA | 1 |
| Hamilton-Dutoit, S | 1 |
| Garne, JP | 1 |
| Ewertz, M | 1 |
| Sørensen, HT | 2 |
| Pedersen, L | 1 |
| Romano-Torres, M | 1 |
| Mischo, M | 1 |
| Nigg, C | 1 |
| Kiss, A | 1 |
| Wade, AG | 1 |
| Saragoussi, D | 1 |
| Despiégel, N | 1 |
| François, C | 1 |
| Guelfucci, F | 1 |
| Toumi, M | 1 |
| Kasckow, JW | 2 |
| Lanouette, NM | 1 |
| Golshan, S | 4 |
| Fellows, I | 3 |
| Vahia, I | 1 |
| Mohamed, S | 4 |
| Rao, S | 1 |
| Waizmann, M | 1 |
| Ackermann, G | 1 |
| Sas, K | 2 |
| Leggio, GM | 1 |
| Flöck, A | 1 |
| Zobel, A | 1 |
| Bauriedel, G | 1 |
| Tuleta, I | 1 |
| Hammerstingl, C | 1 |
| Höfels, S | 1 |
| Schuhmacher, A | 1 |
| Nickenig, G | 1 |
| Skowasch, D | 1 |
| Möller, HJ | 1 |
| Schnitker, J | 1 |
| Flürenbrock, W | 1 |
| Stein, MD | 3 |
| Herman, DS | 3 |
| Kettavong, M | 2 |
| Cioe, PA | 1 |
| Friedmann, PD | 1 |
| Tellioglu, T | 1 |
| Anderson, BJ | 3 |
| Kayiran, S | 1 |
| Dursun, E | 1 |
| Dursun, N | 1 |
| Ermutlu, N | 1 |
| Karamürsel, S | 1 |
| Tuccori, M | 1 |
| Montagnani, S | 1 |
| Testi, A | 1 |
| Ruggiero, E | 1 |
| Mantarro, S | 1 |
| Scollo, C | 1 |
| Pergola, A | 1 |
| Fornai, M | 1 |
| Antonioli, L | 1 |
| Colucci, R | 1 |
| Corona, T | 1 |
| Blandizzi, C | 1 |
| Desbonnet, L | 1 |
| Garrett, L | 1 |
| Clarke, G | 1 |
| Kiely, B | 1 |
| Cryan, JF | 2 |
| Dinan, TG | 1 |
| Canan, F | 1 |
| Ataoglu, A | 1 |
| Aggarwal, A | 1 |
| Kumar, R | 1 |
| Sharma, RC | 1 |
| Sharma, DD | 1 |
| Kasckow, J | 3 |
| Solorzano, E | 2 |
| Meeks, T | 2 |
| Zomkowski, AD | 1 |
| Engel, D | 1 |
| Gabilan, NH | 1 |
| Rodrigues, AL | 1 |
| Bin Salih, S | 1 |
| Al Qahtani, M | 1 |
| Al Anazi, T | 1 |
| Al Hussein, M | 1 |
| Al Hayyan, H | 1 |
| Al Modaimegh, H | 1 |
| Diaconescu, AO | 1 |
| McIntosh, AR | 1 |
| Belli, H | 2 |
| Vardar, MK | 2 |
| Yesilyurt, S | 2 |
| Gul, ES | 2 |
| Ural, C | 2 |
| Hannestad, J | 1 |
| DellaGioia, N | 1 |
| Ortiz, N | 1 |
| Pittman, B | 1 |
| Bhagwagar, Z | 1 |
| Bhagya, V | 1 |
| Srikumar, BN | 1 |
| Raju, TR | 1 |
| Rao, BS | 1 |
| Piubelli, C | 2 |
| Vighini, M | 2 |
| Jiao, J | 1 |
| Nitzke, AM | 1 |
| Doukas, DG | 1 |
| Seiglie, MP | 1 |
| Dulawa, SC | 1 |
| Biernacka, JM | 1 |
| O'Kane, DJ | 1 |
| Black, JL | 1 |
| Cunningham, JM | 1 |
| Drews, MS | 1 |
| Snyder, KA | 1 |
| Stevens, SR | 1 |
| Khazaie, H | 1 |
| Rahimi, M | 1 |
| Tatari, F | 1 |
| Rezaei, M | 1 |
| Najafi, F | 1 |
| Tahmasian, M | 1 |
| Hermann, CR | 1 |
| Ginsberg, R | 1 |
| Eriksson, TM | 1 |
| Delagrange, P | 1 |
| Spedding, M | 1 |
| Ögren, SO | 1 |
| Svenningsson, P | 1 |
| Ahmed, AH | 1 |
| Calvird, M | 1 |
| Gordon, RD | 1 |
| Taylor, PJ | 1 |
| Ward, G | 1 |
| Pimenta, E | 1 |
| Young, R | 1 |
| Stowasser, M | 1 |
| Di Simplicio, M | 1 |
| Korkmaz, S | 1 |
| Korkmaz, H | 1 |
| Günther, L | 1 |
| Rothe, J | 1 |
| Rex, A | 1 |
| Voigt, JP | 1 |
| Millan, MJ | 1 |
| Fink, H | 1 |
| Bert, B | 1 |
| Berriozabal Diaz, L | 1 |
| Zubiaurre Lizarralde, L | 1 |
| Castiella Eguzkiza, A | 1 |
| Zapata Morcillo, E | 1 |
| Tremolizzo, L | 1 |
| Fermi, S | 1 |
| Fusco, ML | 1 |
| Susani, E | 1 |
| Frigo, M | 1 |
| Piolti, R | 1 |
| Ferrarese, C | 1 |
| Appollonio, I | 1 |
| Bobo, WV | 2 |
| Warden, D | 1 |
| Lesser, IM | 1 |
| Kornstein, SG | 1 |
| Shelton, RC | 1 |
| Yamada, M | 1 |
| Kawahara, Y | 1 |
| Kaneko, F | 1 |
| Furushima, Y | 1 |
| Dremencov, E | 1 |
| Kawahara, H | 1 |
| Nishi, A | 1 |
| Aslaner, D | 1 |
| Malkesman, O | 1 |
| Austin, DR | 1 |
| Tragon, T | 1 |
| Henter, ID | 1 |
| Reed, JC | 1 |
| Pellecchia, M | 1 |
| Manji, HK | 1 |
| Wolkowitz, OM | 1 |
| Wolf, J | 1 |
| Shelly, W | 1 |
| Rosser, R | 1 |
| Burke, HM | 1 |
| Lerner, GK | 1 |
| Reus, VI | 1 |
| Nelson, JC | 1 |
| Epel, ES | 1 |
| Mellon, SH | 1 |
| Yilmaz, N | 1 |
| Demirdas, A | 1 |
| Yilmaz, M | 1 |
| Sutcu, R | 1 |
| Kirbas, A | 1 |
| Cure, MC | 1 |
| Eren, I | 1 |
| Bah, TM | 1 |
| Benderdour, M | 1 |
| Kaloustian, S | 1 |
| Karam, R | 1 |
| Rousseau, G | 1 |
| Godbout, R | 1 |
| Kahn, A | 1 |
| Sacher, J | 1 |
| Rusjan, P | 1 |
| van Eimeren, T | 1 |
| Flint, A | 1 |
| Wilson, AA | 1 |
| Mikrouli, E | 1 |
| Wörtwein, G | 2 |
| Soylu, R | 1 |
| Petersén, Å | 2 |
| Christensen, T | 3 |
| Bisgaard, CF | 3 |
| Tsui, JI | 1 |
| Schulberg, HC | 2 |
| Belnap, BH | 1 |
| Houck, PR | 1 |
| Mazumdar, S | 1 |
| Rollman, BL | 1 |
| Denninger, JW | 1 |
| van Nieuwenhuizen, AO | 1 |
| Gollan, JK | 1 |
| Pizzagalli, DA | 1 |
| Nielsen, EØ | 1 |
| Chen, YM | 1 |
| Huang, XM | 1 |
| Thompson, R | 1 |
| Zhao, YB | 1 |
| Xi, G | 1 |
| Hui, J | 1 |
| Zhang, X | 1 |
| Teng, G | 1 |
| Chan, KC | 1 |
| Wu, EX | 1 |
| Nie, B | 1 |
| Shan, B | 1 |
| Li, L | 1 |
| Reynolds, GP | 1 |
| Andersen, NL | 1 |
| Nielsen, OW | 2 |
| Verwimp-Hoeks, MPA | 1 |
| van Herpen, CML | 1 |
| Burger, DM | 1 |
| Haastrup, E | 1 |
| Erikstrup, C | 1 |
| Ullum, H | 1 |
| Peruga, I | 1 |
| Hartwig, S | 1 |
| Merkler, D | 1 |
| Thöne, J | 1 |
| Hovemann, B | 1 |
| Juckel, G | 3 |
| Gold, R | 1 |
| Linker, RA | 1 |
| Colotto, M | 1 |
| Vinci, F | 1 |
| Vo Hong, N | 1 |
| Raimo, O | 1 |
| Castello, A | 1 |
| Carnovale, A | 1 |
| Paciaroni, A | 1 |
| Coletta, P | 1 |
| Bétry, C | 1 |
| Mnie-Filali, O | 1 |
| Etievant, A | 1 |
| Ebert, B | 1 |
| Haddjeri, N | 1 |
| Huston, JP | 2 |
| van den Brink, J | 1 |
| Komorowski, M | 1 |
| Huq, Y | 1 |
| Topic, B | 2 |
| Deshmukh, A | 1 |
| Ulveling, K | 1 |
| Alla, V | 1 |
| Abuissa, H | 1 |
| Airey, K | 1 |
| Dawes, SE | 1 |
| Palmer, BW | 2 |
| Kronenberg, G | 1 |
| Balkaya, M | 1 |
| Prinz, V | 1 |
| Gertz, K | 1 |
| Ji, S | 1 |
| Kirste, I | 1 |
| Heuser, I | 1 |
| Kampmann, B | 1 |
| Hellmann-Regen, J | 1 |
| Gass, P | 1 |
| Sohr, R | 1 |
| Hellweg, R | 1 |
| Waeber, C | 1 |
| Hörtnagl, H | 1 |
| Stumm, R | 1 |
| Endres, M | 1 |
| Chen, YC | 1 |
| Tan, QR | 1 |
| Dang, W | 2 |
| Wang, HN | 1 |
| Zhang, RB | 1 |
| Li, ZY | 1 |
| Lin, H | 1 |
| Liu, R | 2 |
| Messinger-Rapport, BJ | 1 |
| Bose, A | 1 |
| Tsai, J | 1 |
| Li, D | 1 |
| Lung, D | 1 |
| Yeh, K | 1 |
| Kiang, C | 1 |
| Weeke, P | 1 |
| Jensen, A | 1 |
| Folke, F | 1 |
| Gislason, GH | 1 |
| Olesen, JB | 1 |
| Andersson, C | 1 |
| Fosbøl, EL | 1 |
| Larsen, JK | 1 |
| Lippert, FK | 1 |
| Nielsen, SL | 1 |
| Gerds, T | 1 |
| Andersen, PK | 1 |
| Kanters, JK | 1 |
| Poulsen, HE | 1 |
| Pehrson, S | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 1 |
| Araya-Callís, C | 1 |
| Hiemke, C | 2 |
| Abumaria, N | 2 |
| Flugge, G | 2 |
| Jianting, M | 1 |
| Su, C | 1 |
| Tan, Q | 1 |
| Bennett, M | 1 |
| Fitzpatrick, G | 1 |
| Donnelly, M | 1 |
| Pardini, M | 1 |
| Capello, E | 1 |
| Krueger, F | 1 |
| Mancardi, G | 1 |
| Uccelli, A | 1 |
| Purgato, M | 2 |
| Trespidi, C | 2 |
| Imperadore, G | 1 |
| Watanabe, N | 1 |
| Schaefer, M | 2 |
| Sarkar, R | 1 |
| Knop, V | 1 |
| Effenberger, S | 1 |
| Friebe, A | 1 |
| Heinze, L | 1 |
| Spengler, U | 1 |
| Schlaepfer, T | 1 |
| Reimer, J | 1 |
| Buggisch, P | 1 |
| Ockenga, J | 1 |
| Link, R | 1 |
| Rentrop, M | 1 |
| Weidenbach, H | 1 |
| Fromm, G | 1 |
| Lieb, K | 1 |
| Baumert, TF | 1 |
| Heinz, A | 1 |
| Discher, T | 1 |
| Neumann, K | 2 |
| Zeuzem, S | 1 |
| Berg, T | 2 |
| Ineichen, C | 1 |
| Sigrist, H | 1 |
| Spinelli, S | 1 |
| Sautter, E | 1 |
| Pryce, CR | 1 |
| Bedrosian, TA | 1 |
| Weil, ZM | 1 |
| Nelson, RJ | 1 |
| Sivolap, IuP | 1 |
| Wessels, AM | 1 |
| Pollock, BG | 3 |
| Frank, E | 1 |
| Lange, AC | 1 |
| Vrijens, B | 1 |
| Fagiolini, A | 1 |
| Kupfer, DJ | 2 |
| Rucci, P | 1 |
| Kepple, G | 1 |
| Anderton, J | 1 |
| Buttenfield, J | 1 |
| Bies, RR | 2 |
| Lourdusamy, A | 1 |
| Binder, E | 1 |
| Payá-Cano, J | 1 |
| Sluyter, F | 1 |
| Craig, I | 1 |
| Keers, R | 1 |
| Karaiskos, D | 1 |
| Tzavellas, E | 1 |
| Spengos, K | 1 |
| Vassilopoulou, S | 1 |
| Paparrigopoulos, T | 1 |
| Kröger, I | 1 |
| Vildirasova, PG | 1 |
| Koesters, M | 1 |
| Nosè, M | 1 |
| Omori, IM | 1 |
| Arnone, D | 1 |
| McKie, S | 1 |
| Elliott, R | 1 |
| Juhasz, G | 1 |
| Thomas, EJ | 1 |
| Downey, D | 1 |
| Williams, S | 1 |
| Deakin, JF | 1 |
| Anderson, IM | 1 |
| Bak, S | 1 |
| Jensen, ON | 1 |
| Enghild, JJ | 2 |
| I Lorenzini, K | 1 |
| Calmy, A | 1 |
| Ambrosioni, J | 1 |
| Assouline, B | 1 |
| Daali, Y | 1 |
| Fathi, M | 1 |
| Rebsamen, M | 1 |
| Desmeules, J | 1 |
| Samer, CF | 1 |
| Mead, GE | 1 |
| Hsieh, CF | 1 |
| Lee, R | 1 |
| Kutlubaev, MA | 1 |
| Claxton, A | 1 |
| Hackett, ML | 1 |
| Kovárů, H | 1 |
| Kováru, F | 1 |
| Lisá, V | 1 |
| Scuteri, A | 1 |
| Modestino, A | 1 |
| Fedullo, F | 1 |
| Assisi, AP | 1 |
| Gianni, W | 1 |
| Alkhafaji, AA | 1 |
| Trinquart, L | 1 |
| Baron, G | 1 |
| Desvarieux, M | 1 |
| Ravaud, P | 1 |
| Rodríguez, J | 1 |
| Castañeda, G | 1 |
| Muñoz, L | 1 |
| Landman, GW | 1 |
| Delacerda, A | 1 |
| Reichenberg, JS | 1 |
| Magid, M | 1 |
| Heikkinen, T | 1 |
| Ekblad, U | 1 |
| Kero, P | 1 |
| Ekblad, S | 1 |
| Laine, K | 1 |
| Müller-Spahn, F | 1 |
| Baumann, P | 4 |
| Zullino, DF | 1 |
| Eap, CB | 3 |
| Woolley, JB | 1 |
| Heyman, I | 1 |
| Nathan, PJ | 1 |
| Kemp, AH | 1 |
| Harrison, BJ | 1 |
| Giorgi, O | 1 |
| Piras, G | 1 |
| Lecca, D | 1 |
| Hansson, S | 1 |
| Driscoll, P | 1 |
| Corda, MG | 1 |
| Ripoll, N | 1 |
| Dailly, E | 2 |
| Hascoët, M | 1 |
| Bourin, M | 3 |
| van Rheede van Oudtshoorn, E | 1 |
| Muller, JE | 1 |
| Mohr, N | 1 |
| Andersen, S | 1 |
| Halvorsen, TG | 1 |
| Pedersen-Bjergaard, S | 1 |
| Rasmussen, KE | 1 |
| Tanum, L | 1 |
| Refsum, H | 1 |
| Sattar, SP | 1 |
| Ramaswamy, S | 1 |
| Bhatia, SC | 1 |
| Petty, F | 1 |
| Kordon, A | 1 |
| Broocks, A | 1 |
| Hohagen, F | 1 |
| Grammer, GG | 1 |
| Khanzode, SD | 1 |
| Dakhale, GN | 1 |
| Khanzode, SS | 1 |
| Saoji, A | 1 |
| Palasodkar, R | 1 |
| Cuenca, PJ | 1 |
| Holt, KR | 1 |
| Hoefle, JD | 1 |
| McLaughlin, TP | 1 |
| Eaddy, MT | 1 |
| Grudzinski, AN | 1 |
| Ten Have, TR | 1 |
| Katz, II | 1 |
| Mulsant, BH | 1 |
| Brown, GK | 1 |
| McAvay, GJ | 1 |
| Pearson, JL | 1 |
| Tatarczyńska, E | 1 |
| Kłodzińska, A | 1 |
| Stachowicz, K | 1 |
| Chojnacka-Wójcik, E | 1 |
| Solomon, DA | 1 |
| Anthony, JL | 1 |
| Ramsey, SE | 1 |
| Miller, IW | 1 |
| Croom, KF | 1 |
| Plosker, GL | 1 |
| O'Leary, OF | 1 |
| Jin, SH | 1 |
| Friedland, JC | 1 |
| Ouyang, M | 1 |
| Hirsch, BR | 1 |
| Page, ME | 1 |
| Dalvi, A | 1 |
| Thomas, SA | 1 |
| Lucki, I | 1 |
| Keeney, A | 1 |
| Hogg, S | 2 |
| Menza, M | 1 |
| Marin, H | 1 |
| Kaufman, K | 1 |
| Mark, M | 1 |
| Lauritano, M | 1 |
| Campo, JV | 1 |
| Perel, J | 1 |
| Lucas, A | 1 |
| Bridge, J | 1 |
| Ehmann, M | 1 |
| Kalas, C | 1 |
| Monk, K | 1 |
| Axelson, D | 1 |
| Birmaher, B | 1 |
| Ryan, N | 1 |
| Di Lorenzo, C | 1 |
| Brent, DA | 1 |
| Gudkova, OA | 1 |
| Iufereva, IuM | 1 |
| Tikhomirova, EA | 1 |
| Rampello, L | 2 |
| Alvano, A | 2 |
| Chiechio, S | 1 |
| Malaguarnera, M | 2 |
| Raffaele, R | 2 |
| Vecchio, I | 2 |
| Feng, Y | 1 |
| Lotrich, FE | 1 |
| Kirshner, MA | 1 |
| Roose, S | 1 |
| Mogg, K | 1 |
| Brodrick, P | 1 |
| Bradley, BP | 1 |
| Yanik, M | 1 |
| Laguno, M | 1 |
| Blanch, J | 1 |
| Murillas, J | 1 |
| Blanco, JL | 1 |
| León, A | 1 |
| Lonca, M | 1 |
| Larrousse, M | 1 |
| Biglia, A | 1 |
| Martinez, E | 1 |
| García, F | 1 |
| Miró, JM | 1 |
| de Pablo, J | 1 |
| Gatell, JM | 1 |
| Mallolas, J | 1 |
| Brucculeri, M | 1 |
| Kaplan, J | 1 |
| Lande, L | 1 |
| Nikisch, G | 1 |
| Agren, H | 1 |
| Czernik, A | 1 |
| Neznanov, NG | 1 |
| Bortsov, AV | 1 |
| Juan, H | 1 |
| Zhiling, Z | 1 |
| Huande, L | 1 |
| Trivedi, JK | 1 |
| Sharma, S | 1 |
| Tandon, R | 1 |
| Mullins, CD | 2 |
| Shaya, FT | 2 |
| Meng, F | 2 |
| Harrison, D | 1 |
| van Geffen, EC | 1 |
| Hugtenburg, JG | 1 |
| van Hulten, RP | 1 |
| Kalisová-Stárková, L | 1 |
| Fisar, Z | 1 |
| Paclt, I | 1 |
| Hanus, Z | 1 |
| Vevera, J | 1 |
| Lader, M | 1 |
| Andersen, HF | 1 |
| Baekdal, T | 1 |
| de Mendonça Lima, CA | 1 |
| Brawand-Amey, M | 1 |
| Brogli, C | 1 |
| Jacquet, S | 1 |
| Cochard, N | 1 |
| Powell-Golay, K | 1 |
| Kiosses, DN | 1 |
| Heo, M | 1 |
| Murphy, CF | 3 |
| Shanmugham, B | 1 |
| Gunning-Dixon, F | 1 |
| Dunner, DL | 1 |
| Cervo, L | 1 |
| Canetta, A | 1 |
| Calcagno, E | 1 |
| Burbassi, S | 1 |
| Sacchetti, G | 1 |
| Caccia, S | 1 |
| Fracasso, C | 1 |
| Albani, D | 1 |
| Forloni, G | 1 |
| Invernizzi, RW | 1 |
| Falcone, NP | 1 |
| Nappo, A | 1 |
| Neuteboom, B | 1 |
| Rygula, R | 1 |
| Fuchs, E | 1 |
| Rüther, E | 1 |
| Havemann-Reinecke, U | 1 |
| Tack, J | 1 |
| Broekaert, D | 1 |
| Fischler, B | 1 |
| Van Oudenhove, L | 1 |
| Gevers, AM | 1 |
| Janssens, J | 1 |
| Nedostup, AV | 1 |
| Fedorova, VI | 1 |
| Linevich, AIu | 1 |
| Pukhal'skaia, TG | 1 |
| Toropina, GG | 1 |
| Kudrin, VS | 1 |
| Klodt, PM | 1 |
| Mørk, A | 2 |
| Bisgaard, C | 1 |
| Tingström, A | 1 |
| Maciag, D | 1 |
| Williams, L | 1 |
| Coppinger, D | 1 |
| Paul, IA | 1 |
| Gorenkova, N | 1 |
| Schunk, E | 1 |
| Dolgov, O | 1 |
| Bartsch, D | 1 |
| Theobald, DE | 1 |
| Kirsh, KL | 1 |
| Holtsclaw, E | 1 |
| Donaghy, K | 1 |
| Passik, SD | 1 |
| Aydemir, C | 1 |
| Yalcin, ES | 1 |
| Aksaray, S | 1 |
| Kisa, C | 1 |
| Yildirim, SG | 1 |
| Uzbay, T | 1 |
| Goka, E | 1 |
| Bron, MS | 1 |
| Chenu, F | 1 |
| Rapaport, MH | 1 |
| Gharabawi, GM | 1 |
| Canuso, CM | 1 |
| Mahmoud, RA | 1 |
| Keller, MB | 1 |
| Bossie, CA | 1 |
| Turkoz, I | 1 |
| Lasser, RA | 1 |
| Loescher, A | 1 |
| Bouhours, P | 1 |
| Dunbar, F | 1 |
| Selby, P | 1 |
| Wessels-van Middendorp, AM | 1 |
| Timmerman, L | 1 |
| Steinmann, C | 1 |
| Bavbek, N | 1 |
| Kargili, A | 1 |
| Akcay, A | 1 |
| Kaya, A | 1 |
| Freeman, MP | 1 |
| Hill, R | 1 |
| Brumbach, BH | 1 |
| Flores-Suárez, LF | 1 |
| Vega-Memije, ME | 1 |
| Chanussot-Deprez, C | 1 |
| Zahorodna, A | 1 |
| Hess, G | 1 |
| Wade, A | 1 |
| Friis Andersen, H | 1 |
| Bez, Y | 1 |
| Aktolga, S | 1 |
| Balci, M | 1 |
| Nurmedov, S | 1 |
| Topçuoglu, V | 1 |
| Beyenburg, S | 1 |
| Schönegger, K | 1 |
| Gunning-Dixon, FM | 1 |
| Lim, KO | 1 |
| Ardekani, B | 1 |
| Shields, JK | 1 |
| Hrabe, J | 1 |
| Shanmugham, BR | 1 |
| Breuer, ME | 1 |
| Groenink, L | 1 |
| Oosting, RS | 1 |
| Westenberg, HG | 1 |
| Olivier, B | 1 |
| Carvalho, AF | 1 |
| Nunes-Neto, PR | 1 |
| Cavalcante, JL | 1 |
| Oliveira Lima, MC | 1 |
| Rao, N | 1 |
| Vari, G | 1 |
| Beckson, M | 1 |
| Gleason, OC | 1 |
| Fucci, JC | 1 |
| Yates, WR | 1 |
| Philipsen, MA | 1 |
| Dirks, AC | 1 |
| van Hyfte, DM | 1 |
| Mällo, T | 1 |
| Matrov, D | 1 |
| Herm, L | 1 |
| Kõiv, K | 1 |
| Eller, M | 1 |
| Rinken, A | 1 |
| Harro, J | 1 |
| Wilhelm, S | 1 |
| Savaskan, E | 1 |
| Müller, SE | 1 |
| Böhringer, A | 1 |
| Schulz, A | 1 |
| Schächinger, H | 1 |
| Winter, C | 1 |
| von Rumohr, A | 1 |
| Mundt, A | 1 |
| Petrus, D | 1 |
| Klein, J | 1 |
| Lee, T | 1 |
| Morgenstern, R | 1 |
| Kupsch, A | 1 |
| Kraft, K | 1 |
| Gentile, S | 1 |
| Vozzi, F | 1 |
| Csete, K | 1 |
| Vezekényi, Z | 1 |
| Sztriha, L | 1 |
| Vécseil, L | 1 |
| Papp, JG | 1 |
| Artemychyn, R | 1 |
| Shih, YC | 1 |
| Bekele, NB | 1 |
| Bergström, A | 1 |
| Thykjaer, T | 1 |
| Kalender, B | 1 |
| Ozdemir, AC | 1 |
| Yalug, I | 1 |
| Dervisoglu, E | 1 |
| Fallgatter, A | 1 |
| Reis, M | 1 |
| Chermá, MD | 1 |
| Carlsson, B | 1 |
| Bengtsson, F | 2 |
| Teranishi, KS | 1 |
| Garriock, H | 1 |
| Montross, L | 1 |
| Patterson, TL | 1 |
| Lehman, D | 1 |
| Anders, M | 1 |
| Tuma, I | 1 |
| Rösslerova, H | 1 |
| Page, RL | 1 |
| Ruscin, JM | 1 |
| Bainbridge, JL | 1 |
| Brieke, AA | 1 |
| Spencer, D | 1 |
| Klein, MB | 1 |
| Cooper, C | 1 |
| Brouillette, MJ | 1 |
| Sheehan, NL | 1 |
| Benkelfat, C | 1 |
| Annable, L | 1 |
| Weston, F | 1 |
| Kraus, D | 1 |
| Singer, J | 1 |
| Devos, D | 1 |
| Dujardin, K | 1 |
| Poirot, I | 1 |
| Moreau, C | 1 |
| Cottencin, O | 1 |
| Thomas, P | 1 |
| Destée, A | 1 |
| Bordet, R | 1 |
| Defebvre, L | 1 |
| Nakatomi, Y | 1 |
| Yokoyama, C | 1 |
| Kinoshita, S | 1 |
| Masaki, D | 1 |
| Tsuchida, H | 1 |
| Onoe, H | 1 |
| Yoshimoto, K | 1 |
| Fukui, K | 1 |
| Tsygankov, BD | 1 |
| Chazova, IE | 1 |
| Poliakova, EO | 1 |
| Bilge, C | 1 |
| Koçer, E | 1 |
| Koçer, A | 1 |
| Türk Börü, U | 1 |
| Lenox-Smith, AJ | 1 |
| Jiang, Q | 1 |
| Schmutz, JL | 1 |
| Barbaud, A | 1 |
| Tréchot, P | 1 |
| Brown, CS | 1 |
| Franks, AS | 1 |
| Wan, J | 1 |
| Ling, FW | 1 |
| Moser, DJ | 1 |
| Acion, L | 1 |
| Solodkin, A | 1 |
| Small, SL | 1 |
| Fonzetti, P | 1 |
| Hegel, M | 1 |
| Arndt, S | 1 |
| Rochat, B | 1 |
| Amey, M | 1 |
| van Bemmel, AL | 1 |
| van den Hoofdakker, RH | 1 |
| Beersma, DG | 1 |
| Bouhuys, AL | 1 |
| Vestergaard, K | 1 |
| Lauritzen, L | 1 |
| Maudhuit, C | 2 |
| Hamon, M | 2 |
| Adrien, J | 2 |
| Ballenger, CA | 1 |
| Knight, DL | 1 |
| Isacsson, G | 1 |
| Bergman, U | 1 |
| Izumi, J | 1 |
| Washizuka, M | 1 |
| Hayashi-Kuwabara, Y | 1 |
| Yoshinaga, K | 1 |
| Tanaka, Y | 1 |
| Ikeda, Y | 1 |
| Kiuchi, Y | 1 |
| Oguchi, K | 1 |
| Meier, E | 1 |
| Prévot, E | 1 |
| Dangoumau, L | 1 |
| Martin, P | 1 |
| Andiné, P | 1 |
| Rönnbäck, L | 1 |
| Järvholm, B | 1 |
| Sundström, I | 1 |
| Bäckström, T | 1 |
| Wikander, I | 1 |
| Sundblad, C | 1 |
| Andersch, B | 1 |
| Dagnell, I | 1 |
| Zylberstein, D | 1 |
| Favre, MP | 1 |
| Sztajzel, J | 1 |
| Bertschy, G | 1 |
| Meyers, BS | 1 |
| Tan, JY | 1 |
| Levin, GM | 1 |
| Ruiz-Doblado, S | 1 |
| Carrizosa, A | 1 |
| García-Hernández, MJ | 1 |
| Rodríguez-Pichardo, A | 1 |
| Thomas, KV | 1 |
| Holimon, TD | 1 |
| Musshoff, F | 1 |
| Schmidt, P | 1 |
| Madea, B | 1 |
| Neuger, J | 1 |
| Wistedt, B | 1 |
| Sinner, B | 1 |
| Aberg-Wistedt, A | 1 |
| Stain-Malmgren, R | 1 |
| Keeney, AJ | 1 |
| Anderberg, UM | 1 |
| Marteinsdottir, I | 1 |
| von Knorring, L | 1 |
| Naranjo, CA | 1 |
| Knoke, DM | 1 |
| Bremner, KE | 1 |
| Linnet, K | 1 |
| Rosenberg, R | 1 |
| Devarajan, S | 1 |
| Dursun, SM | 1 |
| DeVane, CL | 1 |
| Lantz, MS | 1 |
| Odeh, M | 1 |
| Beny, A | 1 |
| Oliven, A | 1 |
| Greil, W | 1 |
| Horvath, A | 1 |
| Sassim, N | 1 |
| Erazo, N | 1 |
| Grohmann, R | 1 |
| Loft, H | 1 |
| Khan, A | 1 |
| Khan, SR | 1 |
| Leventhal, RM | 1 |
| Brown, WA | 1 |
| Schaller, JL | 1 |
| Behar, D | 1 |
| Thallasinos, A | 1 |
| Carroll, B | 1 |
| Jeste, DV | 1 |
| Inalöz, HS | 1 |
| Kirtak, N | 1 |
| Herken, H | 1 |
| Ozgöztaşi, O | 1 |
| Aynacioğlu, AS | 1 |
| Enos, G | 1 |
| Borrás-Blasco, J | 1 |
| Marco-Garbayo, JL | 1 |
| Bosca-Sanleon, B | 1 |
| Navarro-Ruiz, A | 1 |
| Håkanson, R | 1 |
| Dent, LA | 1 |
| Brown, WC | 1 |
| Murney, JD | 1 |
| Varia, I | 1 |
| Rauscher, F | 1 |
| Hagebeuk, EE | 1 |
| Tans, JT | 1 |
| de Regt, EW | 1 |
| Kudriavtseva, NN | 1 |
| Bakshtanovskaia, IV | 1 |
| Madorskaia, IA | 1 |
| Popova, NK | 1 |
| Marona-Lewicka, D | 1 |
| Vetulani, I | 1 |
| Maj, J | 1 |
| Skuza, G | 1 |
| Sowińska, H | 1 |
| Milne, RJ | 1 |
| Goa, KL | 1 |
| Geoffroy, M | 1 |
| Scheel-Krüger, J | 1 |
| Christensen, AV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement[NCT01278498] | Phase 4 | 444 participants (Anticipated) | Interventional | 2011-01-31 | Active, not recruiting | ||
| Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine for Cognitive Deficits in Persons With Post-COVID-19 Condition[NCT05047952] | Phase 2 | 200 participants (Actual) | Interventional | 2021-09-16 | Completed | ||
| Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)[NCT05017311] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-01-20 | Recruiting | ||
| Integrated Biological Markers for the Prediction of Treatment Response in Depression[NCT01655706] | Phase 3 | 211 participants (Actual) | Interventional | 2012-04-23 | Completed | ||
| Treatment of Geriatric Depression With Mild Cognitive Impairment: A Double-blind Placebo-Controlled Trial of Namenda (Memantine) Augmentation of Lexapro (Escitalopram) in Depressed Patients at Least 60 Years of Age[NCT01902004] | Phase 4 | 115 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Simvastatin add-on to Escitalopram in Patients With Comorbid Obesity and Major Depression: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial[NCT04301271] | Phase 2 | 160 participants (Anticipated) | Interventional | 2020-08-13 | Recruiting | ||
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Efficacy and Safety of Escitalopram in the Treatment of Depressive Patients With Acute Coronary Artery Syndrome: A Double-blind Placebo-controlled Trial[NCT00419471] | Phase 4 | 300 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| The Antidepressant Advisor: A Decision Support System for UK Primary Care - a Feasibility Study: Study 3[NCT04342299] | 45 participants (Actual) | Observational | 2018-08-01 | Completed | |||
| Randomized, Controlled, Open and Unicentric Phase II Clinical Trial, With Two Parallel Groups, to Evaluate the Antidepressant Efficacy of Psychotherapy and Citalopram in Women Diagnosed With Breast Cancer and Major Depression[NCT05063604] | Phase 2 | 40 participants (Actual) | Interventional | 2022-05-10 | Terminated (stopped due to The CAMAD clinical trial has been terminated due to difficulties in recruiting patients.) | ||
| Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer[NCT05724849] | Phase 2 | 64 participants (Anticipated) | Interventional | 2023-08-01 | Not yet recruiting | ||
| International Study to Predict Optimised Treatment - in Depression[NCT00693849] | Phase 4 | 2,688 participants (Anticipated) | Interventional | 2008-09-30 | Active, not recruiting | ||
| Combining Medications to Enhance Depression Outcomes[NCT00590863] | Phase 4 | 665 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of Lu AA21004 vs Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder Experiencing Selective Serotonin Reuptake In[NCT01364649] | Phase 3 | 447 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Perinatal Stress and Gene Influences: Pathways to Infant Vulnerability[NCT00525226] | 1,431 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder[NCT00977353] | Phase 2 | 40 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder: A Randomized Controlled Trial[NCT04975100] | Phase 4 | 60 participants (Actual) | Interventional | 2021-08-26 | Completed | ||
| IL-2 Neuropsychiatric Symptoms: Mechanism and Prevention[NCT00352885] | Phase 4 | 20 participants (Actual) | Interventional | 2006-10-06 | Completed | ||
| Effect of Mirtazapine Versus Placebo on Appetite, Nutritional Status and Quality of Life in Non-small Cell Lung cáncer Patients With Anorexia; Randomized Double-blind Clinical Trial.[NCT04748523] | 86 participants (Actual) | Interventional | 2018-08-29 | Completed | |||
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia[NCT01300364] | Phase 4 | 249 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Combining Antidepressants to Hasten Remission From Depression[NCT00519428] | Phase 4 | 245 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine[NCT05939154] | 400 participants (Anticipated) | Observational | 2023-08-01 | Not yet recruiting | |||
| [NCT00300313] | 450 participants (Anticipated) | Interventional | 2005-06-30 | Completed | |||
| [NCT00000367] | 0 participants | Interventional | 1998-09-30 | Completed | |||
| Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause[NCT05346445] | 91 participants (Actual) | Interventional | 2021-01-20 | Completed | |||
| Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-11-30 | Withdrawn (stopped due to Study timeline is not feasible) | ||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Agomelatine in the Prevention of Poststroke Depression[NCT05426304] | Phase 4 | 420 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| Piloting an Adaption of Cognitive Behavioral Therapy for Insomnia for Shift Workers (CBTI-Shift)[NCT05965609] | 60 participants (Anticipated) | Interventional | 2023-12-08 | Recruiting | |||
| A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome[NCT00140257] | Phase 4 | 240 participants (Actual) | Interventional | 2004-11-30 | Active, not recruiting | ||
| Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes: Role of Inflammation, Kynurenine Pathway, and Structural and Functional Brain Connectivity as Biomarkers[NCT03580967] | Phase 4 | 0 participants (Actual) | Interventional | 2019-07-01 | Withdrawn (stopped due to COVID-19 Pandemic interfered with Pt recruitment) | ||
| Caring for Caregivers With Mind-body Exercise[NCT04019301] | 47 participants (Actual) | Interventional | 2019-04-22 | Active, not recruiting | |||
| Citalopram Augmentation in Older Patients With Schizophrenia[NCT00047450] | 212 participants (Actual) | Interventional | 2001-09-30 | Completed | |||
| Antidepressants During Office-Based Buprenorphine[NCT00475878] | Phase 3 | 147 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Randomized Controlled Experimental Trial Designed to Test the Effects of Probiotics on Mood[NCT03539263] | 39 participants (Actual) | Interventional | 2016-12-20 | Completed | |||
| The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial[NCT02155972] | Phase 2 | 16 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to The trial was terminated because of inability to recruit the needed number of participants) | ||
| "Proof-of-Concept Stress & Anxiety Dampening Effects of Lpc-37"[NCT03494725] | 120 participants (Actual) | Interventional | 2018-04-10 | Completed | |||
| A Randomized Controlled Trial of the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder[NCT03279224] | Phase 2/Phase 3 | 35 participants (Actual) | Interventional | 2018-01-01 | Active, not recruiting | ||
| Clinical Utility of Pharmacogenomics of Psychotropic Medications[NCT03907124] | Phase 4 | 0 participants (Actual) | Interventional | 2019-06-03 | Withdrawn (stopped due to PI left institution prior to recruitment.) | ||
| Treatment of Depression Following Bypass Surgery[NCT00091962] | 453 participants (Actual) | Interventional | 2003-08-31 | Completed | |||
| Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients[NCT00384436] | Phase 4 | 580 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
| Efficacy and Tolerability of Escitalopram for the Prevention of Pegylated Interferon Alfa Associated Depression in Patients With Chronic Hepatitis C Infection: a Randomized Controlled Trial.[NCT00136318] | Phase 3 | 208 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke[NCT02683213] | Phase 3 | 1,500 participants (Actual) | Interventional | 2014-10-20 | Completed | ||
| Escitalopram as a Treatment for Pain in Polyneuropathy. A Double-Blind, Randomized, Placebo Controlled Trial.[NCT00162968] | Phase 4 | 50 participants | Interventional | 2004-12-31 | Completed | ||
| Prevention of Suicide in Primary Care Elderly: Collaborative Trial[NCT00279682] | Phase 4 | 1,200 participants | Interventional | 1999-05-31 | Completed | ||
| Antidepressant Treatment to Reduce HIV Risk Among IDUs[NCT00183768] | Phase 3 | 175 participants | Interventional | 1999-09-30 | Completed | ||
| Motivational Interviewing to Reduce Substance Use Among Depression Patients[NCT02420561] | 307 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)[NCT00271596] | Phase 2 | 33 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Anxiety and Recurrent Abdominal Pain in Children[NCT00962039] | Phase 2/Phase 3 | 81 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers[NCT00748956] | Phase 2 | 10 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder[NCT00442481] | Phase 4 | 25 participants | Interventional | 2007-02-28 | Recruiting | ||
| A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome[NCT00583128] | Phase 2 | 117 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Effects of Horticultural Therapy on Asian Elderly' Mental Health: A Randomized Controlled Trial[NCT02495194] | 69 participants (Actual) | Interventional | 2015-04-30 | Active, not recruiting | |||
| Study of Antidepressants in Parkinson's Disease[NCT00086190] | Phase 3 | 115 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction[NCT02386475] | Phase 4 | 39 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Prevention of Post-Stroke Depression - Treatment Strategy[NCT00071643] | 201 participants (Actual) | Interventional | 2002-09-30 | Completed | |||
| Evaluation of the Efficiency of a Therapeutic Education Program in Standardized Thermal Cure for Fibromyalgia Patients[NCT02406313] | 152 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | |||
| Study to Determine Steady-state Level of Citalopram Pharmacokinetic Parameters in Patients With Short Bowel Syndrome[NCT00876226] | 0 participants (Actual) | Interventional | 2010-05-01 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Neuropsychological battery of tests which included the following domains: learning, delayed recall, and executive functioning. Raw scores were transformed to z-scores for each test score of interest for each participant, and then averaged. These z-scores were averaged within each neuropsychological domain to produce composite scores and then averaged over all tests to calculate a global performance score. Higher scores are indicative of better performance. (NCT01902004)
Timeframe: Measured at 6 months and 12 months
| Intervention | z score (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Escitalopram and Memantine | .02 | 0.03 | .15 |
| Escitalopram and Placebo | -.04 | -.1 | -.26 |
Clinician administered scale measures severity of depressive symptoms. This measure includes 24 items. Response options vary item to item and include the following ranges: [0-2], [0-3], and [0-4]. A score of 0 suggests absence of symptoms and/or difficulties and higher scores represent more severe difficulties. Possible overall score range [0-74], higher scores representing more severe difficulties. (NCT01902004)
Timeframe: Measured at 3 months; 6 months and 12 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | 3 Months | 6 Months | 12 Months | |
| Escitalopram and Memantine | 17.8 | 6.0 | 5.9 | 7.2 |
| Escitalopram and Placebo | 17.7 | 6.7 | 6.9 | 5.4 |
Clinician administered item scale measures severity of depressive symptoms. The 10 items are measured on a 7-point scale ranging from 0 to 6; creating a total range of 0-60. A score of 0 suggests absence of symptoms and higher scores represent greater severity of depression.Severity gradations for the MADRS have been proposed (9-17 = mild, 18-34 = moderate, and ≥ 35 = severe). Treatment remission is defined as an endpoint total score ≤ 10. (NCT01902004)
Timeframe: Measured at 3 months; 6 months and 12 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | 3 Months | 6 Months | 12 Months | |
| Escitalopram and Memantine | 16.7 | 7.1 | 6.0 | 8.8 |
| Escitalopram and Placebo | 14.8 | 8.7 | 8.6 | 8.0 |
The UKU (Udvalg for Kliniske Undersogelser) Side Effect Rating Scale organizes symptoms into 4 categories (i.e., Psychic, Neurologic, Autonomic, Other) containing 8-19 symptoms each. Each symptom receives a score for degree and causal relationship. Degree is scored between 0-3 with higher scores being more severe. Causal relationship is scored as improbable, possible, or probable. (NCT01902004)
Timeframe: Measured at 3, 6 months and 12 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 3 Months | 6 Months | 12 Months | |
| Escitalopram and Memantine | 3 | 3 | 1 |
| Escitalopram and Placebo | 2 | 5 | 0 |
The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram + Bupropion SR | 0.6 |
| Venlafaxine XR + Mirtazapine | 0.4 |
| Escitalopram + Placebo | 0.4 |
Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram + Bupropion SR | 46.6 |
| Venlafaxine XR + Mirtazapine | 41.8 |
| Escitalopram + Placebo | 46.0 |
The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A positive change from Baseline indicates that symptoms have improved. The primary analysis was based on a mixed model for repeated measurements (MMRM) analysis of covariance with treatment, center, week, treatment-by-week interaction as fixed effects, Baseline CSFQ-14 total score-by-week as covariate, and a completely unstructured covariance matrix. (NCT01364649)
Timeframe: Baseline, Week 8
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Vortioxetine | 8.8 |
| Escitalopram | 6.6 |
The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A positive change from Baseline indicates that symptoms have improved. The primary analysis was based on a mixed model for repeated measurements (MMRM) analysis of covariance with treatment, center, week, treatment-by-week interaction as fixed effects, Baseline CSFQ-14 total score-by-week as covariate, and a completely unstructured covariance matrix. (NCT01364649)
Timeframe: Baseline and Weeks 1, 2, 4 and 6
| Intervention | scores on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Week 1 (n=213, 206) | Week 2 (n=203, 200) | Week 4 (n=187, 188) | Week 6 (n=175, 176) | |
| Escitalopram | 2.2 | 3.7 | 4.8 | 6.4 |
| Vortioxetine | 2.5 | 4.9 | 7.0 | 8.0 |
The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. Normal sexual functioning is defined as a CSFQ-14 total score of >41 for women and >47 for men. Abnormal sexual functioning is defined as a CSFQ-14 total score of ≤41 for women and ≤47 for men. All subjects entered the study with abnormal sexual functioning. A shift to normal indicates that symptoms have improved. (NCT01364649)
Timeframe: Baseline and Weeks 1, 2, 4, 6 and 8
| Intervention | number of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 1 (n=213, 205) | Week 2 (n=217, 206) | Week 4 (n=217, 206) | Week 6 (n=217, 206) | Week 8 (n=217, 206) | |
| Escitalopram | 36 | 63 | 84 | 93 | 91 |
| Vortioxetine | 48 | 81 | 93 | 112 | 113 |
The mean number of IL-2 doses tolerated (out of the possible 60 total doses) are presented for each study arm. The standard high dose regimen of IL-2 includes 15 doses per cycle. The dose of IL-2 is reduced, or treatment is stopped entirely, if the side effects become severe. This analysis includes the total number of doses taken at the end of Cycle 4, by all participants who began the trial, regardless of how many cycles each participant completed. (NCT00352885)
Timeframe: Cycle 4 (up to 12 weeks of IL-2 treatment)
| Intervention | IL-2 treatments (Mean) |
|---|---|
| Escitalopram | 18.4 |
| Placebo | 19.8 |
Hamilton Depression Rating Scale (HAM-D) is a 21-item, observer-rated scale which quantifies the severity of depressive symptoms, including depressed mood, loss of interest in usually pleasurable activities, insomnia, anorexia, fatigue, weight loss, and psychomotor retardation or agitation. Participants rate the severity of their symptoms on a scale of 0-2 or 0-4 (depending on the item), where 0 means that the symptom is absent. Total scores are calculated by summing the first 17 items for a total score between 0 and 50. For this study a score of 0-6 indicates a normal state, a score of 7-17 indicates mild depression, a score of 18-24 indicates moderate depression, and a score of greater than 25 indicates severe depression. The HAM-D was administered at screening (baseline value) and once during days 1-3 of each cycle of the four IL-2 treatments. (NCT00352885)
Timeframe: Screening and Cycles 1 - 4 (up to 14 weeks)
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Screening | Cycle 1 | Cycle 2 | Cycle 3 | Cycle 4 | |
| Escitalopram | 7.77 | 11.56 | 12.33 | 14.56 | 14.56 |
| Placebo | 6.45 | 12.73 | 15.00 | 16.64 | 16.00 |
Adrenocorticotropic hormone (ACTH) is a stress hormone that is synthesized by the pituitary in response to corticotropin-releasing hormone (CRH). ACTH stimulates adrenal cortisol production. ACTH levels vary throughout the day and are highest between 6am and 8am. A typical reference range is 10-50 picograms per milliliter (pg/ml) from blood drawn in the morning. Low levels of ACTH can indicate adrenal insufficiency (including adrenal cancers) while high levels may indicate several diseases or stress. IL-2 treatment stimulates the release of ACTH and this stimulation is dose dependent (rising as the dose of IL-2 increases) and tends to increase further with repeated exposure to IL-2. Blood was drawn for measuring ACTH at screening (baseline value) and once during days 1-3 of each cycle of the four IL-2 treatments. (NCT00352885)
Timeframe: Screening and Cycles 1 - 4 (up to 14 weeks)
| Intervention | pg/ml (Mean) | ||||
|---|---|---|---|---|---|
| Screening | Cycle 1 | Cycle 2 | Cycle 3 | Cycle 4 | |
| Escitalopram | 27.55 | 45.66 | 112.59 | 87.89 | 91.25 |
| Placebo | 28.95 | 56.60 | 75.69 | 136.13 | 81.23 |
Cortisol is a steroid hormone made in the adrenal glands in response to fear or stressful situations. A typical reference range is 6-23 micrograms/deciliter (mcg/dL) from blood drawn in the morning. Low levels of cortisol can indicate Addison's disease or a problem with the pituitary gland, while high levels may indicate tumors of the adrenal gland, among other illnesses, or increased stress. Chronic elevation of cortisol is associated with reduced immune function and increased risk of heart disease. IL-2 treatment stimulates the release of cortisol and this stimulation is dose dependent (rising as the dose of IL-2 increases) and tends to increase further with repeated exposure to IL-2. Blood was drawn for measuring cortisol at screening (baseline value) and once during days 1-3 of each cycle of the four IL-2 treatments. (NCT00352885)
Timeframe: Screening and Cycles 1 - 4 (up to 14 weeks)
| Intervention | mcg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Screening | Cycle 1 | Cycle 2 | Cycle 3 | Cycle 4 | |
| Escitalopram | 11.51 | 20.60 | 19.53 | 22.44 | 20.58 |
| Placebo | 10.62 | 17.78 | 18.46 | 19.11 | 18.86 |
Immune system functioning was assessed by measuring plasma concentrations of interleukin 6 (IL-6). IL-6 is a proinflammatory cytokine that is elevated during times of inflammation, infection, in patients with advanced or metastatic cancer, and is also implicated in mood disorders. IL-2 treatments are associated with increased IL 6 levels, in a dose response manner. IL-6 values in healthy individuals are generally less than 16 pg/ml. Blood was drawn for measuring IL-6 at screening (baseline value) and once during days 1-3 of each cycle of the four IL-2 treatments. (NCT00352885)
Timeframe: Screening and Cycles 1 - 4 (up to 14 weeks)
| Intervention | pg/ml (Mean) | ||||
|---|---|---|---|---|---|
| Screening | Cycle 1 | Cycle 2 | Cycle 3 | Cycle 4 | |
| Escitalopram | 11.68 | 290.77 | 210.90 | 305.41 | 283.34 |
| Placebo | 10.12 | 270.11 | 297.94 | 332.49 | 308.09 |
Social adjustment was measured using the Social Adjustment Scale (SAS). The SAS is a self-report scale that assesses depressive symptoms and functioning in nine social and work-related domains generating a total score that is indicative of a subject's overall level of social adjustment. Subjects rate their own social functioning over times on a 5-point scale on items covering work for pay, housework, extended family, parenting, marital status, social activity and leisure, family unit and student status (sub-scales). Mean values of all the sub-scales are used, with a range from 0-5. Higher score = worse outcome … worse functioning (NCT00519428)
Timeframe: 12 weeks
| Intervention | units on the SAS scale (Mean) |
|---|---|
| Escitalopram + Bupropion | 2.65 |
| Escitalopram | 2.63 |
| Bupropion | 2.74 |
"The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) intends to measure quality of life in 16 domains. A summary score is computed by adding the scores and dividing by 16 (or the number of answered items if some are not answered).~The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70. Higher score means more satisfaction." (NCT00519428)
Timeframe: 12 weeks
| Intervention | units on the Q-LES-Q scale (Mean) |
|---|---|
| Escitalopram + Bupropion | 3.0 |
| Escitalopram | 3.0 |
| Bupropion | 3.1 |
Chi square comparison of rates of persistent remission (i.e., no subsequent Hamilton Rating Scale for Depression, 17 items [HAMD-D 17] > 7 once HAMD-D 17 <= 7); Dual rate vs. Escitalopram only rate and Dual rate vs. Bupropion only rate. (NCT00519428)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram + Bupropion | 52 |
| Escitalopram | 46 |
| Bupropion | 34 |
"Last summary score rating on the 17-item Hamilton Rating Scale for Depression Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. Range 0-58.~0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression~≥ 23 = Very Severe Depression" (NCT00519428)
Timeframe: 12 weeks
| Intervention | units on Hamilton Rating Scale for Depre (Mean) |
|---|---|
| Escitalopram + Bupropion | 10 |
| Escitalopram | 9 |
| Bupropion | 12 |
Life Table Survival Analysis run twice, once comparing Dual Therapy (i.e., Bupropion + Escitalopram) to Bupropion alone (i.e., Bupropion + Placebo) and once comparing Dual Therapy to Escitalopram alone (i.e., Escitalopram + Placebo). Because both analyses must significantly favor Dual Therapy, each individual analysis must reach a critical alpha = .0916 in order to reach an over-all alpha = .05. (NCT00519428)
Timeframe: 12 weeks
| Intervention | weeks (Mean) |
|---|---|
| Escitalopram + Bupropion | 8 |
| Escitalopram | 9 |
| Bupropion | 10 |
Depressive symptoms, as measured by self-report during study interviews, using the Beck Depression Inventory II. Scores ranged from 0-63; higher scores indicate more depressive symptoms. (NCT00475878)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| 10 mg Escitalopram | 12.31 |
| Placebo | 11.35 |
Drop-out is defined as 7 or more days of missed Buprenorphine doses (NCT00475878)
Timeframe: 3 months
| Intervention | percentage of participants (Number) |
|---|---|
| 10 mg Escitalopram | 33.3 |
| Placebo | 44.0 |
Efficacy of the intake of Lpc-37 on reduction of the increase of the diastolic BP in response to the TSST compared to placebo. (NCT03494725)
Timeframe: 3 minutes before the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | mmHg (Mean) | |
|---|---|---|
| Pre-TSST -3min | Post-TSST +1min | |
| Lpc-37 | 79.13 | 90.38 |
| Placebo | 78.41 | 88.36 |
"Efficacy of the intake of Lpc-37 on the increase of mood scale scores over the course of the treatment~Measured with a daily online diary. Mood was rated by participants on an 11-point scale (0-10; very bad to very well) and monitored through the washout phase (week 1 and 2) and the subsequent treatment phase (weeks 3-7). Higher scores indicate a better mood. Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one average value for each week and participant. Values reflect summary measures for mood ratings on a scale from 0 to 10 for the averaged ratings per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | score (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 7.31 | 7.53 | 7.66 | 7.77 | 7.73 | 7.90 | 7.77 |
| Placebo | 7.27 | 7.49 | 7.46 | 7.53 | 7.50 | 7.40 | 7.55 |
"Efficacy of the intake of Lpc-37 on the increase of perceived health status scores over the course of the treatment.~Measured with a daily online diary. Health status was rated by participants on an 11-point scale (0-10; not at all to very) and monitored through the wash-out phase (week 1 and 2) and the subsequent treatment phase (weeks 3-7). Higher scores indicate a high perceived health.Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant. Values reflect summary measures for perceived health status on a scale from 0 to 10 for the averaged ratings per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | score (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 7.80 | 7.89 | 7.88 | 7.91 | 8.05 | 8.11 | 7.91 |
| Placebo | 7.86 | 7.92 | 7.92 | 8.01 | 7.92 | 7.73 | 7.75 |
"Efficacy of the intake of Lpc-37 on the increase of perceived productivity scores over the course of the treatment~Measured with a daily online diary. Productivity was rated by participants on an 11-point scale (0-10; not at all to very) and monitored through the wash-out phase (week 1 and 2) and the subsequent treatment phase (weeks 3-7). Higher scores indicate a higher perceived productivity. Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group.Time is coded as a continuous variable with one value for each day and participant. The values reflect summary measures for perceived productivity on a scale from 0 to 10 for the averaged ratings per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | score (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 6.98 | 7.34 | 7.53 | 7.48 | 7.59 | 7.57 | 7.50 |
| Placebo | 7.15 | 7.29 | 7.30 | 7.34 | 7.43 | 7.31 | 7.32 |
"Efficacy of the intake of Lpc-37 on the decrease of reported number of sleep disruptions over the course of the treatment measured with a daily online diary (mean of week summary).~Sleep disruptions were monitored through the wash-out phase (Week 1 and 2) and the subsequent treatment phase (Weeks 3-7). In the count version, the value can be 0 or a natural number for each day and each participant. Efficacy is defined as a decrease, or (in case of a general increase) reduced increase for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant. Values reflect summary measures for sleep disruptions (count) for the summed counts per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | sleep disruptions per participant & week (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 7.30 | 5.50 | 4.89 | 5.43 | 3.52 | 3.80 | 4.66 |
| Placebo | 6.09 | 5.49 | 5.11 | 4.30 | 3.53 | 4.02 | 5.83 |
"Efficacy of the intake of Lpc-37 on the decrease of sleep disruptions over the course of the treatment measured with a daily online diary (Proportion (yes/total)).~Sleep disruptions were monitored through the wash-out phase and the subsequent treatment phase for each week. In the binary version, the value is either Yes or No for each day and each participant.~Efficacy is defined as a decrease, or (in case of a general increase) reduced increase for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant.~The proportion of participants with at least one sleep disruption by treatment group is given, treatment commenced after week 2. Data listed here reflect the proportion of participants who answered Yes (e.g. 0,477 * 44 = 20.99 participants answered with Yes in week 1 in the Lpc-37 group)." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | Proportion of participants (yes/total) (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 0.477 | 0.435 | 0.354 | 0.367 | 0.306 | 0.279 | 0.290 |
| Placebo | 0.465 | 0.426 | 0.418 | 0.310 | 0.292 | 0.331 | 0.389 |
Efficacy of the intake of Lpc-37 on reduction of the increase of salivary Alpha-Amylase (sAA) in response to the TSST compared to placebo. (NCT03494725)
Timeframe: 1 minute before the TSST and 1, 10, 20, 30 and 45 minutes after the TSST after 5 weeks of study product intake
| Intervention | U/ml (Mean) | |||||
|---|---|---|---|---|---|---|
| Pre-TSST -2min | Post-TSST +1min | Post-TSST +10min | Post-TSST +20min | Post-TSST +30min | Post-TSST +45min | |
| Lpc-37 | 154.04 | 246.29 | 146.53 | 130.11 | 125.19 | 141.13 |
| Placebo | 161.67 | 270.55 | 158.85 | 141.49 | 138.48 | 148.15 |
Efficacy of the intake of Lpc-37 on reduction of the increase of salivary cortisol in response to the TSST compared to placebo. (NCT03494725)
Timeframe: 1 minute before the TSST and 1, 10, 20, 30 and 45 minutes after the TSST after 5 weeks of study product intake
| Intervention | nmol/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Pre-TSST -2min | Post-TSST +1min | Post-TSST +10min | Post-TSST +20min | Post-TSST +30min | Post-TSST +45min | |
| Lpc-37 | 4.79 | 6.96 | 9.48 | 9.89 | 8.04 | 6.21 |
| Placebo | 4.82 | 6.85 | 8.97 | 9.21 | 7.71 | 6.16 |
"Efficacy of the intake of Lpc-37 on the increase of sleep duration over the course of the treatment.~Sleep duration was monitored through the wash-out phase (week 1 and 2) and the subsequent treatment phase (weeks 3-7). Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant. Summary measures for Sleep duration for the averaged ratings per participant and week" (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | min (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 447.27 | 444.01 | 449.45 | 450.62 | 454.50 | 450.88 | 445.60 |
| Placebo | 447.45 | 448.13 | 456.90 | 459.81 | 457.26 | 450.16 | 459.66 |
"Efficacy of the intake of Lpc-37 on the increase of sleep related recovery scores over the course of the treatment.~Measured with a daily online diary. Sleep related recovery was rated by participants on an 11-point scale (0-10; not at all to very) and monitored throughout the wash-out phase (Week 1 and 2) and the subsequent treatment phase (weeks 3-7). High scores indicate a high recovery.~Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant. Summary measures for sleep related recovery for the averaged ratings per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | score (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 6.71 | 7.07 | 7.32 | 7.30 | 7.36 | 7.42 | 7.31 |
| Placebo | 6.91 | 7.15 | 7.27 | 7.29 | 7.36 | 7.10 | 7.28 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of STAI-State scores in response to the TSST compared to placebo.~Measured with the german version of the State-Trait-Anxiety Inventory, scale anxiety as a temporary emotional state (STAI-X1). Answers are given on a four-point rating scale ranging from 1=not at all to 4=very true. The score range is 20-80; Higher scores indicate more anxiety." (NCT03494725)
Timeframe: 10 minutes before the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | |
|---|---|---|
| Pre-TSST -10min | Post-TSST +1min | |
| Lpc-37 | 36.09 | 42.38 |
| Placebo | 36.83 | 43.60 |
Efficacy of the intake of Lpc-37 on reduction of the increase of the systolic BP in response to the TSST compared to placebo. (NCT03494725)
Timeframe: 3 minutes before the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | mmHg (Mean) | |
|---|---|---|
| Pre-TSST -3min | Post-TSST +1min | |
| Lpc-37 | 115.11 | 127.47 |
| Placebo | 114.33 | 129.19 |
Efficacy was defined as a lower increase in HR in response to the TSST following intervention with Lpc-37, compared to placebo. (NCT03494725)
Timeframe: Continuous measurement starting 20 minutes before and ending 20 minutes after the TSST after 5 weeks of product intake. Mean values were calculated per group at seven-time windows before, during and after the TSST
| Intervention | bpm (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Pre-TSST -20min | Pre-TSST -10min | Pre-TSST -3min | during TSST (Interview) | during TSST (Arithmetic) | Post-TSST +10min | Post-TSST +20min | |
| Lpc-37 | 74.84 | 88.15 | 97.34 | 107.56 | 102.77 | 93.32 | 75.88 |
| Placebo | 74.34 | 86.69 | 97.62 | 105.66 | 100.81 | 90.81 | 74.97 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of VAS anxiety scores in response to the TSST compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater anxiety." (NCT03494725)
Timeframe: 10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | ||
|---|---|---|---|
| Pre-TSST -10min | Interview TSST (during) | Post-TSST +1min | |
| Lpc-37 | 6.80 | 20.85 | 10.68 |
| Placebo | 8.50 | 22.47 | 11.74 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of VAS exhaustion scores in response to the TSST compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater exhaustion." (NCT03494725)
Timeframe: 10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | ||
|---|---|---|---|
| Pre-TSST -10min | Interview TSST (during) | Post-TSST +1min | |
| Lpc-37 | 21.18 | 19.20 | 22.12 |
| Placebo | 19.79 | 21.30 | 25.68 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of VAS insecurity scores in response to the TSST compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater insecurity." (NCT03494725)
Timeframe: 10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | ||
|---|---|---|---|
| Pre-TSST -10min | Interview TSST (during) | Post-TSST +1min | |
| Lpc-37 | 14.47 | 45.08 | 23.92 |
| Placebo | 17.19 | 52.19 | 23.69 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of VAS Stress perception scores in response to the TSST compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating higher perceived stress." (NCT03494725)
Timeframe: 10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | ||
|---|---|---|---|
| Pre-TSST -10min | Interview TSST (during) | Post-TSST +1min | |
| Lpc-37 | 19.89 | 47.71 | 31.72 |
| Placebo | 18.52 | 51.51 | 32.85 |
"Efficacy of the intake of Lpc-37 on the reduction of Beck Anxiety Inventory (BAI) scores compared to placebo.~Measured with the german version of the Beck Anxiety Inventory as a self-rating scale designed to measure anxiety. It comprises 21 sentences describing feelings that can occur when being anxious. These sentences are rated on a four-point rating scale ranging from 0=not at all to 3=severely, considering the last 7 days. The score range is 0-63; Higher scores indicate higher anxiety." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 5.51 | 4.75 |
| Placebo | 5.85 | 6.33 |
"Efficacy of the intake of Lpc-37 on the reduction of Depression Anxiety Stress Scale (DASS) anxiety scores compared to placebo.~Measured with the german version of the DASS as a 42-item self report instrument designed to measure negative emotional states of depression, anxiety and stress during the past week. The DASS includes three scales (depression, anxiety and stress) of which each scale includes 14 items that are divided into subscales of 2-5 items of similar content.~Items are answered on a four point rating scale ranging from 0 = not at all to 3 = very much. Scores of each scale are calculated by summing the scores for the relevant items.~The anxiety scale assesses autonomic arousal, skeletal muscle effects, situational anxiety, and subjective experience of anxious affect. The items are 2, 4, 7, 9, 15, 19, 20, 23, 25, 28, 30, 36, 40, 41 and individual scores can range from 0 to 42 with higher scores indicating greater severity of the symptoms." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 2.60 | 2.44 |
| Placebo | 3.07 | 3.45 |
"Efficacy of the intake of Lpc-37 on the reduction of Depression Anxiety Stress Scale (DASS) depression scores compared to placebo.~Measured with the german version of the DASS as a 42-item self report instrument designed to measure negative emotional states of depression, anxiety and stress during the past week. The DASS includes three scales (depression, anxiety and stress) of which each scale includes 14 items that are divided into subscales of 2-5 items of similar content.~Items are answered on a four point rating scale ranging from 0 = not at all to 3 = very much. Scores of each scale are calculated by summing the scores for the relevant items.~The Depression scale assesses dysphoria, hopelessness, devaluation of life, self-deprecation, lack of interest/involvement, anhedonia, and inertia. The items are 3, 5, 10, 13, 16, 17, 21, 24, 26, 31, 34, 37, 38, 42 and individual scores can range from 0 to 42 with higher scores indicating greater severity of the symptoms." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 4.60 | 4.15 |
| Placebo | 5.21 | 5.10 |
"Efficacy of the intake of Lpc-37 on the reduction of Depression Anxiety Stress Scale (DASS) stress scores compared to placebo.~Measured with the german version of the DASS as a 42-item self report instrument designed to measure negative emotional states of depression, anxiety and stress during the past week. The DASS includes three scales (depression, anxiety and stress) of which each scale includes 14 items that are divided into subscales of 2-5 items of similar content.~Items are answered on a four point rating scale ranging from 0 = not at all to 3 = very much. Scores of each scale are calculated by summing the scores for the relevant items.~The stress scale (items) is sensitive to levels of chronic non-specific arousal.The stress scale items are 1, 6, 8, 11, 12, 14, 18, 22, 27, 29, 32, 33, 35, 39 and individual scores can range from 0 to 42 with higher scores indicating greater severity of the symptoms." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 9.76 | 8.91 |
| Placebo | 9.41 | 10.09 |
Efficacy of the intake of Lpc-37 on the reduction of diastolic BP. (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 71.89 | 73.18 |
| Placebo | 71.68 | 74.62 |
"Efficacy of the intake of Lpc-37 on the reduction of Perceived Stress Scale (PSS) scores compared to placebo.~Measured with the german version of the PSS as a psychological instrument for measuring stress perception. It assesses how unpredictable, uncontrollable and overloaded participants perceived their lives to have been within the last month. The PSS comprises 14 items that are answered on a five-point rating scale ranging from 0 = never to 4 = very often. Individual scores on the PSS can range from 0 to 56 with higher scores indicating higher perceived stress." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 21.89 | 20.49 |
| Placebo | 20.72 | 21.56 |
"Efficacy of the intake of Lpc-37 on the reduction of State-Trait-Anxiety-Inventory (STAI)-state scores compared to placebo.~Measured with the german version of the State-Trait-Anxiety Inventory, scale anxiety as a temporary emotional state (STAI-X1). Answers are given on a four-point rating scale ranging from 1=not at all to 4=very true. The score range is 20-80; Higher scores indicate more anxiety." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 33.65 | 35.18 |
| Placebo | 34.33 | 35.33 |
Efficacy of the intake of Lpc-37 on the reduction of systolic blood pressure (BP). (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 119.60 | 121.87 |
| Placebo | 119.66 | 122.86 |
"Efficacy of the intake of Lpc-37 on the reduction of VAS anxiety scores compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater anxiety." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 7.29 | 9.26 |
| Placebo | 7.58 | 7.85 |
"Efficacy of the intake of Lpc-37 on the reduction of VAS exhaustion scores compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater exhaustion." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 29.56 | 24.66 |
| Placebo | 23.19 | 18.45 |
"Efficacy of the intake of Lpc-37 on the reduction of VAS insecurity scores compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater insecurity." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 13.58 | 16.44 |
| Placebo | 15.91 | 17.30 |
"Efficacy of the intake of Lpc-37 on the reduction of Visual Analog Scale (VAS) stress perception scores compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating higher perceived stress." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 19.11 | 23.32 |
| Placebo | 19.34 | 20.67 |
"Efficacy of the intake of Lpc-37 on the reduction of the difference of cortisol at 8 pm values to the respective mean before and after 5 weeks of treatment~Efficacy for the CAR variable cortisol at 8 pm is defined in terms of a normalization: Number of participants with normal values (between first and third quantile of reference measures) and numbers of participants with low or high values are compared before treatment and after treatment. More participants in the normal range after treatment is defined as efficacy." (NCT03494725)
Timeframe: Baseline (average of 2 days before first product intake) and end of study (average of 2 days before last product intake
| Intervention | number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline (<25% quantile) | Baseline (25% - 75% quantile) | Baseline (>75% quantile) | End of Study (<25% quantile) | End of Study (25% - 75% quantile) | End of Study (>75% quantile) | |
| Lpc-37 | 4 | 20 | 29 | 3 | 28 | 22 |
| Placebo | 6 | 23 | 26 | 7 | 18 | 30 |
"Efficacy of the intake of Lpc-37 on the reduction of the difference of Cortisol Awakening Response (CAR) area under the curve with respect to the ground (AUCg) values to the respective mean before and after 5 weeks of treatment.~The CAR is summarized in the variables AUCg, AUCi, mean increase and peak value. These cortisol indices are frequently used to describe hypothalamic-pituitary-adrenal axis activity and represent information either of the total cortisol production or of the change in cortisol levels. AUCg is the total area under the curve of all measurements (i.e., the intensity or magnitude of the response).~Efficacy for the CAR variables AUCg is defined in terms of a normalization: Number of participants with normal values (between first and third quantile of reference measures) and numbers of participants with low or high values are compared before treatment and after treatment. More participants in the normal range after treatment is defined as efficacy." (NCT03494725)
Timeframe: Baseline (average of 2 days before first product intake) and end of study (average of 2 days before last product intake)
| Intervention | number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline (<25% quantile) | Baseline (25% - 75% quantile) | Baseline (>75% quantile) | End of Study (<25% quantile) | End of Study (25% - 75% quantile) | End of Study (>75% quantile) | |
| Lpc-37 | 6 | 36 | 11 | 11 | 28 | 14 |
| Placebo | 12 | 30 | 13 | 7 | 35 | 13 |
"Efficacy of the intake of Lpc-37 on the reduction of the difference of Cortisol at Awakening values to the respective mean before and after 5 weeks of treatment~Efficacy for the CAR variable cortisol at awakening is defined in terms of a normalization: Number of participants with normal values (between first and third quantile of reference measures) and numbers of participants with low or high values are compared before treatment and after treatment. More participants in the normal range after treatment is defined as efficacy." (NCT03494725)
Timeframe: Baseline (average of 2 days before first product intake) and end of study (average of 2 days before last product intake)
| Intervention | number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline (<25% quantile) | Baseline (25% - 75% quantile) | Baseline (>75% quantile) | End of Study (<25% quantile) | End of Study (25% - 75% quantile) | End of Study (>75% quantile) | |
| Lpc-37 | 14 | 31 | 8 | 19 | 26 | 8 |
| Placebo | 16 | 26 | 13 | 12 | 34 | 9 |
"Efficacy of the intake of Lpc-37 on the reduction of the difference of CAR area under the curve with respect to the increase (AUCi) values to the respective mean before and after the treatment.~The CAR is summarized in the variables AUCg, AUCi, mean increase and peak value. These cortisol indices are frequently used to describe hypothalamic-pituitary-adrenal axis activity and represent information either of the total cortisol production or of the change in cortisol levels. AUCi is calculated with reference to the baseline measurement and it ignores the distance from zero for all measurements and emphasizes the changes over time. Efficacy for the CAR variables AUCi is defined in terms of a normalization: Number of participants with normal values (between first and third quantile of reference measures) and numbers of participants with low or high values are compared before treatment and after treatment. More participants in the normal range after treatment is defined as efficacy." (NCT03494725)
Timeframe: Baseline (average of 2 days before first product intake) and end of study (average of 2 days before last product intake)
| Intervention | number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline (<25% quantile) | Baseline (25% - 75% quantile) | Baseline (>75% quantile) | End of Study (<25% quantile) | End of Study (25% - 75% quantile) | End of Study (>75% quantile) | |
| Lpc-37 | 16 | 34 | 3 | 15 | 34 | 4 |
| Placebo | 22 | 28 | 5 | 15 | 36 | 4 |
The 12-item Duke Activity Status Index (DASI). Scores range from 0-58.2, and higher scores the better the functional capacity (Am J Cardiol. 1989;64(10):651-654). (NCT00091962)
Timeframe: 8 months post CABG
| Intervention | units on a scale (Mean) |
|---|---|
| Depressed Intervention | 25.2 |
| Depressed Usual Care | 21.4 |
| Non-Depressed Control | 33.2 |
"The 36-item Medical Outcomes Study Form (v.2) Mental Component Scale (SF-36 MCS). Range 0-100; Population norm is 50 with standard deviation of 10. Higher scores are better.~Ware J, Kosinski M, Keller S. SF-36 Physical and Mental Health Summary Scales: A User's Manual. 2nd ed. Boston, MA: New England Medical Center; 1994." (NCT00091962)
Timeframe: Measured 8 months post-CABG
| Intervention | units on a scale (Mean) |
|---|---|
| Depressed Intervention | 50.0 |
| Depressed Usual Care | 46.2 |
| Non-Depressed Control | 57.2 |
"The 36-item Medical Outcomes Study Form (v.2) Physical Component Scale (SF-36 PCS). Range 0-100; Population norm is 50 with standard deviation of 10. Higher scores are better.~Ware J, Kosinski M, Keller S. SF-36 Physical and Mental Health Summary Scales: A User's Manual. 2nd ed. Boston, MA: New England Medical Center; 1994." (NCT00091962)
Timeframe: 8 months post CABG
| Intervention | participants (Mean) |
|---|---|
| Depressed Intervention | 44.0 |
| Depressed Usual Care | 41.4 |
| Non-Depressed Control | 48.7 |
The 17-item Depression Interview and Structured Hamilton (DISH) version of the Hamilton Rating Scale for Depression Standard provides an accurate DSM-IV diagnosis of a cardiac patient's mood disorder and a reliable HRS-D score. Range 0-52. Higher scores are worse. Psychosom Med. 2002;64(6):897-905 (NCT00091962)
Timeframe: 8 months post CABG
| Intervention | units on a scale (Mean) |
|---|---|
| Depressed Intervention | 9.0 |
| Depressed Usual Care | 11.4 |
| Non-Depressed Control Group | 3.8 |
(NCT00136318)
Timeframe: major depression during 24 or 48 weeks of antiviral therapy
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 8 |
| Placebo | 17 |
"Clinically relevant depression (MADRS score of 13 or higher) during antiviral treatment presented as percentage of participants with MADRS scores > 13 (entire time period: from starting study medication until end of antiviral treatment = 48 weeks in patients with genotype 1 or 4 and 24 weeks for patients with genotype 2 or 3)" (NCT00136318)
Timeframe: 50 weeks for genotypes 1 or 4 and 26 weeks for patients with genotype 2 or 3
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 32 |
| Placebo | 59 |
Number of patients who did not develop at any time of antiviral treatment (up to 48 weeks) a MADRS score of 13 or more as a sign of clinically relevant depression (NCT00136318)
Timeframe: Patients free of depression during 24 or 48 weeks of antiviral therapy
| Intervention | participants (Number) |
|---|---|
| Escitalopram | 60 |
| Placebo | 40 |
(NCT00136318)
Timeframe: severe depression during 24 or 48 weeks of antiviral therapy
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 1 |
| Placebo | 12 |
(negative Polymerase Chain Reaction (PCR) 6 months after the end of antiviral treatment) (NCT00136318)
Timeframe: assessed 24 weeks after end of antiviral treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 56 |
| Placebo | 46 |
Full Scale Name: The Executive Composite Score (ECS). Definition: Subscales were averaged to compute this composite total score. The ECS is the weighted average of performance on 6 subtests of executive function, including (1) the Controlled Oral Word Association Test, (2) Symbol Digit Modalities test; (3) Stroop Color Word Test (Interference Trial), (4) Trail Making test (Part B), (5) Letter-Number Sequencing, and (6) Animal Naming. Construct Measured: Thinking tasks involving planning, working memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, and task switching. ECS Scale Range: The ECS score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on executive functioning tasks. Change Calculation Details: Compares change in executive functioning performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.005 |
| Placebo | 0.172 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: Compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.67 |
| Placebo | 1.23 |
Full Scale Name: Letter Number Sequencing (LNS) subtest from the Wechsler Adult Intelligence Scale (WAIS) third edition. Definition: LNS is a task that requires the reordering of an initially unordered set of letters and numbers. Construct Measured: Working memory. LNS Score Range: Raw scores may range from 0 to 21, where lower scores indicate poorer performance in working memory. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.113 |
| Placebo | 0.225 |
Semantic Fluency Score. Definition: The Semantic Fluency Score is the number of words a person can produce given a category, including naming (1) Animal names, (2) Fruit names, (3) Boy names, (4) Girl names, and (5) Vegetable names. Construct Measured: Working memory and verbal initiation. Scale Range: The Semantic Fluency Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on working memory tasks. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) where patients named fruit names to the weighted average of visits 5 (week 12) & 6 (week 15) where patients named girl names and vegetable names respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.386 |
| Placebo | 0.664 |
"Full Scale Name: Stroop Interference subtest from The Stroop Color and Word Test. Definition: Participants are asked to name the ink color in which a word is printed when the word itself (which is irrelevant to the task) is the name of a different color rather than the same color. For example, participants may be asked to say red to the word blue printed in red ink. Constructs Measured: Selective attention, response inhibition, cognitive flexibility, and processing speed. Scale Range: The Stroop Interference score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.256 |
| Placebo | -0.046 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: This analysis was restricted to a subgroup and, accordingly, does not reflect the total number of participants as reported in the Participant Flow. This analysis compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.10 |
| Placebo | 1.50 |
Full Scale Name: The Symbol Digit Modalities Test (SDMT). Definition: The SDMT screens for organic cerebral dysfunction by having the examinee use a reference key to pair specific numbers with given geometric figures in 90 seconds. Construct Measured: Attention, processing speed, and working memory. SDMT Scale Range: Raw scores may range from 0 to 110, where lower scores indicate poorer performance. Change Calculation Details: Compares change in performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.227 |
| Placebo | -0.170 |
Full Scale Name: The Total Functional Capacity (TFC) subscale from the Unified Huntington's Disease Rating Scale (UHDRS). Definition: The TFC is a score that classifies five stages of Huntington's Disease and five levels of function in the domains of workplace, finances, domestic chores, activities of daily living and requirements for unskilled or skilled care. Construct Measured: Activities of Daily Living. Scale Range: The TFC score ranges from 0 to 13, where lower scores indicate poorer performance in activities of daily living. Change Calculation Details: Compares change in TFC performance from Baseline (week -4) to the weighted average of visits 4 (week 6) and 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.54 |
| Placebo | -0.06 |
"Full Scale Name: Trail Making Test Part B (TMT-B). Definition: The TMT-B test requires participants to connect-the-dots of 25 consecutive targets on a sheet of paper where the subject alternates between numbers and letters, going in both numerical and alphabetical order. Constructs Measured: Attention, set shifting, and processing speed. Scale range: The TMT-B score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.087 |
| Placebo | 0.405 |
Full Scale Name: The Verbal Fluency Score (VFC). Definition: The VFC is the number of words a person can produce given a letter, including (1) Naming words that start with F, A, and S; (2) naming words that start with K, W, and R; (3) naming words that start with V, I, and P; (4) naming words that start with O, G, and B; (5) naming words that start with E, N, and T; and (6) naming words that start with J, C, and S. Construct Measured: Verbal initiation and flexibility. Scale Range: The Verbal Fluency Composite Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in verbal initiation and flexibility from visit 2 (week 0) where patients named words starting with O, G, and B to the weighted average of visits 5 (week 12) and 6 (week 15) where patients named words starting with E, N, and T, and J, C, and S respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.140 |
| Placebo | 0.071 |
The API is a well-validated and reliable measure of abdominal pain assessing the frequency, duration, and intensity of abdominal pain consisting of five items assessing the frequency, duration, and intensity of abdominal pain experienced during the prior 2 weeks. Two of the items are scored from 0 to 5, one is scaled 0 to 8, and two are scaled 0 to 10, with lower scores considered to be better than higher scores. Item scores are standardized using Z-scores and then summed to yield an index of abdominal pain that has been sensitive to change in previous epidemiological and treatment studies of FAP. Alpha reliability ranged from 0.80 to 0.93. The API will be a continuous primary outcome measure of abdominal pain. (NCT00962039)
Timeframe: Weeks 0, 2, 4, and 8
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| API-C Week 0 | API-C Week 2 | API-C Week 4 | API-C Week 8 | |
| Citalopram | 0.45 | -0.14 | -0.21 | -0.36 |
| Placebo | 0.47 | 0.06 | 0.08 | -0.03 |
Children's Depression Rating Scale - Revised (CDRS-R) is a clinician administered measure of depression in children and adolescents and provides data necessary to diagnose depressive disorder and rate the severity of depressive symptoms over time. The CDRS-R is composed of 17 items, most rated on a 1 to 7 scale, with a minimum score of 17 and a maximum of 113. Higher scores reflect greater depression severity, with scores of 40 and above generally considered to be reflective of a depressive diagnosis. (NCT00962039)
Timeframe: Weeks 0, 2, 4, and 8
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| CDRS-R Week 0 | CDRS-R Week 2 | CDRS-R Week 4 | CDRS-R Week 8 | |
| Citalopram | 34.50 | 27.81 | 24.97 | 23.88 |
| Placebo | 39.23 | 31.89 | 28.35 | 28.39 |
Children's Global Assessment Scale (C-GAS) is an interview-based adaptation of the Global Assessment Scale developed to assess child and adolescent functioning during a specified time period. Scores range from one to 100, with scores of 70 or below reflecting abnormally low functioning and higher scores reflecting better functioning. The C-GAS has demonstrated reliability, as well as discriminant and concurrent validity. A CGAS score of < 70 will be a requirement at study entry. (NCT00962039)
Timeframe: Weeks 0, 2, 4, and 8
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| CGAS Week 0 | CGAS Week 2 | CGAS Week 4 | CGAS Week 8 | |
| Citalopram | 54.42 | 59.24 | 63.27 | 66.72 |
| Placebo | 54.07 | 58.05 | 59.14 | 61.22 |
Clinical Global Impression Scale - Improvement (CGI-I) is a 7-point scale, with lower values being more favorable, used to assess overall global illness improvement. The CGI is a clinician-completed measure, with values ranging from 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), to 7 (very much worse). CGI-I scores of 1 (very much improved) or 2 (much improved) were considered to indicate an acceptable treatment response. A global measure of functional status was chosen as a primary outcome due to the broad array of symptomatology seen in pediatric RAP and the ambiguous relationship between functional status and symptoms of pain, anxiety, and depression in pediatric RAP. The CGI-I is a dichotomous primary outcome measure of global clinical improvement with clinical response be defined as a CGI-I score of 1 or 2 for at least two consecutive weeks. (NCT00962039)
Timeframe: The CGI will be completed at weeks 2, 4, and 8
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| CGI-I Week 2 | CGI-I Week 4 | CGI-I Week 8 | |
| Citalopram | 3.48 | 3.03 | 2.65 |
| Placebo | 3.68 | 3.38 | 3.24 |
Clinical Global Impression Scale - Severity (CGI-S) is a 7-point scale is a clinician-completed measure that requires the clinician to rate the severity of the patient's illness at the time of assessment relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of illness at the time of rating, with values ranging from 1 (normal, not at all ill), 2 (borderline ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), to 7 (extremely ill). (NCT00962039)
Timeframe: Weeks 0, 2, 4, and 8
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| CGI-S Week 0 | CGI-S Week 2 | CGI-S Week 4 | CGI-S Week 8 | |
| Citalopram | 4.31 | 3.83 | 3.56 | 2.76 |
| Placebo | 4.39 | 4.03 | 3.86 | 3.51 |
Pediatric Anxiety Rating Scale (PARS) is a clinician administered measure of anxiety in children and adolescents. The PARS is comprised of a 50-item symptom checklist used to determine the presence or absence of specific anxiety symptoms during the prior week and 7 severity/impairment items, each scored from 0 to 5 . The the score on the 7 items allows the clinician to rate symptom severity and associated impairment on a range from 0 to 35, with higher scores reflecting greater symptom severity and associated impairment. The PARS is characterized by high interrater reliability (ICC = 0.97), adequate internal consistency (α = 0.64), and fair test-retest reliability (ICC = 0.55). There is preliminary support for convergent and divergent validity, and the PARS has demonstrated sensitivity to treatment effects in previously conducted clinical trials. (NCT00962039)
Timeframe: Weeks 0, 2, 4, and 8
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| PARS Week 0 | PARS Week 2 | PARS Week 4 | PARS Week 8 | |
| Citalopram | 7.38 | 4.00 | 2.57 | 2.69 |
| Placebo | 9.73 | 6.78 | 5.76 | 5.55 |
Levels of Neuropeptide Y in the cerebrospinal fluid (NCT00748956)
Timeframe: on study day 2
| Intervention | pg/mL (Mean) |
|---|---|
| High Dose NPY | 329.4 |
| Placebo | 351.0 |
Number of participants with serious adverse events (NCT00748956)
Timeframe: on study day 2
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Dose NPY | 0 |
| High Dose NPY | 0 |
| Placebo | 0 |
Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BDI-II score (Mean) |
|---|---|
| Paroxetine | -9.7 |
| Venlafaxine Extended Release | -9.6 |
| Placebo | -5.2 |
Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BPRS score (Mean) |
|---|---|
| Paroxetine | -9.0 |
| Venlafaxine Extended Release | -9.8 |
| Placebo | -4.4 |
Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in GDS score (Mean) |
|---|---|
| Paroxetine | -6.9 |
| Venlafaxine Extended Release | -6.9 |
| Placebo | -2.8 |
Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in HAM-D score (Mean) |
|---|---|
| Paroxetine | -13.0 |
| Venlafaxine Extended Release | -11.0 |
| Placebo | -6.8 |
Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in MADRS score (Mean) |
|---|---|
| Paroxetine | -13.6 |
| Venlafaxine Extended Release | -10.9 |
| Placebo | -6.6 |
Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 Emotional score (Mean) |
|---|---|
| Paroxetine | -21.4 |
| Venlafaxine Extended Release | -20.7 |
| Placebo | -10.9 |
Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 score (Mean) |
|---|---|
| Paroxetine | -8.0 |
| Venlafaxine Extended Release | -8.4 |
| Placebo | -5.3 |
Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PQSI score (Mean) |
|---|---|
| Paroxetine | -2.1 |
| Venlafaxine Extended Release | -2.6 |
| Placebo | -1.1 |
Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 mental score (Mean) |
|---|---|
| Paroxetine | 11.4 |
| Venlafaxine Extended Release | 9.5 |
| Placebo | 4.8 |
Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Mental Health score (Mean) |
|---|---|
| Paroxetine | 16.7 |
| Venlafaxine Extended Release | 17.4 |
| Placebo | 9.7 |
Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Role score (Mean) |
|---|---|
| Paroxetine | 39.5 |
| Venlafaxine Extended Release | 26.9 |
| Placebo | 12.7 |
Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 vitality score (Mean) |
|---|---|
| Paroxetine | 13.5 |
| Venlafaxine Extended Release | 9.1 |
| Placebo | 4.7 |
Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in CAS score (Mean) |
|---|---|
| Paroxetine | -3.6 |
| Venlafaxine Extended Release | -3.2 |
| Placebo | -2.4 |
Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS score (Mean) |
|---|---|
| Paroxetine | -8.7 |
| Venlafaxine Extended Release | -7.0 |
| Placebo | -4.3 |
Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-Bulbar score (Mean) |
|---|---|
| Paroxetine | -1.4 |
| Venlafaxine Extended Release | -1.4 |
| Placebo | -0.5 |
Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-motor score (Mean) |
|---|---|
| Paroxetine | -4.3 |
| Venlafaxine Extended Release | -2.0 |
| Placebo | -1.0 |
Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-tremor score (Mean) |
|---|---|
| Paroxetine | 0.4 |
| Venlafaxine Extended Release | 0.5 |
| Placebo | -0.6 |
51 reviews available for citalopram and Depression
| Article | Year |
|---|---|
Understanding treatment-resistant depression using "omics" techniques: A systematic review.
Topics: Antidepressive Agents; Calcium; Citalopram; Depression; Depressive Disorder, Treatment-Resistant; Hu | 2022 |
Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: A network meta-analysis.
Topics: Antidepressive Agents; China; Citalopram; Depression; Depressive Disorder, Major; Humans; Network Me | 2020 |
Mood disorders and outcomes in lung cancer patients undergoing surgery: a brief summery.
Topics: Anxiety; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Humans; Lu | 2020 |
Methylphenidate use in geriatric depression: A systematic review.
Topics: Aged; Citalopram; Depression; Depressive Disorder, Major; Humans; Methylphenidate; Middle Aged; Pros | 2021 |
Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis.
Topics: Citalopram; Depression; Fluoxetine; Fractures, Bone; Humans; Selective Serotonin Reuptake Inhibitors | 2021 |
What are the risks associated with different Selective Serotonin Re-uptake Inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence.
Topics: Adult; Anxiety; Citalopram; Depression; Female; Humans; Paroxetine; Pregnancy; Pregnancy Complicatio | 2017 |
Antidepressants for Depression Associated with Traumatic Brain Injury: A Meta-analytical Study of Randomised Controlled Trials.
Topics: Antidepressive Agents; Brain Injuries, Traumatic; Citalopram; Depression; Humans; Randomized Control | 2017 |
Meta-analysis: Second generation antidepressants and headache.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Citalopram; Depression; Double- | 2018 |
Efficacy and Safety of Citalopram for the Treatment of Poststroke Depression: A Meta-Analysis.
Topics: Antidepressive Agents, Second-Generation; Chi-Square Distribution; Citalopram; Depression; Humans; O | 2018 |
Efficacy and acceptability of antidepressants in patients with ischemic heart disease: systematic review and meta-analysis.
Topics: Adult; Antidepressive Agents; Citalopram; Depression; Humans; Myocardial Ischemia; Quality of Life; | 2019 |
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disor | 2019 |
'It's the way that you look at it'--a cognitive neuropsychological account of SSRI action in depression.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Anxiety; Citalopram; Cognitive Behavioral | 2013 |
Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder.
Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Depressive Disor | 2013 |
Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Double-Blind Method; Hepatitis C, C | 2013 |
Clinical pharmacology review of escitalopram for the treatment of depression.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Depression; Depressive | 2014 |
A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
Topics: Allosteric Site; Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressi | 2014 |
Towards limiting QT interval prolongation and arrhythmia risk in citalopram use.
Topics: Arrhythmias, Cardiac; Citalopram; Depression; Electrocardiography; Global Health; Humans; Incidence; | 2014 |
Efficacy and Safety of Citalopram in Treating Post-Stroke Depression: A Meta-Analysis.
Topics: Citalopram; Depression; Humans; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhib | 2015 |
Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials.
Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Humans; Paroxetine; Psych | 2016 |
Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis.
Topics: Adult; Antidepressive Agents; Citalopram; Depression; Fluoxetine; Humans; Kidney Failure, Chronic; P | 2016 |
Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bip | 2016 |
S-adenosyl methionine (SAMe) for depression in adults.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Depression; Humans; Imipramine; M | 2016 |
Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Clinical Trials as Topic; Data | 2017 |
Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis.
Topics: Adrenergic Uptake Inhibitors; Citalopram; Clinical Trials as Topic; Depression; Dose-Response Relati | 2009 |
Escitalopram versus other antidepressive agents for depression.
Topics: Antidepressive Agents; Citalopram; Depression; Humans; Randomized Controlled Trials as Topic; Select | 2009 |
Depression and cognitive complaints following mild traumatic brain injury.
Topics: Antidepressive Agents, Tricyclic; Brain; Brain Injuries; Central Nervous System Stimulants; Choline; | 2009 |
[Depression].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; C | 2010 |
Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update.
Topics: Abnormalities, Drug-Induced; Cardiovascular Abnormalities; Citalopram; Depression; Female; Fluoxetin | 2010 |
[Effect of treatment with selective serotonin reuptake inhibitors on lipid profile: state of the art].
Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder; Double-Blind Method; Dyslipidemi | 2012 |
Citalopram versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressi | 2012 |
Duloxetine versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Desvenlafaxine Succinate; Dibenzothiaz | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Costs and Cost Analysis; Depression; Fem | 2012 |
Intravenous antidepressant treatment: focus on citalopram.
Topics: Administration, Oral; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind | 2002 |
Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Fluoxetine; Humans; Menta | 2002 |
Escitalopram.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depression; Humans | 2002 |
Overview of the safety of citalopram.
Topics: Citalopram; Depression; Humans; Selective Serotonin Reuptake Inhibitors | 2003 |
[Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Age | 2003 |
Spotlight on the pharmacoeconomics of escitalopram in depression.
Topics: Citalopram; Clinical Trials as Topic; Cost-Benefit Analysis; Depression; Economics, Pharmaceutical; | 2004 |
[A new quality of the therapy of anxiety and depression--escitalopram].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antidepressive Agents, Second-Generation; Anxie | 2005 |
[Suspected depression].
Topics: Adult; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressiv | 2006 |
The onset of effect for escitalopram and its relevance for the clinical management of depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Humans; Male; | 2006 |
The clinical pharmacokinetics of escitalopram.
Topics: Adolescent; Adult; Age Factors; Aged; Anxiety Disorders; Child; Citalopram; Depression; Drug Interac | 2007 |
[New developments in hypericum extracts: data on efficacy and interactions].
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bridg | 2007 |
Restless legs syndrome induced by escitalopram: case report and review of the literature.
Topics: Adult; Citalopram; Depression; Dose-Response Relationship, Drug; Female; Humans; Restless Legs Syndr | 2008 |
The STAR*D study: treating depression in the real world.
Topics: Algorithms; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depression; Disease Progres | 2008 |
Treatment of uncontrolled crying after stroke.
Topics: Cerebrovascular Disorders; Citalopram; Crying; Depression; Humans; Male; Middle Aged | 1995 |
Depression and dementia: comorbidities, identification, and treatment.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Benzamides; Citalopram; Clomipramine; Cog | 1998 |
Citalopram in the treatment of depression and other potential uses in psychiatry.
Topics: Citalopram; Depression; Drug Interactions; Humans; Obsessive-Compulsive Disorder; Panic Disorder; Ra | 1999 |
Citalopram: a comprehensive review.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Clinical Trials | 2001 |
Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
Topics: Animals; Citalopram; Depression; Humans | 1991 |
166 trials available for citalopram and Depression
| Article | Year |
|---|---|
Depression and inflammation: Correlation between changes in inflammatory markers with antidepressant response and long-term prognosis.
Topics: Adult; Antidepressive Agents; Biomarkers; Citalopram; Depression; Depressive Disorder, Major; Female | 2022 |
Comparative effectiveness of antidepressants on geriatric depression: Real-world evidence from a population-based study.
Topics: Aged; Antidepressive Agents; Citalopram; Depression; Escitalopram; Humans; Sertraline; Treatment Out | 2022 |
Clinical efficacy of Danzhi Xiaoyao Powder in the treatment of post-stroke depression: A protocol for randomized, double-blind clinical study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depression; Double-Blind Method; Drug Th | 2021 |
Emotional blunting with bupropion and serotonin reuptake inhibitors in three randomized controlled trials for acute major depressive disorder.
Topics: Adult; Antidepressive Agents; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Humans; | 2022 |
Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for mild-to-moderate depression: An assessor-blinded, randomized, non-inferiority trial.
Topics: Acupuncture Points; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escital | 2023 |
Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for mild-to-moderate depression: An assessor-blinded, randomized, non-inferiority trial.
Topics: Acupuncture Points; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escital | 2023 |
Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for mild-to-moderate depression: An assessor-blinded, randomized, non-inferiority trial.
Topics: Acupuncture Points; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escital | 2023 |
Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for mild-to-moderate depression: An assessor-blinded, randomized, non-inferiority trial.
Topics: Acupuncture Points; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escital | 2023 |
Sexual function improves as depressive symptoms decrease during treatment with escitalopram: results of a naturalistic study of patients with major depressive disorder.
Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Escitalopram; Humans; Sel | 2023 |
Impact of prestroke physical activity and citalopram treatment on poststroke depressive symptoms: a secondary analysis of data from the TALOS randomised controlled trial in Denmark.
Topics: Aged; Brain Ischemia; Citalopram; Denmark; Depression; Exercise; Female; Humans; Ischemic Stroke; Ma | 2023 |
A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents; Citalopram; Cognition; Depression; Depressive Disorder, Major; Female; | 2023 |
Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial.
Topics: Antidepressive Agents; Aripiprazole; Citalopram; Cognition; Depression; Depressive Disorder, Major; | 2024 |
A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder.
Topics: Adolescent; Adult; Aged; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Fe | 2019 |
Changes in typical beliefs in response to complicated grief treatment.
Topics: Bereavement; Citalopram; Depression; Female; Grief; Humans; International Classification of Diseases | 2020 |
Estimating dose-response for time to remission with instrumental variable adjustment: the obscuring effects of drug titration in Genome Based Therapeutic Drugs for Depression Trial (GENDEP): clinical trial data.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricy | 2020 |
Impact of sleep on complicated grief severity and outcomes.
Topics: Bereavement; Citalopram; Comorbidity; Depression; Female; Grief; Humans; Male; Middle Aged; Quality | 2020 |
Depressive Symptoms in Stroke Patients: Are There Sex Differences?
Topics: Affect; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Depression; D | 2020 |
Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression.
Topics: Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Meman | 2021 |
The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Apathy; Citalopram; Depression; F | 2020 |
Combined treatment with escitalopram and memantine increases gray matter volume and cortical thickness compared to escitalopram and placebo in a pilot study of geriatric depression.
Topics: Adult; Aged; Citalopram; Depression; Double-Blind Method; Female; Gray Matter; Humans; Memantine; Pi | 2020 |
The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression.
Topics: Citalopram; Depression; Humans; Phototherapy; Sleep Initiation and Maintenance Disorders; Sleep Wake | 2021 |
Post-Stroke Depressive Symptoms: Varying Responses to Escitalopram by Individual Symptoms and Lesion Location.
Topics: Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Selec | 2021 |
Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial.
Topics: Berlin; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Humans; Multicenter | 2020 |
Distinct trajectories of response to prefrontal tDCS in major depression: results from a 3-arm randomized controlled trial.
Topics: Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Humans; Transcranial Direct | 2021 |
Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial.
Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; | 2021 |
Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial.
Topics: Adrenergic Uptake Inhibitors; Adult; Citalopram; Depression; Female; Humans; Male; Menopause; Middle | 2021 |
Neural correlates of citalopram and placebo response in acute bipolar depression: A randomized trial.
Topics: Bipolar Disorder; Citalopram; Depression; Double-Blind Method; Humans; Placebo Effect; Selective Ser | 2021 |
Early Symptom Trajectories as Predictors of Treatment Outcome for Citalopram Versus Placebo.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Citalopram; Decision Support Techniques; Depres | 2017 |
Amelioration of mild and moderate depression through Pranic Healing as adjuvant therapy: randomised double-blind controlled trial.
Topics: Adult; Citalopram; Combined Modality Therapy; Depression; Depressive Disorder; Double-Blind Method; | 2018 |
Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Carrier Proteins; Citalopram; Depression; Female; Ge | 2018 |
A Machine Learning Approach to Identifying Placebo Responders in Late-Life Depression Trials.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; H | 2018 |
Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Biomarkers; Body | 2018 |
Analysis of curative effect of fluoxetine and escitalopram in the depression treatment based on clinical observation.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Cytokines; Depression; Female; Fluoxeti | 2018 |
Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients.
Topics: Adolescent; Adult; Age Factors; Aged; Antidepressive Agents; Asian People; Brain-Derived Neurotrophi | 2018 |
Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressi | 2018 |
Effects of SSRI medication on heart rate and blood pressure in individuals with hypertension and depression.
Topics: Blood Pressure; Citalopram; Depression; Double-Blind Method; Female; Heart Rate; Humans; Hypertensio | 2019 |
Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: Findings from the EsDEPACS study.
Topics: Acute Coronary Syndrome; Aged; Antidepressive Agents; Citalopram; Depression; Diagnostic and Statist | 2019 |
Role of Ginkgo biloba extract as an adjunctive treatment of elderly patients with depression and on the expression of serum S100B.
Topics: Aged; Chemotherapy, Adjuvant; Citalopram; Cognition; Depression; Depressive Disorder; Female; Ginkgo | 2018 |
Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Female; Head | 2018 |
Heart rate variability as a biomarker of anxious depression response to antidepressant medication.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Biomarkers; Citalopram; Depression; Depress | 2019 |
The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.
Topics: Adult; Aged; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Drug Therapy, Combinatio | 2019 |
Methylation of the glucocorticoid receptor gene associated with depression in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Antidepressive Agents; Citalopram; CpG Islands; Depression; De | 2019 |
Predicting treatment response to antidepressant medication using early changes in emotional processing.
Topics: Adolescent; Adult; Aged; Algorithms; Antidepressive Agents; Citalopram; Depression; Diagnosis, Compu | 2019 |
Abrupt Symptom Improvements in Antidepressant Clinical Trials: Transient Placebo Effects or Therapeutic Reality?
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressiv | 2018 |
Citalopram in first episode schizophrenia: The DECIFER trial.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Humans; | 2019 |
Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram.
Topics: Adult; Citalopram; Depression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Sele | 2020 |
A controlled study of the efficacy and safety of tandospirone citrate combined with escitalopram in the treatment of vascular depression: A pilot randomized controlled trial at a single-center in China.
Topics: Aged; Antidepressive Agents; Cerebrovascular Disorders; China; Citalopram; Depression; Drug Therapy, | 2019 |
A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRes
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Depression; Double-Blind Meth | 2019 |
Increase in work productivity of depressed individuals with improvement in depressive symptom severity.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Cyclohexan | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Antidepressive Agents; Antineoplastic Agents; Citalopram; | 2013 |
Treatment of depression in type 2 diabetic patients: effects on depressive symptoms, quality of life and metabolic control.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Diabetes Mellitus, Type 2; D | 2013 |
Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study.
Topics: Adult; Anxiety; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Dou | 2014 |
Examining relations between alpha power as well as anterior cingulate cortex-localized theta activity and response to single or dual antidepressant pharmacotherapies.
Topics: Adult; Alpha Rhythm; Antidepressive Agents, Second-Generation; Brain Mapping; Bupropion; Citalopram; | 2014 |
Prevention of depression in patients with acute coronary syndrome (DECARD) randomized trial: effects on and by self-reported health.
Topics: Acute Coronary Syndrome; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Dou | 2015 |
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Citalopram; Depression; Double- | 2014 |
Neuroanatomical correlates of apathy in late-life depression and antidepressant treatment response.
Topics: Aged; Aged, 80 and over; Anisotropy; Antidepressive Agents, Second-Generation; Apathy; Citalopram; D | 2014 |
Neuroplasticity-based computerized cognitive remediation for treatment-resistant geriatric depression.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Case-Control Studies; Citalopram; | 2014 |
Effects of escitalopram prophylaxis during antiviral treatment for chronic hepatitis C in patients with a history of intravenous drug use and depression.
Topics: Aged; Antiviral Agents; Citalopram; Comorbidity; Depression; Female; Hepatitis C, Chronic; Humans; I | 2014 |
Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial.
Topics: Abdominal Pain; Adolescent; Antidepressive Agents, Second-Generation; Anxiety; Child; Citalopram; De | 2014 |
Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: an open trial.
Topics: Administration, Intranasal; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Ci | 2015 |
[Psychopharmacological approach with the usage of selective serotonin reuptake inhibitors in functional dyspepsia treatment].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anxiety; Citalopram; Depression; Drug Therapy, Combination | 2014 |
Correlates and Escitalopram Treatment Effects on Sleep Disturbance in Patients with Acute Coronary Syndrome: K-DEPACS and EsDEPACS.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Citalopram; | 2015 |
Treatment of maternal depression in a medication clinical trial and its effect on children.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Child; Child of Impaired Parents; Citalo | 2015 |
Escitalopram in the prevention of posttraumatic stress disorder: a pilot randomized controlled trial.
Topics: Adult; Analysis of Variance; Anxiety; Citalopram; Depression; Double-Blind Method; Drug Monitoring; | 2015 |
Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression.
Topics: Antidepressive Agents; Biomarkers; Cerebral Cortex; Citalopram; Depression; Female; Humans; Male; Po | 2015 |
Poorer Drinking Outcomes with Citalopram Treatment for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Aged; Alcoholism; Citalopram; Depression; Double-Blind Method; Female; Follow-Up Studies; Hum | 2015 |
Antidepressant medication can improve hypertension in elderly patients with depression.
Topics: Aged; Aged, 80 and over; Amlodipine; Antidepressive Agents; Antihypertensive Agents; Citalopram; Dep | 2015 |
The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome.
Topics: Adult; Anxiety Disorders; Bulimia; Citalopram; Depression; Feeding and Eating Disorders; Female; Hum | 2015 |
Multimorbidity, Depression, and Mortality in Primary Care: Randomized Clinical Trial of an Evidence-Based Depression Care Management Program on Mortality Risk.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Comorbidity; Depression; Disease Managem | 2016 |
Comparison of citalopram and venlafaxine's role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial.
Topics: Citalopram; Depression; Double-Blind Method; Female; Hot Flashes; Humans; Iran; Middle Aged; Postmen | 2016 |
Personality Predictors of Drinking Outcomes in Depressed Alcohol-Dependent Patients.
Topics: Adult; Alcoholism; Character; Citalopram; Depression; Drug Therapy, Combination; Female; Humans; Mal | 2016 |
No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Citalopram; Depr | 2016 |
EEG Abnormalities Are Associated With Poorer Depressive Symptom Outcomes With Escitalopram and Venlafaxine-XR, but Not Sertraline: Results From the Multicenter Randomized iSPOT-D Study.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Electroencephalography; Fem | 2017 |
Effect of escitalopram versus placebo on GRα messenger RNA expression in peripheral blood cells of healthy individuals with a family history of depression - a secondary outcome analysis from the randomized AGENDA trial.
Topics: Adult; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypo | 2016 |
SSRI enhances sensitivity to background outcomes and modulates response rates: A randomized double blind study of instrumental action and depression.
Topics: Adolescent; Adult; Citalopram; Depression; Double-Blind Method; Female; Humans; Learning; Male; Midd | 2016 |
Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cognitive Dysfunction; Depression; Femal | 2016 |
Influences of the Big Five personality traits on the treatment response and longitudinal course of depression in patients with acute coronary syndrome: A randomised controlled trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressi | 2016 |
Determinants and escitalopram treatment effects on suicidal ideation in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies.
Topics: Acute Coronary Syndrome; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Cross- | 2016 |
Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.
Topics: Affect; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Depression; Dru | 2016 |
Predictive value of homocysteine for depression after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Antidepressive Agents; Biomarkers, Tumor; Citalopram; Depressi | 2016 |
The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects.
Topics: Affect; Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Citalo | 2017 |
Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Drug Ad | 2017 |
Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Drug Ad | 2017 |
Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Drug Ad | 2017 |
Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Drug Ad | 2017 |
Prevention of Poststroke Mortality Using Problem-Solving Therapy or Escitalopram.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Female; | 2017 |
Cognitive Behavioral Insomnia Therapy for Those With Insomnia and Depression: A Randomized Controlled Clinical Trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Depressio | 2017 |
Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules.
Topics: Adult; Aged; Aorta; Cell Adhesion; Cell Survival; Chronic Disease; Citalopram; Depression; Endotheli | 2010 |
Superiority of escitalopram to paroxetine in the treatment of depression.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Citalopram; Depression; Dose- | 2009 |
[Clinical efficacy of escitalopram in patients with ischemic heart disease and comorbid depression].
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Humans; Male; | 2009 |
Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Case-Control Studies; Citalopram; | 2009 |
Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD).
Topics: Acute Coronary Syndrome; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Bl | 2009 |
Serotonin modulation of cerebral glucose metabolism in depressed older adults.
Topics: Aged; Brain Mapping; Cerebral Cortex; Citalopram; Depression; Female; Fluorodeoxyglucose F18; Geriat | 2009 |
The impact of nonclinical factors on care use for patients with depression: a STAR*D report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Causality; Citalopram; Depression | 2009 |
Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder.
Topics: Adolescent; Adult; Citalopram; Depression; Dose-Response Relationship, Drug; Female; Humans; Male; M | 2009 |
Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Bl | 2010 |
The wish to die and 5-year mortality in elderly primary care patients.
Topics: Aged; Attitude to Death; Citalopram; Depression; Female; Geriatric Assessment; Health Services for t | 2010 |
The B-VITAGE trial: a randomized trial of homocysteine lowering treatment of depression in later life.
Topics: Age Factors; Antidepressive Agents; Biomarkers; Citalopram; Depression; Double-Blind Method; Drug Th | 2010 |
Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety; Caregivers; Citalopram; | 2010 |
A study of central serotoninergic activity in healthy subjects and patients with Type 2 diabetes treated by traditional one-to-one care or Group Care.
Topics: Antidepressive Agents; Central Nervous System; Citalopram; Depression; Diabetes Mellitus, Type 2; Fe | 2010 |
Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Depression; | 2010 |
Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline.
Topics: Adult; Antidepressive Agents; Blood Platelets; Citalopram; Depression; Female; Humans; Male; Middle | 2010 |
Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons.
Topics: Adult; Antidepressive Agents; Buprenorphine; Citalopram; Depression; Double-Blind Method; Female; Hu | 2010 |
Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial.
Topics: Adolescent; Adult; Anxiety; Citalopram; Depression; Female; Fibromyalgia; Humans; Middle Aged; Neuro | 2010 |
Treatment of subsyndromal depressive symptoms in middle-age and older patients with schizophrenia: effect of age on response.
Topics: Age Factors; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; Depression; | 2010 |
Citalopram reduces endotoxin-induced fatigue.
Topics: Adult; Anxiety; Behavior; Citalopram; Cytokines; Depression; Double-Blind Method; Endotoxins; Fatigu | 2011 |
CYP2C19 variation and citalopram response.
Topics: Adolescent; Adult; Aged; Algorithms; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydr | 2011 |
Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram?
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Chi-Square Distribution; Cital | 2011 |
Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients.
Topics: Adult; Aldosterone; Antidepressive Agents; Blood Pressure; Citalopram; Depression; Humans; Hydrocort | 2011 |
Short-term antidepressant administration reduces negative self-referential processing in the medial prefrontal cortex in subjects at risk for depression.
Topics: Adult; Cerebrovascular Circulation; Citalopram; Depression; Emotions; Female; Functional Neuroimagin | 2012 |
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; | 2011 |
Serum BDNF levels before treatment predict SSRI response in depression.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Cross-Over Studies; Dep | 2011 |
Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression.
Topics: Aged; Aniline Compounds; Brain; Citalopram; Depression; Female; Glucose; Humans; Male; Positron-Emis | 2011 |
Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; | 2011 |
Treating post-CABG depression with telephone-delivered collaborative care: does patient age affect treatment and outcome?
Topics: Age Factors; Aged; Citalopram; Coronary Artery Bypass; Depression; Female; Health Services for the A | 2011 |
Changes in depressive symptoms and social functioning in the sequenced treatment alternatives to relieve depression study.
Topics: Adult; Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Female; Humans; Ma | 2011 |
Clinical features and efficacy of escitalopram treatment for geriatric depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Humans; Male; Severi | 2011 |
Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD).
Topics: Acute Coronary Syndrome; Aged; Antidepressive Agents; Citalopram; Depression; Double-Blind Method; F | 2012 |
No evidence for an anti-inflammatory effect of escitalopram intervention in healthy individuals with a family history of depression.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Antidepressive Agents, Second-Generation; Bloo | 2012 |
Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression?
Topics: Adult; Aging; Antidepressive Agents; Citalopram; Cognition Disorders; Comorbidity; Depression; Doubl | 2012 |
Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Dopamine | 2012 |
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depression; Dep | 2012 |
Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Citalopram; Depression; Double-Blind Method; | 2012 |
Adherence to escitalopram treatment in depression: a study of electronically compiled dosing histories in the 'Depression: the search for phenotypes' study.
Topics: Adult; Citalopram; Depression; Female; Follow-Up Studies; Humans; Male; Medical Records Systems, Com | 2012 |
Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue.
Topics: Activities of Daily Living; Adult; Aged; Antidepressive Agents; Anxiety; Citalopram; Depression; Dul | 2012 |
Depression treatment selectively modifies arterial stiffness in older participants.
Topics: Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Blood Pressure; Cardio | 2013 |
Citalopram in pregnancy and lactation.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Child Development; Citalopram | 2002 |
Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.
Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Adult; Citalopram; Comorbidity; Cross-Over Studi | 2003 |
Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors.
Topics: Adult; Antioxidants; Ascorbic Acid; Citalopram; Depression; Female; Fluoxetine; Humans; Lipid Peroxi | 2003 |
Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Algorithms; Antidepressive Agents; Citalopram; Combined Modality Therapy; D | 2004 |
Adherence to treatment of depression in active injection drug users: the minerva study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cocaine-Related Disorders; Cognitive Beh | 2004 |
Adherence to treatment of depression in active injection drug users: the minerva study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cocaine-Related Disorders; Cognitive Beh | 2004 |
Adherence to treatment of depression in active injection drug users: the minerva study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cocaine-Related Disorders; Cognitive Beh | 2004 |
Adherence to treatment of depression in active injection drug users: the minerva study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cocaine-Related Disorders; Cognitive Beh | 2004 |
Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition.
Topics: Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Cognition; Depression; Disabili | 2004 |
Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study.
Topics: Abdominal Pain; Adolescent; Anxiety Disorders; Child; Citalopram; Comorbidity; Depression; Female; H | 2004 |
[Clinical efficacy of citalopram in patients with hypertension and concomitant depression].
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antidepressive Agents, Second-Generation; Ant | 2004 |
Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache.
Topics: Adult; Amitriptyline; Analysis of Variance; Antidepressive Agents; Citalopram; Comorbidity; Depressi | 2004 |
Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects.
Topics: Administration, Oral; Adult; Aged; Algorithms; Bipolar Disorder; Black People; Blood Specimen Collec | 2004 |
Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder.
Topics: Adult; Affect; Agoraphobia; Citalopram; Cognition; Cross-Sectional Studies; Depression; Female; Huma | 2004 |
Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Citalopram; Corticotropin-Rel | 2005 |
The effect of escitalopram on sleep problems in depressed patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Bl | 2005 |
Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients.
Topics: Aged; Aged, 80 and over; Aging; Antidepressive Agents; Citalopram; Depression; Dose-Response Relatio | 2005 |
Executive dysfunction and the course of geriatric depression.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Demography; Depression; Female; Geriatri | 2005 |
A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Cross-Ov | 2006 |
[Anxiodepressive and neuromediatory disorders in hypertensive patients. Effects of cypramil therapy].
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antihypertensive Agents; Anxiety; Citalopram; | 2005 |
New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram.
Topics: Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depression; Dose-Response Relat | 2006 |
Attention network dysfunction and treatment response of geriatric depression.
Topics: Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Attention; Citalopram; Depress | 2006 |
An open label pilot study of citalopram for depression and boredom in ambulatory cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antidepressive Agents, Second-Generation; Bore | 2003 |
Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chi-Square Distribution; Citalopra | 2006 |
Escitalopram for perimenopausal depression: an open-label pilot study.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Humans; Middle Aged | 2006 |
White-matter integrity predicts stroop performance in patients with geriatric depression.
Topics: Aged; Aged, 80 and over; Anisotropy; Antidepressive Agents, Second-Generation; Brain Mapping; Citalo | 2007 |
Open-label escitalopram treatment for pathological skin picking.
Topics: Adult; Anxiety; Citalopram; Comorbidity; Depression; Dose-Response Relationship, Drug; Female; Human | 2007 |
Antidepressive therapy with escitalopram improves mood, cognitive symptoms, and identity memory for angry faces in elderly depressed patients.
Topics: Affect; Aged; Antidepressive Agents; Citalopram; Cognition; Depression; Emotions; Female; Geriatrics | 2008 |
Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF).
Topics: Affect; Citalopram; Cognition; Depression; Double-Blind Method; Follow-Up Studies; Heart Failure; Hu | 2007 |
Therapeutic drug monitoring of escitalopram in an outpatient setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Body Size; Citalopram; Depression; Dose-Response | 2007 |
Subsyndromal depressive symptoms in middle-aged and older persons with schizophrenia.
Topics: Age Factors; Chronic Disease; Citalopram; Comorbidity; Depression; Depressive Disorder, Major; Doubl | 2007 |
A surveillance study of escitalopram treatment of depressed patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Body Mass Inde | 2008 |
CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy.
Topics: Antidepressive Agents, Second-Generation; Antiviral Agents; Canada; Citalopram; Depression; Double-B | 2008 |
Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
Topics: Aged; Antidepressive Agents; Citalopram; Depression; Desipramine; Double-Blind Method; Female; Human | 2008 |
Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Topics: Adult; Antidepressive Agents, Second-Generation; Australia; Citalopram; Cyclohexanols; Delayed-Actio | 2008 |
Citalopram in the treatment of women with chronic pelvic pain: an open-label trial.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Depression | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Topics: Aged; Citalopram; Depression; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disor | 2008 |
Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram.
Topics: Adult; Affect; Citalopram; Depression; Female; Humans; Male; Middle Aged; Polysomnography; Psychiatr | 1993 |
Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram.
Topics: Adult; Aged; Aged, 80 and over; Cerebrovascular Disorders; Citalopram; Cohort Studies; Depression; D | 1994 |
Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial.
Topics: Adult; Affect; Citalopram; Depression; Eye Movements; Female; Humans; Libido; Middle Aged; Pregnanol | 1998 |
Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Dose-Response Relationship, | 1998 |
Selective serotonin re-uptake inhibitors (SSRIs) and alopecia areata.
Topics: Adult; Alopecia Areata; Anxiety Disorders; Citalopram; Depression; Female; Humans; Middle Aged; Psyc | 1999 |
Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study.
Topics: Acetaminophen; Activities of Daily Living; Adult; Analgesics, Non-Narcotic; Antidepressive Agents; C | 2000 |
Variations in response to citalopram in men and women with alcohol dependence.
Topics: Adult; Alcoholism; Anxiety; Citalopram; Depression; Female; Humans; Male; Prospective Studies; Selec | 2000 |
Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.
Topics: Animals; Antidepressive Agents, Second-Generation; Appetite; Behavior, Animal; Citalopram; Depressio | 2001 |
Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Databases, Factual | 2001 |
Citalopram augmentation of antipsychotic treatment in older schizophrenia patients.
Topics: Aged; Antipsychotic Agents; Citalopram; Depression; Drug Therapy, Combination; Female; Humans; Male; | 2001 |
Treatment of generalized anxiety disorder with citalopram.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anxiety Disorders; Citalopram; Depression; Drug Resistan | 2002 |
365 other studies available for citalopram and Depression
| Article | Year |
|---|---|
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2018 |
The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antidepressive Agents; Binding Sites; Brain; Choli | 2022 |
Distinct Effects of Escitalopram and Vortioxetine on Astroglial L-Glutamate Release Associated with Connexin43.
Topics: Animals; Astrocytes; Chromatography, High Pressure Liquid; Citalopram; Connexin 43; Depression; Fema | 2021 |
Galanin(1-15) Potentiates the Antidepressant-like Effects Induced by Escitalopram in a Rat Model of Depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Citalopram; Depression; Drug Th | 2021 |
Comparison of inflammatory markers as moderators of depression outcomes: A CO-MED study.
Topics: Biomarkers; Citalopram; Depression; Depressive Disorder, Major; Drug Therapy, Combination; Humans; T | 2021 |
Hippocampal Over-Expression of Cyclooxygenase-2 (COX-2) Is Associated with Susceptibility to Stress-Induced Anhedonia in Mice.
Topics: Anhedonia; Animals; Antidepressive Agents; Celecoxib; Citalopram; Cyclooxygenase 2; Depression; Hind | 2022 |
Prenatal exposure of citalopram elicits depression-like and anxiety-like behaviors and alteration of morphology and protein expression of medial prefrontal cortex in young adult mice.
Topics: Animals; Anxiety; Citalopram; Depression; Depressive Disorder, Major; Female; Male; Mice; Mice, Inbr | 2022 |
Neuroprotective role of Bacopa monnieri extract in modulating depression in an experimental rat model.
Topics: Animals; Bacopa; Brain-Derived Neurotrophic Factor; Citalopram; Depression; Dopamine; Humans; Male; | 2022 |
Partial resistance to citalopram in a Wistar-Kyoto rat model of depression: An evaluation using resting-state functional MRI and graph analysis.
Topics: Animals; Citalopram; Depression; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; H | 2022 |
Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study-ADDENDUM.
Topics: Acute Coronary Syndrome; Citalopram; Depression; Depressive Disorder; Humans | 2021 |
Synergistic antidepressant effects of citalopram and SB-334867 in the REM sleep-deprived mice: Possible role of BDNF.
Topics: Animals; Antidepressive Agents; Benzoxazoles; Brain-Derived Neurotrophic Factor; Citalopram; Depress | 2022 |
Predicting relapse from the time to remission during the acute treatment of depression: A re-analysis of the STAR*D data.
Topics: Chronic Disease; Citalopram; Depression; Depressive Disorder, Major; Humans; Recurrence; Treatment O | 2023 |
Low Escitalopram Concentrations in Patients with Depression predict Treatment Failure: A Naturalistic Retrospective Study.
Topics: Citalopram; Cross-Sectional Studies; Depression; Escitalopram; Humans; Retrospective Studies; Treatm | 2023 |
Increased Brain-Derived Neurotrophic Factor and Hippocampal Dendritic Spine Density Are Associated with the Rapid Antidepressant-like Effect of Iron-citalopram and Iron-Imipramine Combinations in Mice.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Deferoxamine; Dendrit | 2023 |
Do sociodemographic and clinical factors affect the selection of initial antidepressant treatment for depression in older adults? Results from a nationwide descriptive study in Denmark.
Topics: Aged; Antidepressive Agents; Citalopram; Cross-Sectional Studies; Denmark; Depression; Escitalopram; | 2023 |
Effects of prenatal exposure to (es)citalopram and maternal depression during pregnancy on DNA methylation and child neurodevelopment.
Topics: Child; Citalopram; Cohort Studies; Depression; DNA Methylation; Female; Humans; Infant, Newborn; Pre | 2023 |
Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression.
Topics: Animals; Citalopram; Depression; Disease Models, Animal; Escitalopram; gamma-Aminobutyric Acid; Glut | 2023 |
Vitamins C and D Exhibit Similar Antidepressant Effects to Escitalopram Mediated by NOx and FKBPL in a Stress-Induced Mice Model.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Ascorbic Acid; Cell Cycle Proteins; Citalopram; | 2023 |
Cognitive, Disability, and Treatment Outcome Implications of Symptom-Based Phenotyping in Late-Life Depression.
Topics: Aged; Anhedonia; Citalopram; Cognition; Depression; Escitalopram; Fatigue; Humans; Sleep Initiation | 2023 |
Toward Personalized Treatment of Depression: An Affordable Citalopram Test based on a Solid-Contact Potentiometric Electrode for at-Home Monitoring of the Antidepressant Dosage.
Topics: Antidepressive Agents; Citalopram; Depression; Electrodes; Humans; Precision Medicine | 2023 |
Potential Anti-Inflammatory Effect of Escitalopram in Iodoacetamide-Induced Colitis in Depressed Ovariectomized Rats: Role of α7-nAChR.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti-Inflammatory Agents; Citalopram; Colitis; Dep | 2019 |
Expression alteration of microRNAs in Nucleus Accumbens is associated with chronic stress and antidepressant treatment in rats.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Gene Expression; Male; MicroRNAs; Nucleus Ac | 2019 |
Brain region-dependent changes in the expression of endocannabinoid-metabolizing enzymes in rats following antidepressant drugs.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Endocannabinoids; Lipoprotein Lipase; Male; | 2019 |
Folic acid ameliorates depression-like behaviour in a rat model of chronic unpredictable mild stress.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Behavior, Animal; Biogenic | 2020 |
Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Brain; Citalopram; Corticosterone; Cytokin | 2020 |
Predictors of Cognitive Improvement Following Treatment for Late-Life Depression.
Topics: Aged; Citalopram; Cognition; Depression; Depressive Disorder, Major; Humans; Quality of Life | 2021 |
Selective Inhibition of the Serotonin Transporter in the Treatment of Depression: Sertraline, Fluoxetine and Citalopram.
Topics: Citalopram; Depression; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Serotonin Plasm | 2020 |
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Topics: Anhedonia; Biomarkers; Canada; Citalopram; Depression; Depressive Disorder, Major; Humans; Magnetic | 2020 |
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Topics: Anhedonia; Biomarkers; Canada; Citalopram; Depression; Depressive Disorder, Major; Humans; Magnetic | 2020 |
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Topics: Anhedonia; Biomarkers; Canada; Citalopram; Depression; Depressive Disorder, Major; Humans; Magnetic | 2020 |
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Topics: Anhedonia; Biomarkers; Canada; Citalopram; Depression; Depressive Disorder, Major; Humans; Magnetic | 2020 |
Synergistic antidepressant-like effect of capsaicin and citalopram reduces the side effects of citalopram on anxiety and working memory in rats.
Topics: Amitriptyline; Animals; Antidepressive Agents; Anxiety; Capsaicin; Citalopram; Depression; Dose-Resp | 2020 |
Using prefrontal and midline right frontal EEG-derived theta cordance and depressive symptoms to predict the differential response or remission to antidepressant treatment in major depressive disorder.
Topics: Adult; Antidepressive Agents; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Electro | 2020 |
Escitalopram-Induced Hair Loss.
Topics: Adult; Alopecia; Anxiety; Citalopram; Depression; Female; Humans; Selective Serotonin Reuptake Inhib | 2020 |
Does citalopram effectively treat post-stroke depression?: A protocol for systematic review and meta analysis.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Humans; Meta-Analysis as Topic; Re | 2020 |
Citalopram-induced pathways regulation and tentative treatment-outcome-predicting biomarkers in lymphoblastoid cell lines from depression patients.
Topics: Biomarkers; Cell Line; Citalopram; Depression; Depressive Disorder, Major; Humans; Selective Seroton | 2020 |
A Serotonin "Cocktail".
Topics: Buspirone; Citalopram; Depression; Drug Therapy, Combination; Female; Humans; Middle Aged; Selective | 2020 |
Depression-Associated Gene
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Tricyclic; Cell Adhesion Molecules, Ne | 2020 |
To Be Continued? Long-Term Treatment Effects of Antidepressant Drug Classes and Individual Antidepressants on the Risk of Developing Dementia: A German Case-Control Study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Case-Control Studi | 2020 |
The Effect of Chronic Mild Stress and Escitalopram on the Expression and Methylation Levels of Genes Involved in the Oxidative and Nitrosative Stresses as Well as Tryptophan Catabolites Pathway in the Blood and Brain Structures.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Catalase; Chronic Disease; Citalopram; Dep | 2020 |
Inclusion of genetic variants in an ensemble of gradient boosting decision trees does not improve the prediction of citalopram treatment response.
Topics: Antidepressive Agents; Area Under Curve; Biomarkers, Pharmacological; Citalopram; Databases, Factual | 2021 |
Molecular imaging of beta-amyloid deposition in late-life depression.
Topics: Age Factors; Aged; Alzheimer Disease; Amyloid beta-Peptides; Antidepressive Agents, Second-Generatio | 2021 |
Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression.
Topics: Amines; Antidepressive Agents; Carnitine; Citalopram; Depression; Depressive Disorder, Major; Humans | 2021 |
Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy.
Topics: Animals; Antidepressive Agents; Anxiety; Cell Adhesion Molecules; Citalopram; Corticosterone; Depres | 2021 |
Characterization of gut microbiome in mice model of depression with divergent response to escitalopram treatment.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Gastrointestinal Microbiome; Humans; Metabol | 2021 |
Antidepressants Differentially Regulate Intracellular Signaling from α1-Adrenergic Receptor Subtypes In Vitro.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Fluoxetine; Gene Expression Reg | 2021 |
Escitalopram Targets Oxidative Stress, Caspase-3, BDNF and MeCP2 in the Hippocampus and Frontal Cortex of a Rat Model of Depression Induced by Chronic Unpredictable Mild Stress.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Brain-Derived Neurotrophic Fact | 2021 |
Targeting the Oxytocin System to Ameliorate Early Life Depressive-Like Behaviors in Maternally-Separated Rats.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Brain; Citalopram; Depression; Enzyme-L | 2021 |
Is Really Crocus Sativus as Effective as Citalopram in the Treatment of Depression?
Topics: Citalopram; Crocus; Depression; Depressive Disorder; Humans; Phytotherapy; Plant Extracts | 2018 |
Suppression of reward-induced dopamine release in the nucleus accumbens in animal models of depression: Differential responses to drug treatment.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Disease Models, Animal; Dopamine; Inhibition | 2017 |
Escitalopram or novel herbal treatments differentially alter cytokine and behavioral responses to immune challenge.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Cytokines; Depression; Illness Behavi | 2017 |
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depre | 2017 |
Adolescent escitalopram prevents the effects of maternal separation on depression- and anxiety-like behaviours and regulates the levels of inflammatory cytokines in adult male mice.
Topics: Age Factors; Animals; Animals, Newborn; Anxiety, Separation; Brain; Citalopram; Cytokines; Depressio | 2017 |
Serotonin syndrome caused by drug to drug interaction between escitalopram and dextromethorphan.
Topics: Antitussive Agents; Citalopram; Cough; Depression; Dextromethorphan; Drug Interactions; Female; Huma | 2017 |
Mouse strain differences in SSRI sensitivity correlate with serotonin transporter binding and function.
Topics: Animals; Citalopram; Depression; Fluoxetine; Hindlimb Suspension; Male; Mice, Inbred C57BL; Mice, In | 2017 |
Molecular changes associated with escitalopram response in a stress-based model of depression.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Citalopram; Corticosterone; Corticotrop | 2018 |
Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt, Slc6a15 and Adora1 gene expression.
Topics: Amino Acid Transport Systems, Neutral; Animals; Antidepressive Agents, Second-Generation; Behavior, | 2017 |
Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Cit | 2017 |
Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression.
Topics: Aged; Alzheimer Disease; Citalopram; Cognitive Dysfunction; Depression; Humans; Kaplan-Meier Estimat | 2018 |
Effects of Xiao Yao San on interferon-α-induced depression in mice.
Topics: Animals; Antidepressive Agents; Calcium-Binding Proteins; Citalopram; Depression; Disease Models, An | 2018 |
HTR1A/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Asian People; Citalopram; Depression; Depressive Di | 2018 |
The role of chronic nutritional supplements consumption in a fulminant serotonin syndrome due to citalopram intoxication.
Topics: Adult; Alcohol Drinking; Antidepressive Agents, Second-Generation; Citalopram; Depression; Dietary S | 2019 |
Major Depression Comorbid with Medical Conditions: Analysis of Quality of Life, Functioning, and Depressive Symptom Severity.
Topics: Adult; Antidepressive Agents; Citalopram; Comorbidity; Depression; Depressive Disorder, Major; Femal | 2018 |
Serotonin 5-HT
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Disease Models, Animal; Dose-Response Relati | 2018 |
Post-mortem analysis of suicide victims shows ABCB1 haplotype 1236T-2677T-3435T as a candidate predisposing factor behind adverse drug reactions in females.
Topics: Adult; Alleles; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; Autopsy; Cital | 2018 |
Composite carbohydrate interpenetrating polyelectrolyte nano-complexes (IPNC) as a controlled oral delivery system of citalopram HCl for pediatric use: in-vitro/in-vivo evaluation and histopathological examination.
Topics: Administration, Oral; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Brain; Ch | 2018 |
Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Cytochrome P-4 | 2018 |
Efficacy of escitalopram oxalate for patients with post-stroke depression.
Topics: Acupressure; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Humans; | 2018 |
Escitalopram alleviates stress-induced Alzheimer's disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity.
Topics: Alzheimer Disease; Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; C | 2018 |
Which Patients Are Prescribed Escitalopram?: Predictors for Escitalopram Prescriptions and Functional Outcomes among Patients with Acute Ischemic Stroke.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Humans; Logistic Mod | 2018 |
Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzofurans; Citalopram; Depression; Depr | 2018 |
Possible SAMe-induced mania.
Topics: Adult; Bipolar Disorder; Citalopram; Depression; Drug Therapy, Combination; Female; Hallucinations; | 2018 |
Differential effects of citalopram on sleep-deprivation-induced depressive-like behavior and memory impairments in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; CREB-Binding Protein; Depression; Dis | 2019 |
Changing the Way We Think About (and With) Antidepressants.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cognition; Cognitive Behavioral Therapy; Depre | 2018 |
DPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral tests.
Topics: Adenosine A1 Receptor Antagonists; Animals; Antidepressive Agents; Brain; Citalopram; Depression; Dr | 2018 |
Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice.
Topics: Animals; Antidepressive Agents; Chemotherapy, Adjuvant; Citalopram; Cytidine Diphosphate Choline; De | 2018 |
Antidepressants in breast milk; comparative analysis of excretion ratios.
Topics: Adult; Antidepressive Agents; Breast Feeding; Child Development; Citalopram; Depression; Female; Hum | 2019 |
Predicting Treatment Response in Depression: The Role of Anterior Cingulate Cortex.
Topics: Adult; Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Emotions; Facial E | 2018 |
Predicting Treatment Response in Depression: The Role of Anterior Cingulate Cortex.
Topics: Adult; Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Emotions; Facial E | 2018 |
Predicting Treatment Response in Depression: The Role of Anterior Cingulate Cortex.
Topics: Adult; Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Emotions; Facial E | 2018 |
Predicting Treatment Response in Depression: The Role of Anterior Cingulate Cortex.
Topics: Adult; Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Emotions; Facial E | 2018 |
Exploring the Relationship Between Depression and Dementia.
Topics: Adult; Aged, 80 and over; Antidepressive Agents; Citalopram; Cognitive Dysfunction; Dementia; Depres | 2018 |
Non-Fatal Intoxication with a High Dose of Citalopram in a Suicidal 14-Year-Old Girl.
Topics: Adolescent; Citalopram; Depression; Diagnostic Tests, Routine; Drug Overdose; Female; Humans; Select | 2019 |
The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Citalopram; Cytochrome P450 Family 2; Depr | 2018 |
Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Depressive Disorder; Depre | 2019 |
Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Citalopram; Depression; Depressive Disorder; Heart; Humans | 2018 |
Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Citalopram; Depression; Depressive Disorder; Heart; Humans | 2018 |
Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Citalopram; Depression; Depressive Disorder; Heart; Humans | 2018 |
CGRP in a gene-environment interaction model for depression: effects of antidepressant treatment.
Topics: Amygdala; Animals; Antidepressive Agents; Brain; Calcitonin Gene-Related Peptide; Citalopram; Depres | 2019 |
Effects of escitalopram and ibuprofen on a depression-like phenotype induced by chronic stress in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Cor | 2019 |
Antidepressant activities of escitalopram and blonanserin on prenatal and adolescent combined stress-induced depression model: Possible role of neurotrophic mechanism change in serum and nucleus accumbens.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Cor | 2019 |
Escitalopram-Induced Rash.
Topics: Anxiety; Citalopram; Depression; Drug Eruptions; Exanthema; Female; Humans; Selective Serotonin Reup | 2019 |
Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiac Conduction System Disease; Citalopram; Death, Sudden, | 2019 |
Escitalopram related edema in a patient with Hashimoto's thyroiditis.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Citalopram; Depression; Edema; Female; Hashimoto Di | 2019 |
Exposure to prenatal antidepressant alters medial prefrontal-striatal synchronization in mice.
Topics: Animals; Antidepressive Agents; Anxiety; Brain; Citalopram; Corpus Striatum; Dendrites; Depression; | 2019 |
Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; C-Reactive Prot | 2019 |
Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study.
Topics: Antidepressive Agents; Arrhythmias, Cardiac; Citalopram; Depression; Humans; Retrospective Studies; | 2019 |
Modifying effects of depression on the association between BDNF methylation and prognosis of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Antidepressive Agents, Second-Generation; Brain-Derived Neurot | 2019 |
Cerebral MAO Activity Is Not Altered by a Novel Herbal Antidepressant Treatment.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Citalopram; Corpus Striatum; Crataegus; Depress | 2019 |
Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depression; Depressive Disorder, Major; | 2019 |
5-HT₂A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system.
Topics: Adrenergic Neurons; Animals; Antidepressive Agents; Citalopram; Depression; Dose-Response Relationsh | 2013 |
Serotonin syndrome: pills, thrills and shoulder aches.
Topics: Accidental Falls; Citalopram; Depression; Diagnosis, Differential; Humans; Male; Selective Serotonin | 2013 |
Prenatal exposure to escitalopram and/or stress in rats: a prenatal stress model of maternal depression and its treatment.
Topics: Animals; Citalopram; Corticosterone; Darkness; Depression; Disease Models, Animal; Female; Infusion | 2013 |
Assessing the comparative-effectiveness of antidepressants commonly prescribed for depression in the US Medicare population.
Topics: Age Factors; Aged; Antidepressive Agents; Citalopram; Comparative Effectiveness Research; Depression | 2012 |
Comments and questions regarding the safety of citalopram.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Humans; Practice Guidelines as Top | 2013 |
In reply.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Humans; Practice Guidelines as Top | 2013 |
HTR2A gene-child abuse interaction and association with a history of suicide attempt among Caucasian depressed psychiatric inpatients.
Topics: Adult; Antidepressive Agents, Second-Generation; Child; Child Abuse; Citalopram; Depression; Epistas | 2013 |
[Dermatomyositis].
Topics: Aged; Antidepressive Agents, Second-Generation; Chemical and Drug Induced Liver Injury; Citalopram; | 2013 |
Self-inflicted trans-oral intracranial stab wound.
Topics: Amines; Analgesics; Antidepressive Agents; Brain Injuries; Cerebellum; Citalopram; Cyclohexanecarbox | 2013 |
[Escitalopram for intervention of psychiatric adverse events during peginterferon-alfa-2a and ribavirin treatment for chronic hepatitis C].
Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depression; Female; H | 2013 |
A novel herbal treatment reduces depressive-like behaviors and increases BDNF levels in the brain of stressed mice.
Topics: Animals; Brain Chemistry; Brain-Derived Neurotrophic Factor; Citalopram; Crataegus; Depression; Dise | 2014 |
Competitive EDge or over the cliff?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Fatigue; Humans; Hypercalcemia; Ma | 2013 |
Impact of antidepressants on cytokine production of depressed patients in vitro.
Topics: Adult; Antidepressive Agents; CD40 Antigens; Citalopram; Cytokines; Depression; Female; Humans; Inte | 2013 |
Variations in central serotonergic activity - relevance of the 5-HTTLPR, life events and their interaction.
Topics: Adolescent; Adult; Citalopram; Depression; Depressive Disorder; Double-Blind Method; Female; Genetic | 2015 |
Effects of escitalopram on serum BDNF levels in elderly patients with depression: a preliminary report.
Topics: Aged; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Case-Control Studies; Citalopram; Co | 2014 |
Use of SSRIs among Danish children: a nationwide study.
Topics: Adolescent; Age Distribution; Antipsychotic Agents; Child; Child, Preschool; Citalopram; Denmark; De | 2014 |
A case report on escitalopram-induced hyperglycaemia in a diabetic patient.
Topics: Aged, 80 and over; Antidepressive Agents; Citalopram; Depression; Diabetes Mellitus; Drug Therapy, C | 2013 |
The discovery of Yuanzhi-1, a triterpenoid saponin derived from the traditional Chinese medicine, has antidepressant-like activity.
Topics: Animals; Antidepressive Agents; Citalopram; Cocaine; Depression; Disease Models, Animal; Female; Flu | 2014 |
Melatonin synergizes with citalopram to induce antidepressant-like behavior and to promote hippocampal neurogenesis in adult mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Antioxidants; Behavior, Animal; Citalopram; Depre | 2014 |
Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial.
Topics: Adult; Antidepressive Agents; Citalopram; Depression; Female; Humans; Linear Models; Male; Middle Ag | 2014 |
Clinical and functional outcomes of patients who experience partial response to citalopram: secondary analysis of STAR*D.
Topics: Adult; Citalopram; Comorbidity; Cost of Illness; Demography; Depression; Depressive Disorder, Major; | 2014 |
Treatment with citalopram, but not with agomelatine, adversely affects sperm parameters: a case report and translational review.
Topics: Acetamides; Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressi | 2014 |
Depression and seizures as the main neuropsychiatric manifestation of mixed connective tissue disorder.
Topics: Adult; Antibodies, Antinuclear; Anticonvulsants; Antidepressive Agents, Second-Generation; Azathiopr | 2014 |
Depression and diabetes: impact of antidepressant medications on glycaemic control.
Topics: Adolescent; Adult; Antidepressive Agents; Blood Glucose; Citalopram; Depression; Diabetes Mellitus, | 2013 |
The depressogenic-like effect of acute and chronic treatment with dexamethasone and its influence on the activity of antidepressant drugs in the forced swim test in adult mice.
Topics: Amitriptyline; Animals; Antidepressive Agents; Citalopram; Depression; Dexamethasone; Dose-Response | 2014 |
Should I prevent my patient from developing depression after stroke? What is the best available option?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Humans; Stroke | 2014 |
Chronic but not acute antidepresant treatment alters serum zinc/copper ratio under pathological/zinc-deficient conditions in mice.
Topics: Animals; Antidepressive Agents; Bupropion; Citalopram; Copper; Depression; Disease Models, Animal; I | 2014 |
Depressive symptoms associated with dabigatran: a case report.
Topics: Antithrombins; Atrial Fibrillation; Citalopram; Dabigatran; Depression; Drug Interactions; Humans; M | 2015 |
The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor.
Topics: Animals; Antidepressive Agents; Citalopram; Corpus Striatum; Depression; Disease Models, Animal; Dru | 2015 |
The Role of the Two-Pore Domain Potassium Channel TREK-1 in the Therapeutic Effects of Escitalopram in a Rat Model of Poststroke Depression.
Topics: Animals; Body Weight; Brain; Cell Proliferation; Citalopram; Depression; Disease Models, Animal; Exp | 2015 |
Mental health: thinking from the gut.
Topics: Animals; Anxiety; Autistic Disorder; Bacteroides fragilis; Bifidobacterium; Blood-Brain Barrier; Bra | 2015 |
Exploring the role of drug-metabolising enzymes in antidepressant side effects.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricy | 2015 |
An unusual presentation of dose dependent SIADH secondary to mirtazapine therapy.
Topics: Aged; Antidepressive Agents; Citalopram; Depression; Dose-Response Relationship, Drug; Humans; Inapp | 2015 |
Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [123 I]β-CIT SPECT study.
Topics: Adult; Aged; Antidepressive Agents; Brain; Citalopram; Depression; Dopamine Plasma Membrane Transpor | 2015 |
Study of antidepressant drugs in GPR39 (zinc receptor⁻/⁻) knockout mice, showing no effect of conventional antidepressants, but effectiveness of NMDA antagonists.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Dizocilpine Maleate; Excitatory Amino Acid A | 2015 |
Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Depressive Disorder, Major | 2015 |
Effect of Treating Mothers' Depression on Children's Well-Being.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Child of Impaired Parents; Citalopram; Depressi | 2015 |
Evaluation of the role of NMDA receptor function in antidepressant-like activity. A new study with citalopram and fluoxetine in the forced swim test in mice.
Topics: 2-Amino-5-phosphonovalerate; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generatio | 2015 |
Cognitive control, reward-related decision making and outcomes of late-life depression treated with an antidepressant.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Anxiety; Citalopram; Cognition; Decision Making; Dep | 2015 |
Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.
Topics: Animals; Anxiety; Behavior, Animal; Body Weight; Brain; Citalopram; Corticosterone; Depression; Diet | 2015 |
Chronic selective serotonin reuptake inhibition modulates endothelial dysfunction and oxidative state in rat chronic mild stress model of depression.
Topics: Animals; Citalopram; Cyclooxygenase Inhibitors; Depression; Drug Administration Schedule; Endotheliu | 2015 |
Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress.
Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Behavior, Animal; Body Weight; Brain-Derived Neurotro | 2015 |
Antidepressant Prescription Pattern in the Presence of Medical Co-morbidity: REAP-AD 2013 Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; | 2015 |
Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depression; Fe | 2016 |
Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse.
Topics: Animals; Antidepressive Agents; Brain; Cell Proliferation; Cell Survival; Citalopram; Depression; Di | 2016 |
Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning.
Topics: Adolescent; Adult; Antidepressive Agents; Child; Child, Preschool; Citalopram; Cohort Studies; Datab | 2016 |
Hyponatremia Due to Escitalopram and Thiazide Use After Cardiac Surgery.
Topics: Antidepressive Agents; Citalopram; Coronary Artery Bypass; Depression; Drug Therapy, Combination; Em | 2016 |
Effects of Escitalopram on a Rat Model of Persistent Stress-Altered Hedonic Activities: Towards a New Understanding of Stress and Depression.
Topics: Age Factors; Animals; Antidepressive Agents, Second-Generation; Citalopram; Corticosterone; Depressi | 2015 |
Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory.
Topics: Animals; Anxiety; Brain; Citalopram; Depression; Disease Models, Animal; Fear; Memory; Rats; Rats, W | 2016 |
Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration.
Topics: Animals; Behavior, Animal; Citalopram; Depression; Interleukin-10; Lipopolysaccharides; Mice; Mice, | 2016 |
Bullous pemphigoid induced by escitalopram in a patient with depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Biopsy; Citalopram; Depression; Diagnosis, Different | 2016 |
Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Disease Models, Animal; Ex | 2016 |
Residual symptoms and functionality in depressed outpatients: A one-year observational study in Switzerland with escitalopram.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder, Major; | 2016 |
The Effects of Fluvoxamine on the Steady-State Plasma Concentrations of Escitalopram and Desmethylescitalopram in Depressed Japanese Patients.
Topics: Asian People; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Depression; | 2016 |
Combination of Escitalopram and Rasagiline Induced Serotonin Syndrome: A Case Report and Review Literature.
Topics: Aged; Citalopram; Depression; Humans; Indans; Male; Parkinson Disease; Selective Serotonin Reuptake | 2015 |
Plant Natural Product Puerarin Ameliorates Depressive Behaviors and Chronic Pain in Mice with Spared Nerve Injury (SNI).
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biological Products; Brain-Derived Neurotrophic Fa | 2017 |
When Good Medications Go Bad, Don't DILI Dally.
Topics: Aged; Antidepressive Agents, Second-Generation; Chemical and Drug Induced Liver Injury; Citalopram; | 2016 |
May depressed and anxious patients with carcinoid syndrome benefit from treatment with selective serotonin reuptake inhibitors (SSRIs)?: findings from a case report.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Anxiety; Carcinoid Heart | 2016 |
The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Citalopram; Clinical Trials, Phase III | 2016 |
Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice.
Topics: Acamprosate; Alcohol Drinking; Animals; Anxiety; Citalopram; Depression; Drug Therapy, Combination; | 2016 |
Positive allosteric modulation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptors differentially modulates the behavioural effects of citalopram in mouse models of antidepressant and anxiolytic action.
Topics: Allosteric Regulation; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Citalopram; Depressi | 2016 |
Therapeutic effects of 10-HzPulsed wave lasers in rat depression model: A comparison between near-infrared and red wavelengths.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Combined Modality Therapy; D | 2016 |
Plasminogen Activator Inhibitor-1 in depression: Results from Animal and Clinical Studies.
Topics: Animals; Behavior, Animal; Body Weight; Case-Control Studies; Chronic Disease; Citalopram; Depressio | 2016 |
Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antidepressive Agents; Antipsychotic Agents; Benza | 2016 |
Neuropsychiatric Presentation of Wilson Disease in an Adolescent Male.
Topics: Adenosine Triphosphatases; Adolescent; Aggression; Antidepressive Agents; Antipsychotic Agents; Arip | 2016 |
The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Anxiety; Behavior, Animal; Cit | 2016 |
Perinatal exposure to the selective serotonin reuptake inhibitor citalopram alters spatial learning and memory, anxiety, depression, and startle in Sprague-Dawley rats.
Topics: Age Factors; Amphetamines; Animals; Animals, Newborn; Anxiety; Body Weight; Citalopram; Depression; | 2016 |
17β-Estradiol augments antidepressant efficacy of escitalopram in ovariectomized rats: Neuroprotective and serotonin reuptake transporter modulatory effects.
Topics: Acetylcholinesterase; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Cogn | 2016 |
Highly polygenic architecture of antidepressant treatment response: Comparative analysis of SSRI and NRI treatment in an animal model of depression.
Topics: Animals; Antidepressive Agents; Citalopram; Cyclic AMP Response Element-Binding Protein; Depression; | 2017 |
Network analysis of the Quick Inventory of Depressive Symptomatology: Reanalysis of the STAR*D clinical trial.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depres | 2016 |
Escitalopram and Outcomes Among Patients With Depression and Heart Failure.
Topics: Citalopram; Depression; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method; Heart | 2016 |
Escitalopram and Outcomes Among Patients With Depression and Heart Failure-Reply.
Topics: Citalopram; Depression; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method; Heart | 2016 |
Recent trends in primary-care antidepressant prescribing to children and young people: an e-cohort study.
Topics: Adolescent; Antidepressive Agents; Anxiety; Child; Citalopram; Cohort Studies; Databases, Factual; D | 2016 |
Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment.
Topics: Animals; Anxiety; Anxiety Disorders; Behavior, Animal; Black or African American; Brain-Derived Neur | 2017 |
Sobering news about post-stroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Double-Blind Method; Humans; Stroke | 2017 |
Depressive-like effect of prenatal exposure to DDT involves global DNA hypomethylation and impairment of GPER1/ESR1 protein levels but not ESR2 and AHR/ARNT signaling.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Brain; Citalopram; DDT; Depress | 2017 |
Anhedonia and activity deficits in rats: impact of post-stroke depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Citalopram; Depression; Disease | 2009 |
Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Disease Models, Animal; Fe | 2009 |
Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines.
Topics: Antidepressive Agents, Second-Generation; Arrhythmias, Cardiac; Azabicyclo Compounds; Benzodiazepine | 2008 |
[Case of the month. A malignant brain tumor presenting with depression and hallucinations].
Topics: Antidepressive Agents, Second-Generation; Brain Neoplasms; Citalopram; Depression; Glioblastoma; Hal | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Escitalopram, problem-solving therapy, and poststroke depression.
Topics: Citalopram; Depression; Depressive Disorder; Humans; Problem Solving; Psychotherapy; Selective Serot | 2008 |
Acute voluntary intoxication with selective serotonin reuptake inhibitors during the third trimester of pregnancy: therapeutic management of mother and fetus.
Topics: Adrenal Cortex Hormones; Adult; Antidotes; Calcium Channel Blockers; Charcoal; Citalopram; Depressio | 2008 |
[Sexsomnia during treatment with a selective serotonin reuptake inhibitor].
Topics: Adult; Citalopram; Depression; Humans; Male; Paraphilic Disorders; Parasomnias; Remission, Spontaneo | 2008 |
Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response.
Topics: Citalopram; Depression; DNA; Fluoxetine; Haplotypes; Humans; Monoamine Oxidase; Pharmacogenetics; Po | 2009 |
Medication and talk therapy help prevent depression after a stroke. Antidepressants and problem-solving therapy can prevent or delay the onset of post-stroke depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Depression; Hu | 2008 |
Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain-Derived Neuro | 2009 |
Schizencephaly associated with bipolar II disorder.
Topics: Bipolar Disorder; Brain; Citalopram; Depression; Diagnosis, Differential; Dibenzothiazepines; Humans | 2009 |
The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression.
Topics: Antidepressive Agents, Second-Generation; Case-Control Studies; Chromatography, High Pressure Liquid | 2009 |
Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Databases as Topic; Depression; Drug Co | 2009 |
Citalopram associated with complex visual hallucination: a case report.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Hallucinations; Huma | 2009 |
The brain 5-HT4 receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration.
Topics: Animals; Antidepressive Agents, Second-Generation; Autoradiography; Brain; Citalopram; Depression; D | 2009 |
Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cost of Illness; Depression; Drug Admini | 2010 |
Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cost of Illness; Depression; Drug Admini | 2010 |
Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cost of Illness; Depression; Drug Admini | 2010 |
Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cost of Illness; Depression; Drug Admini | 2010 |
Two cases of herpes zoster, occurring 4 and 6 weeks after the initiation of citalopram treatment.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Herpes Zoster; Human | 2009 |
Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study.
Topics: Adult; Aged; Antidepressive Agents; Biomarkers; Citalopram; Depression; Diabetes Mellitus, Type 1; D | 2009 |
Antidepressant properties of the 5-HT4 receptor partial agonist, SL65.0155: behavioral and neurochemical studies in rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents; bcl-2-Associated X Protein; Behavior, Animal; | 2009 |
Corticotropin-releasing factor, serotonin, and sex: keys to the castle of depressive illness.
Topics: Animals; Citalopram; Corticotropin-Releasing Hormone; Depression; Genotype; Hindlimb Suspension; Hum | 2009 |
The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression.
Topics: Animals; Antidepressive Agents; Bromodeoxyuridine; Cell Proliferation; Citalopram; Depression; Disea | 2010 |
Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women.
Topics: Adiponectin; Adult; Aged; Antidepressive Agents; Blood Glucose; Body Mass Index; Chi-Square Distribu | 2009 |
Decreased expression of serotonin 1A receptor in the dentate gyrus in association with chronic mild stress: a rat model of post-stroke depression.
Topics: Animals; Citalopram; Dentate Gyrus; Depression; Disease Models, Animal; Down-Regulation; Exploratory | 2009 |
Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Blood Platelets; Citalopram; Depression; Drug | 2010 |
Depression masked as paroxysmal hypertension episodes.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Diagnosis, Differential; Humans; H | 2010 |
Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents, Second-Generation; Anxiety; | 2010 |
Early-life stress and antidepressant treatment involve synaptic signaling and Erk kinases in a gene-environment model of depression.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Citalopram; Depression; Disease | 2010 |
Notch1 signaling related hippocampal neurogenesis in adult poststroke depression rats: a valid index for an efficient combined citalopram and WAY100635 pharmacotherapy.
Topics: Animals; Behavior, Animal; Citalopram; Depression; Disease Models, Animal; Drug Evaluation, Preclini | 2010 |
Diagnostic crossover from obesity to atypical anorexia nervosa - a case report.
Topics: Adolescent; Amenorrhea; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Behavior Therapy | 2009 |
Hippocampal GABAergic dysfunction in a rat chronic mild stress model of depression.
Topics: Action Potentials; Animals; Antidepressive Agents, Second-Generation; Citalopram; Dentate Gyrus; Dep | 2011 |
The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Corticosterone; Depr | 2010 |
Aging impairs the antidepressant-like response to citalopram in male rats.
Topics: Aging; Animals; Antidepressive Agents; Citalopram; Depression; Disease Models, Animal; Drinking; Foo | 2010 |
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neopl | 2010 |
Estradiol valerate elicits antidepressant-like effects in middle-aged female rats under chronic mild stress.
Topics: Aging; Animals; Antidepressive Agents; Chronic Disease; Citalopram; Conditioning, Operant; Depressio | 2010 |
Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK.
Topics: Adolescent; Adult; Aged; Citalopram; Cyclohexanols; Depression; Drugs, Generic; Female; Health Care | 2010 |
High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin.
Topics: Adult; Antidepressive Agents; Antiviral Agents; Buprenorphine; Citalopram; Depression; Directly Obse | 2010 |
Potential role of glutamate neurotransmission in the pathogenesis of ischemic brain damage and of depression. Effects of L-kynurenine on the survival of the hippocampal neurons and on the corticocerebral blood flow in ischemic animal models.
Topics: Animals; Brain Ischemia; Cell Survival; Cerebrovascular Circulation; Chromatography, High Pressure L | 2010 |
Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality.
Topics: Alleles; Antineoplastic Agents, Hormonal; Biotransformation; Breast Neoplasms; Citalopram; Cytochrom | 2010 |
The beta3 adrenoceptor agonist, amibegron (SR58611A) counteracts stress-induced behavioral and neurochemical changes.
Topics: Adrenergic beta-3 Receptor Agonists; Animals; Antidepressive Agents; Antidepressive Agents, Tricycli | 2010 |
Factors associated with response in depressed elderly outpatients treated with escitalopram in a naturalistic setting in Germany.
Topics: Aged; Aged, 80 and over; Bipolar Disorder; Citalopram; Dementia; Depression; Depressive Disorder; De | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
The effect of escitalopram on platelet activity.
Topics: Antidepressive Agents; Blood Platelets; Citalopram; Depression; Humans; Platelet Aggregation; Treatm | 2011 |
Escitalopram and ischemic stroke: cause or chance association?
Topics: Adult; Citalopram; Depression; Humans; Male; Selective Serotonin Reuptake Inhibitors; Stroke | 2010 |
Involvement of NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test.
Topics: Animals; Antidepressive Agents, Second-Generation; Arginine; Citalopram; Cyclic GMP; Depression; Exp | 2010 |
Metabolic acidosis and generalized seizures secondary to citalopram overdose: a case report.
Topics: Acidosis; Anticonvulsants; Citalopram; Depression; Drug Overdose; Female; Humans; Lorazepam; Seizure | 2010 |
Distinct functional networks associated with improvement of affective symptoms and cognitive function during citalopram treatment in geriatric depression.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antidepressive Agents, Second-Generation; Brain Mappi | 2011 |
Citalopram related euprolactinaemic galactorrhoea: a case report.
Topics: Adult; Citalopram; Depression; Female; Galactorrhea; Humans; Selective Serotonin Reuptake Inhibitors | 2010 |
Chronic escitalopram treatment restores spatial learning, monoamine levels, and hippocampal long-term potentiation in an animal model of depression.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Animals, Newborn; Antidepressive Agents, Second | 2011 |
Escitalopram affects cytoskeleton and synaptic plasticity pathways in a rat gene-environment interaction model of depression as revealed by proteomics. Part II: environmental challenge.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Citalopram; Cytoskeleton; Depre | 2011 |
Escitalopram modulates neuron-remodelling proteins in a rat gene-environment interaction model of depression as revealed by proteomics. Part I: genetic background.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Citalopram; Depression; Disease | 2011 |
Antidepressant response to chronic citalopram treatment in eight inbred mouse strains.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Citalopram; Depression; Disease | 2011 |
The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome.
Topics: Administration, Oral; Aged; Brain; Citalopram; Depression; Female; Fluorodeoxyglucose F18; Glucose; | 2011 |
Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration.
Topics: AIDS-Related Complex; Analysis of Variance; Animals; Avoidance Learning; Benzopyrans; Brain-Derived | 2012 |
[Hypertension induced by escitalopram].
Topics: Citalopram; Depression; Humans; Hypertension; Male; Middle Aged; Selective Serotonin Reuptake Inhibi | 2011 |
5-HT(1A)-receptor over-expressing mice: genotype and sex dependent responses to antidepressants in the forced swim-test.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Behavior, Animal; Cerebral Cortex; Cit | 2011 |
[Parkinsonism due to clebopride].
Topics: Aged; Antidepressive Agents; Antiemetics; Benzamides; Citalopram; Depression; Dyspepsia; Female; Hum | 2011 |
Generalized action myoclonus associated with escitalopram in a patient with mixed dementia.
Topics: Aged; Citalopram; Dementia; Depression; Female; Humans; Myoclonus | 2011 |
Comparison of the depression-like behavior and serotonergic system between Wistar and Wistar-Kyoto rat strains.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Disease Models, Animal; R | 2011 |
Escitalopram related erectile dysfunction and spontaneous ejaculation during micturition.
Topics: Adult; Citalopram; Depression; Ejaculation; Erectile Dysfunction; Humans; Male; Selective Serotonin | 2010 |
Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants.
Topics: Aniline Compounds; Animals; Antidepressive Agents; Apoptosis Inducing Factor; Apoptosis Regulatory P | 2012 |
Effects of venlafaxine and escitalopram treatments on NMDA receptors in the rat depression model.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depression; Disease Mo | 2011 |
Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Citalopram; Cytokines; Depr | 2011 |
Increased numbers of orexin/hypocretin neurons in a genetic rat depression model.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Body Weight; Citalopram; Depres | 2011 |
Biomarkers of anhedonic-like behavior, antidepressant drug refraction, and stress resilience in a rat model of depression.
Topics: Anhedonia; Animals; Biomarkers; Citalopram; Depression; Disease Models, Animal; Drug Resistance; Eat | 2011 |
Combined α7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antidepressive Agents; Behavior, Animal; Benzamide | 2012 |
Learning and memory alterations are associated with hippocampal N-acetylaspartate in a rat model of depression as measured by 1H-MRS.
Topics: Animals; Aspartic Acid; Behavior, Animal; Citalopram; Creatine; Depression; Disease Models, Animal; | 2011 |
Aprepitant quetiapine: a clinically significant drug interaction in a patient treated for head and neck cancer.
Topics: Adult; Antidepressive Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Carcinoma; Chemoradiot | 2012 |
Endogenous ciliary neurotrophic factor modulates anxiety and depressive-like behavior.
Topics: Amitriptyline; Animals; Anxiety; Biogenic Monoamines; Cell Count; Ciliary Neurotrophic Factor; Cital | 2012 |
Synergistic antidepressant-like action of gaboxadol and escitalopram.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Dentate Gyrus; Depression; Disease Mod | 2012 |
Antidepressants reduce extinction-induced withdrawal and biting behaviors: a model for depressive-like behavior.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Disease Models, Animal; Extinction, Psycholo | 2012 |
Prolonged QTc interval and torsades de pointes induced by citalopram.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depre | 2012 |
Exofocal dopaminergic degeneration as antidepressant target in mouse model of poststroke depression.
Topics: Animals; Brain-Derived Neurotrophic Factor; Citalopram; Corticosterone; Depression; Disease Models, | 2012 |
The effect of citalopram on chronic stress-induced depressive-like behavior in rats through GSK3β/β-catenin activation in the medial prefrontal cortex.
Topics: Animals; Antidepressive Agents; Behavior, Animal; beta Catenin; Blotting, Western; Chronic Disease; | 2012 |
Geriatrics update 2012: what parts of our practice to change, what to 'think about'.
Topics: Accidental Falls; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Citalopram; Cognitive D | 2012 |
Delayed, fatal cardiotoxicity associated with bupropion and citalopram overdose.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cardiotoxins; Citalopram; Delayed-Action | 2012 |
Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study.
Topics: Aged; Antidepressive Agents; Case-Control Studies; Citalopram; Death, Sudden, Cardiac; Denmark; Depr | 2012 |
Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampus.
Topics: Animals; Antidepressive Agents, Second-Generation; Astrocytes; Behavior, Animal; Chronic Disease; Ci | 2012 |
Citalopram alleviates chronic stress induced depression-like behaviors in rats by activating GSK3β signaling in dorsal hippocampus.
Topics: Anhedonia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; beta Catenin; Blottin | 2012 |
Zinc deficiency induces behavioral alterations in the tail suspension test in mice. Effect of antidepressants.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Body Weight; Citalopram; Depression; Drug Resistan | 2012 |
Rhabdomyolysis associated with polydipsia induced hyponatraemia.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Diagnosis, Differential; Hu | 2011 |
Reward responsiveness and fatigue in multiple sclerosis.
Topics: Adult; Anxiety; Attention; Bupropion; Citalopram; Cognition; Depression; Disability Evaluation; Diso | 2013 |
Summaries for Patients. Prevention of depression in patients treated for chronic hepatitis C virus infection with interferon-alpha.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depression; Dou | 2012 |
Establishing a probabilistic reversal learning test in mice: evidence for the processes mediating reward-stay and punishment-shift behaviour and for their modulation by serotonin.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Conditioning, Operant; Depression; Fe | 2012 |
Chronic citalopram treatment ameliorates depressive behavior associated with light at night.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Circadian Rhythm; Citalopram; C | 2012 |
[Antidepressants in the treatment of alcoholism].
Topics: Alcoholism; Antidepressive Agents; Citalopram; Comorbidity; Depression; Humans | 2012 |
Considerations on safety concerns about citalopram prescribing.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Dose-Response Relationship, Drug; | 2012 |
Antidepressant-dependent mRNA changes in mouse associated with hippocampal neurogenesis in a mouse model of depression.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Disease Models, Animal; Hippocampus; Mice; N | 2012 |
Indices of extinction-induced "depression" after operant learning using a runway vs. a cued free-reward delivery schedule.
Topics: Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Citalopram; Conditioning, Operant; Depr | 2012 |
State-dependent changes in hippocampal grey matter in depression.
Topics: Adult; Brain; Case-Control Studies; Citalopram; Cross-Sectional Studies; Depression; Female; Hippoca | 2013 |
Vesicular signalling and immune modulation as hedonic fingerprints: proteomic profiling in the chronic mild stress depression model.
Topics: Anhedonia; Animals; Citalopram; Depression; Disease Models, Animal; Hippocampus; Immune System; Lase | 2012 |
Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient.
Topics: Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Citalopram; Coinfection; Cy | 2012 |
Effect of fluoxetine and adenosine receptor NECA agonist on G alpha q/11 protein of C6 glioma cells.
Topics: Adenosine-5'-(N-ethylcarboxamide); Animals; Brain Neoplasms; Cell Line, Tumor; Citalopram; Depressio | 2012 |
Rapid determination of letrozole, citalopram and their metabolites by high performance liquid chromatography-fluorescence detection in urine: Method validation and application to real samples.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents; Breast Neoplasms; Chromatography, H | 2013 |
Escitalopram for the prevention of peginterferon-α2a-associated depression.
Topics: Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depression; Female; Hepatiti | 2013 |
Escitalopram for the prevention of peginterferon-α2a-associated depression.
Topics: Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depression; Female; Hepatiti | 2013 |
Successful treatment of patients previously labeled as having "delusions of parasitosis" with antidepressant therapy.
Topics: Antidepressive Agents; Anxiety; Citalopram; Delusions; Depression; Diagnosis, Differential; Female; | 2012 |
Escitalopram (lexapro) for depression.
Topics: Citalopram; Depression; Dose-Response Relationship, Drug; Female; Humans; Male; Sexual Dysfunctions, | 2002 |
Dexamphetamine for obsessive-compulsive disorder.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2003 |
Antidepressants and emotional processing.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Citalopram; Depression; Emotions; Humans | 2003 |
Differential neurochemical properties of central serotonergic transmission in Roman high- and low-avoidance rats.
Topics: Animals; Anxiety; Autoradiography; Avoidance Learning; Behavior, Animal; Binding, Competitive; Brain | 2003 |
There is a new antidepressant escitalopram (Lexapro) that is a cousin of citalopram (Celexa). How are these two different and does the newer drug have any advantages?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Humans; Selective Serotonin Reupta | 2003 |
Antidepressant-like effects in various mice strains in the tail suspension test.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, An | 2003 |
Stereospecific determination of citalopram and desmethylcitalopram by capillary electrophoresis and liquid-phase microextraction.
Topics: Adolescent; Adult; Chromatography, High Pressure Liquid; Citalopram; Depression; Electrophoresis, Ca | 2003 |
Somnambulism due to probable interaction of valproic acid and zolpidem.
Topics: Bipolar Disorder; Citalopram; Depression; Drug Interactions; Drug Therapy, Combination; Humans; Male | 2003 |
Escitalopram-associated mania.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Citalopram; Depression; Humans; M | 2003 |
Seizure secondary to citalopram overdose.
Topics: Adenosine; Adult; Anti-Arrhythmia Agents; Anticonvulsants; Antidepressive Agents, Second-Generation; | 2004 |
A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges.
Topics: Adolescent; Adult; Aged; Citalopram; Cohort Studies; Costs and Cost Analysis; Depression; Female; Hu | 2004 |
Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cita | 2004 |
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Dopamine beta-Hydroxylase; Drox | 2004 |
Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Disease Models, Animal; Do | 2004 |
Neonatal complications after intrauterine exposure to SSRI antidepressants.
Topics: Antidepressive Agents; Citalopram; Depression; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; F | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; | 2004 |
Spontaneous orgasm started with venlafaxine and continued with citalopram.
Topics: Ambulatory Care; Antidepressive Agents, Second-Generation; Citalopram; Combined Modality Therapy; Cy | 2004 |
Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Drug Therapy, Combination; | 2004 |
Reversal of citalopram-induced junctional bradycardia with intravenous sodium bicarbonate.
Topics: Aged; Aged, 80 and over; Arrhythmia, Sinus; Bradycardia; Citalopram; Depression; Drug Overdose; Elec | 2005 |
Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI).
Topics: Antidepressive Agents, Tricyclic; Chromatography, High Pressure Liquid; Citalopram; Cyclohexanols; D | 2005 |
Depression in general clinical practice.
Topics: Age Factors; Aged; Antidepressive Agents; Citalopram; Depression; Family Practice; Female; Fluoxetin | 2004 |
Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents; Anxiety Disorders; Citalopram; Cohort Studies | 2005 |
Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation.
Topics: Adult; Citalopram; Depression; Female; Fluoxetine; Humans; Male; Middle Aged; Netherlands; Paroxetin | 2005 |
Red blood cell triiodothyronine uptake as membrane parameter of depression.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Citalopram; Depression; Erythrocyte Membrane; Fe | 2006 |
Interactive case conference. First episode: depression and panic disorder.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Citalopram; Clonazepam; Depression; | 2005 |
Genotype-dependent activity of tryptophan hydroxylase-2 determines the response to citalopram in a mouse model of depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Disease Models, Animal; D | 2005 |
Interferon beta-1a overdose in a multiple sclerosis patient.
Topics: Adult; Antidepressive Agents; Citalopram; Depression; Depressive Disorder; Drug Overdose; Emergencie | 2005 |
Citalopram counteracts depressive-like symptoms evoked by chronic social stress in rats.
Topics: Administration, Oral; Animals; Antidepressive Agents; Citalopram; Depression; Disease Models, Animal | 2006 |
Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Antidepressive Agents, Second-Generati | 2006 |
Hippocampal cytogenesis correlates to escitalopram-mediated recovery in a chronic mild stress rat model of depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Bromodeox | 2006 |
Neonatal citalopram exposure produces lasting changes in behavior which are reversed by adult imipramine treatment.
Topics: Adrenergic Uptake Inhibitors; Animals; Animals, Newborn; Antidepressive Agents, Tricyclic; Behavior, | 2006 |
Selective effects of citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress.
Topics: Animals; Body Weight; Chronic Disease; Citalopram; Depression; Drinking; Hindlimb Suspension; Immers | 2006 |
Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Case | 2006 |
Comparison of first refill rates among users of sertraline, paroxetine, and citalopram.
Topics: Adolescent; Adult; Anxiety Disorders; Citalopram; Cohort Studies; Cost Sharing; Databases, Factual; | 2006 |
Effect of antidepressant drugs on 6-OHDA-treated mice in the FST.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2007 |
Psychopharmacology of smoking cessation in patients with mental illness.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Arousal; Bupropion; Citalopram; Depression; Depre | 2006 |
[Galactorrhoea and the use of selective serotonin reuptake inhibitors].
Topics: Adult; Citalopram; Depression; Female; Galactorrhea; Humans; Prolactin; Selective Serotonin Reuptake | 2006 |
Recurrent hyponatremia associated with citalopram and mirtazapine.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Depression; Diagnosis, Di | 2006 |
Cutaneous vasculitis during selective serotonin reuptake inhibitor therapy.
Topics: Adolescent; Citalopram; Depression; Female; Humans; Selective Serotonin Reuptake Inhibitors; Time Fa | 2006 |
Imipramine and citalopram reverse corticosterone-induced alterations in the effects of the activation of 5-HT(1A) and 5-HT(2) receptors in rat frontal cortex.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamines; Animals; Antidepressive Agents, Second-Generat | 2006 |
Citalopram-induced SIADH in a hypertensive patient on salt restricted diet.
Topics: Antidepressive Agents, Second-Generation; Antihypertensive Agents; Citalopram; Depression; Diet, Sod | 2007 |
Severe bradycardia in a stroke patient caused by a single low dose of escitalopram.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antidepressive Agents, Second-Generation | 2007 |
Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Dise | 2007 |
Amisulpride augmentation after the failure of citalopram for depression: a case report.
Topics: Adult; Amisulpride; Citalopram; Depression; Dopamine Antagonists; Drug Therapy, Combination; Female; | 2007 |
Escitalopram-associated serotonin toxicity.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Drug-Related Side Effects a | 2007 |
Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study.
Topics: Adolescent; Adult; Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Drug Therapy, Co | 2007 |
Recurrent hyponatremia after substitution of citalopram with duloxetine.
Topics: Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depression; Duloxetine Hydrochlorid | 2007 |
Tickling-induced 50-kHz ultrasonic vocalization is individually stable and predicts behaviour in tests of anxiety and depression in rats.
Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Chromatography, High Pressure Liquid; Cita | 2007 |
Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Anim | 2007 |
Consecutive exposure to lamotrigine and citalopram during pregnancy.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depression; Drug Administration Sched | 2007 |
Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits.
Topics: Animals; Antidepressive Agents, Second-Generation; Blood Pressure; Brain Ischemia; Carotid Arteries; | 2007 |
Proteomic investigation of the ventral rat hippocampus links DRP-2 to escitalopram treatment resistance and SNAP to stress resilience in the chronic mild stress model of depression.
Topics: Animal Feed; Animals; Citalopram; Cytoskeletal Proteins; Depression; Disease Models, Animal; Drug Re | 2007 |
Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Topics: Aged; Aged, 80 and over; Algorithms; Bayes Theorem; Citalopram; Cost-Benefit Analysis; Depression; D | 2007 |
Molecular pathways associated with stress resilience and drug resistance in the chronic mild stress rat model of depression: a gene expression study.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Disease Models, Animal; D | 2007 |
Antidepressant treatment increases quality of life in patients with chronic renal failure.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depression; Female; Humans; Kidney Failure, Chronic; | 2007 |
Variants in PDE11A and PDE1A are not associated with citalopram response.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Alleles; Antidepressive Agents, Second-Generation; Citalopram; | 2007 |
Hippocampal neurogenesis and behavioural studies on adult ischemic rat response to chronic mild stress.
Topics: Adaptation, Physiological; Adaptation, Psychological; Animals; Antidepressive Agents, Second-Generat | 2008 |
Serotonergic mediation of the antidepressant-like effect of the green leaves odor in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain Chemistry; Citalopram; Depression; Disease M | 2008 |
[Psychopharmacotherapy of patients with arterial hypertension complicated with metabolic disturbances and depression].
Topics: Antihypertensive Agents; Citalopram; Depression; Drug Therapy, Combination; Female; Follow-Up Studie | 2007 |
Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample.
Topics: Case-Control Studies; Citalopram; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Depressi | 2008 |
Depression and functional outcome after stroke: the effect of antidepressant therapy on functional recovery.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; F | 2008 |
Escitalopram reduces increased hippocampal cytogenesis in a genetic rat depression model.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Bromodeoxyuridine; Cell Pro | 2008 |
[Escitalopram, labial pigmentation and lichenoid eruption].
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Drug Eruptions; Female; Hum | 2008 |
Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Citalopram; Depression; Female; Humans; Male; Mid | 1995 |
Effects of chronic treatment with zimelidine and REM sleep deprivation on the regulation of raphe neuronal activity in a rat model of depression.
Topics: Animals; Citalopram; Clomipramine; Depression; Dose-Response Relationship, Drug; Electrophysiology; | 1996 |
Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hypercorticosteronemia, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat.
Topics: Amphetamines; Animals; Blood Platelets; Brain; Brain Mapping; Carrier Proteins; Citalopram; Corticos | 1996 |
Risks with citalopram in perspective.
Topics: Antidepressive Agents; Citalopram; Depression; Drug Overdose; Humans; Risk Factors; Selective Seroto | 1996 |
Protective effect of citalopram against the attenuation of the alpha 1-potentiation of cAMP formation in Fischer 344 strain rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Body Weight; Brain Chemistry; Citalopram; C | 1997 |
Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Topics: 1-Naphthylamine; Aggression; Animals; Anxiety; Binding, Competitive; Citalopram; Depression; Fluoxet | 1997 |
Antidepressant treatment in helpless rats: effect on the electrophysiological activity of raphe dorsalis serotonergic neurons.
Topics: Action Potentials; Animals; Antidepressive Agents; Citalopram; Depression; Male; Neurons; Raphe Nucl | 1997 |
Successful use of a selective serotonin reuptake inhibitor in a patient with multiple chemical sensitivities.
Topics: Aerosols; Antidepressive Agents, Second-Generation; Citalopram; Depression; Humans; Male; Middle Age | 1997 |
Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Buspirone; Citalopram; Depression; Disease Models, Animal; Dose-Resp | 1998 |
Citalopram for depression.
Topics: Citalopram; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Double-Blind Met | 1998 |
Bradycardia during citalopram treatment: a case report.
Topics: Antidepressive Agents, Second-Generation; Arrhythmia, Sinus; Bradycardia; Citalopram; Depression; Fe | 1999 |
Citalopram versus other selective serotonin-reuptake inhibitors.
Topics: Adolescent; Adult; Aged; Citalopram; Depression; Female; Humans; Male; Middle Aged; Selective Seroto | 1999 |
Fatality caused by a combined trimipramine-citalopram intoxication.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depression; | 1999 |
The effect of citalopram treatment on platelet serotonin function in panic disorders.
Topics: Adult; Anxiety; Blood Platelets; Citalopram; Depression; Female; Humans; Male; Middle Aged; Panic Di | 2000 |
Behavioural consequences of repeated social defeat in the mouse: preliminary evaluation of a potential animal model of depression.
Topics: Aggression; Alcohol Drinking; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; B | 1999 |
The selective sigma2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricy | 2000 |
The effect of acute citalopram on extracellular 5-HT levels is not augmented by lithium: an in vivo microdialysis study.
Topics: Animals; Citalopram; Depression; Drug Administration Schedule; Drug Therapy, Combination; Extracellu | 2000 |
Citalopram plus reboxetine in treatment-resistant depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Citalopram; Depression; Drug Therapy, Combination; Female; Huma | 2000 |
Interaction potential of selective serotonin-reuptake inhibitors.
Topics: Citalopram; Cytochrome P-450 Enzyme System; Depression; Drug Interactions; Humans; Selective Seroton | 2000 |
Serotonin syndrome. A common but often unrecognized psychiatric condition.
Topics: Aged; Anxiety Disorders; Buspirone; Citalopram; Depression; Female; Humans; Selective Serotonin Reup | 2001 |
Severe symptomatic hyponatremia during citalopram therapy.
Topics: Aged; Citalopram; Depression; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Selective Se | 2001 |
Disinhibition of libido: an adverse effect of SSRI?
Topics: Adult; Adverse Drug Reaction Reporting Systems; Citalopram; Depression; Female; Humans; Libido; Male | 2001 |
Too much hypothalamic serotonin transporter is bad for your mood.
Topics: Adolescent; Alleles; Carrier Proteins; Child; Citalopram; Depression; Genetic Predisposition to Dise | 2001 |
Brief report: citalopram in child and adolescent depression with anxiety.
Topics: Adolescent; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Child; Citalopra | 2001 |
Citalopram-induced photopigmentation.
Topics: Citalopram; Depression; Diagnosis, Differential; Face; Female; Forearm; Humans; Hyperpigmentation; M | 2001 |
Tapping the potential of isomer science.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Depression; Humans; | 2002 |
Probable interaction between citalopram and acenocoumarol.
Topics: Acenocoumarol; Citalopram; Depression; Drug Interactions; Female; Gingival Hemorrhage; Humans; Inter | 2002 |
S-enantiomer of the selective serotonin reuptake inhibitor citalopram compared with racemate citalopram (S+R).
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Disease Models, Animal; D | 2001 |
Citalopram-induced priapism.
Topics: Citalopram; Depression; Humans; Male; Middle Aged; Priapism; Selective Serotonin Reuptake Inhibitors | 2002 |
A stroke patient with a non-convulsive status epilepticus during citalopram therapy.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Humans; Status Epile | 2002 |
[Experimental model of depression: neurochemical changes and the effects of imipramine and citalopram].
Topics: Animals; Antidepressive Agents; Brain; Catecholamines; Citalopram; Depression; Disease Models, Anima | 1992 |
Effects of MK-801 and antidepressant drugs in the forced swimming test in rats.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Dizocilpine Maleate; Haloperidol; Imipramine | 1992 |
Effect of imipramine in the "learned helplessness" model of depression in rats is not mimicked by combinations of specific reuptake inhibitors and scopolamine.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Behavior, Animal; Citalopram; Depression; Drug S | 1990 |